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Zusammenfassung 
Mikrobielle Naturstoffproduzenten stehen aufgrund der zunehmenden Ausbildung von 
Antibiotikaresistenzen erneut im Fokus der Suche nach pharmazeutisch relevanten Wirkstoffen. In 
diesem Kontext befasst sich die vorliegende Arbeit sowohl mit der Charakterisierung neuer 
myxobakterieller Naturstoffe und deren Biosynthese als auch mit der Entwicklung einer analytischen 
Methode zur Analyse komplexer biologischer Extrakte. 
Im Rahmen dieser Arbeit wurden die Naturstoffe Pellasoren und Microsclerodermin aus dem 
genomsequenzierten Stamm Sorangium cellulosum So ce38 isoliert. Neben der Strukturaufklärung des 
Pellasoren konnte ein zugehöriges Biosynthese-Gencluster identifiziert und dadurch die Biosynthese 
aufgeklärt werden. Zudem wurden in einem umfangreichen Screening-Projekt mehrere terrestrische 
Myxobakterien als Produzenten des marinen Naturstoffes Microsclerodermin identifiziert. Dies ist einer 
der wenigen bekannten Fälle der Auffindung identischer Sekundärmetabolite aus marinen und 
terrestrischen Quellen. Die Isolierung zweier neuer Derivate führte schließlich zur Charakterisierung der 
zugehörigen Biosynthesegene in zwei myxobakteriellen Stämmen. Dabei konnten die strukturellen 
Unterschiede der gefundenen Derivate durch die Unterschiede im Biosynthesecluster erklärt werden. 
Des Weiteren wurde eine Methode zur Steigerung des Informationsgehalts von LC-MS/MS Daten 
entwickelt. Durch statistische Auswertung von LC-MS Datensätzen können Signale, welche aus dem 
Metabolismus des Bakteriums hervorgehen, identifiziert und daraufhin unabhängig von der jeweiligen 
Signalintensität fragmentiert werden. Die Anwendung dieser Methode führte zur Auffindung und 
Aufklärung der Struktur der Lipothiazole, einer neuen Substanzklasse aus S. cellulosum So ceGT47. 
  
  
Abstract 
The rapid emergence of antibiotic resistance enforces the search for new pharmaceutically 
relevant compounds. Here, especially natural products from microbial sources are becoming important 
once again. In this regard, the present work deals with the characterization of new myxobacterial 
natural products and their biosynthesis alongside with the development of an improved method for the 
chemical analysis of complex biological samples. 
This thesis covers the isolation of two natural products, pellasoren and microsclerodermin, both 
derived from the crude extracts of the genome-sequenced strain Sorangium cellulosum So ce38. Full 
structure elucidation of pellasoren led to the identification of its biosynthetic gene cluster and the 
underlying biosynthesis. Furthermore, as a result of a comprehensive screening project, several 
terrestrial myxobacteria were unambiguously identified as producers of the marine natural product 
microsclerodermin. This finding resembles one of the few known cases of an identical metabolite 
derived from terrestrial and marine habitats. The isolation and subsequent characterization of two new 
derivatives from different strains resulted in the identification of two biosynthetic gene clusters. As a 
consequence, structural differences of the derivatives could be rationalized based on slight variations 
within both clusters. 
In addition, a method to optimize the informational content of LC-MS/MS data was developed. 
Statistical evaluation of LC-MS data facilitated the identification of signals linked to bacterial 
metabolism, which were subjected to MS/MS analysis irrespective of their intensity. This methodology 
was successfully applied to identify the novel lipothiazole compound class in S. cellulosum So ceGT47. 
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1 Introduction 
1.1 The Role of Natural Product Research 
Throughout history humans have been suffering from numerous infectious diseases. Especially 
infant and child mortality is strongly linked to the occurrence of pathogens as causative agents of 
infections as they exploit the rather weak immune response during the first months after birth. Even 
among adults infectious diseases remain to be a major threat to health. There are approximately 200 
infectious diseases caused by bacteria, viruses, fungi, protozoa, parasites and prions whereas the most 
part is related to bacteria and viruses. It is noteworthy that only a small subset of all bacteria is harmful to 
the human organism albeit those can cause severe health problems or even death to the infected person. 
With the rise of antibiotic application in the 19th century, humans managed to fight against such 
infectious diseases for the first time in a broadly applicable manner. There has been always certain 
knowledge of how to heal infections; a knowledge usually based on elderly wisdom or witchcraft based 
solely on trial and error and the cultural heritage evolved thereof.1 However, the underlying principles for 
the observed healing effect were not understood, although used successfully. This changed with the 
understanding that microorganisms are causative for infections as first postulated by Jakob Henle and 
Edwin Kleb and finally proven by Robert Koch and Friedrich Löffler.2,3  
The use of antibiotics gained momentum in the early 20th century when scientists realized that 
certain microbes are able to inhibit the growth of other microorganisms.1 Finally, the steadily increasing 
knowledge in chemistry resulted in the identification of single compounds being responsible for the 
observed effects, e.g. the widely renowned penicillin which was the first isolated natural product showing 
an antibiotic effect. It represents the archetype of a natural product bearing antimicrobial activity. 
Nowadays, natural products are by definition chemical compounds produced by a living organism that 
have biological or pharmacological activity. As many infectious diseases are caused by bacterial or fungal 
microorganisms that may be per se harmful or exploit at least opportunistic pathogenicity, a suitable way 
to tackle such infections is to kill the pathogenic bacterium (bactericidal activity) or stop its growth 
(bacteriostatic activity). A reason for the production of compounds exhibiting antibiotic properties could 
be a defense mechanism against other microorganisms, presumably as a consequence of the dense 
communities microorganisms live in and the resulting cope for nutrients and living space. According to 
this circumstance, it is not surprising that many microbes are equipped with the genetic capabilities to 
produce molecules that can affect the life of other microbes. Such compounds are not required for the 
basic metabolic processes of life; hence, they are named secondary metabolites to emphasize their role in 
14 Introduction  
 
metabolism. It is noteworthy that secondary metabolites do not exhibit antibacterial activity per 
definition. In particular, for many secondary metabolites it remains unknown for which reason they are 
produced by the respective microbe.4 
In the end, the number of natural products is literally uncountable since the biosynthesis of natural 
products evolves together with the organisms, thereby creating a plethora of different chemical 
structures. Some of those structures were the basis for the antibiotic era of mankind which started 
around 100 years ago and led to a previously unseen gain in life quality and extension of human life time. 
The important role of natural products becomes obvious in light of the drugs that are derived from 
natural products (Figure 1).5 
 
Figure 1: Approved anti-infective and anticancer drugs categorized according to their origin. Graphic adapted from 
Newman and Cragg.
5
 
However, the current trend of increasing resistance against available antibiotics amongst pathogenic 
bacteria could easily end in a new pre-antibiotic era.6,7 Some pathogenic bacteria are now even pan-
resistant, i.e. resistant against all available antibiotics. Among all pathogenic bacteria a group of seven is 
regarded as highly problematic. These so-called ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa, and 
Enterobacter species) do frequently “escape” the available antibiotics and eventually lead to death of the 
patients.8 The situation demands to use again old drugs that were not longer on the market due to their 
toxic side effects. Some of these drugs such as colistin are the last resort against gram-negative multi-
resistant bacteria.9 The only way to overcome this scenario lies in new antibiotics reaching the market. 
Novel chemical scaffolds are necessary to identify new mode of actions that circumvent current 
resistance mechanisms. Since only a low percentage of new natural products make it to the stage of 
clinical trials and even less finally are approved as drugs it is obvious that there is a huge demand for new 
compounds to furnish the pharmaceutical pipelines. In conclusion, the discovery and development of 
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new natural products are important for human health. However, the “low-hanging fruits” among 
antimicrobial natural products have already been harvested. It is therefore important to carefully choose 
promising sources for further investigation. Such sources are usually found in biological niches or in 
habitats that are rather underexploited. In particular, this understanding led to an increased interest in 
the rich marine habitats and in uncommon types of bacteria and fungi, following the current notion that 
chemical diversity comes along with phylogenetic diversity. The myxobacteria are one of these 
underexploited types of bacteria that have been steadily yielding new natural products with promising 
modes of action.10  
1.2 Myxobacteria – a Special Group of δ-Proteobacteria 
Within the class of δ-proteobacteria the order Myxococcales represents an uncommon type of gram-
negative bacteria. These myxobacteria show an intriguing “social behavior” and a complex life cycle. 
Although myxobacteria are single cell organisms, they are able to form multi-cellular fruiting bodies that 
contain spores to endure times of limited nutrition supply or unfavorable environmental conditions. 
Fruiting body morphology and spore shape are useful as classifiers to characterize the different 
myxobacterial families.11 Myxobacteria are also able to move on surfaces by swarming and creeping in 
order to find nutrient resources, which is certainly a remarkable type of behavior for proteobacteria. 
Preferred nutrients are macromolecules that are lysed by suitable exo-enzymes, but some strains are 
even able to prey on live microorganisms such as yeast or E. coli.12  
 
Figure 2: A Stereophotomicrograph of Sorangium cellulosum radiating swarm from edges of filter paper. B 
Brightfield photomicrograph of Sorangium cellulosum fruiting bodies at the edge of filter paper. C Rod-shaped, blunt 
end vegetative cells of Sorangium cellulosum So ce38 in liquid medium. D Stereophotomicrograph of  Jahnella sp. 
MSr9139 swarming on agar.(Pictures by Ronald Garcia) 
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The fascinating characteristics of myxobacteria are linked to the complex interplay of intercellular 
signaling, cell differentiation and morphological changes.13,14 Some of these processes, such as the ability 
to move by gliding require the interaction of numerous proteins.13 The fact that myxobacteria seem to 
have the largest genomes amongst bacteria sounds reasonable in light of the aforementioned 
capabilities.15 
Most myxobacteria isolated to date are of terrestrial origin although a few marine strains have been 
characterized.11,16,17 Marine habitats are currently underexploited in terms of screening for myxobacteria, 
thus the low numbers of known marine strains could be attributed to insufficient sampling efforts. 
However, phylogenetic analysis of marine sponges based on 16S rRNA analysis suggests that 
myxobacteria may be present in sponges and marine sediments.18,19 Although this evidence is still 
awaiting ultimate confirmation by isolation and cultivation of sponge-derived myxobacteria, it points 
towards a huge potential resource of new marine myxobacteria, providing much-desired phylogenetic 
diversity for future screening campaigns. Past and ongoing screening efforts have revealed myxobacteria 
as a valuable source for new natural product classes that frequently show promising modes of action.10 
This biotechnological potential is partly owing to the exceptional size of myxobacterial genomes.20 
Comprising frequently more than 10 Mio. base pairs, the genomes of the genus Sorangium cellulosum 
seem to be the largest bacterial genomes with sizes of 13.0 Mbp for strain So ce56 and 14.8 Mbp for 
strain So0157-2 .15,21 In addition to their size, myxobacterial genomes are uncommon as they feature a 
high GC content of around 70 %.15 Currently, several myxobacteria are sequenced and primary results 
indicate similar genome sizes and GC contents. 
Interestingly, the majority of the biologically active secondary metabolites act against fungi or 
bacteria, which are common competitors of myxobacteria in their natural habitat.10 For example, a 
cellulose-degrading S. cellulosum strain may combat cellulose-degrading fungi by producing antifungal 
compounds whereas proteolytic myxobacteria benefit from antibacterial compounds that can act on 
other proteolytic competitors or prey.22,23 Other compounds have cytotoxic, anti-viral, or anti-
inflammatory activity, which do not per se confer an evolutionary advantage to the producing strain and 
may be a serendipitous effect of the compound. This can be attributed to the limited number of protein 
folds that are known. At the time of writing this thesis, the SCOP database listed only 1360 different fold 
types for proteins.24 In view of this circumstance, it seems quite obvious that some compounds can 
interact simply by chance with a protein. There are also compounds showing no activity against other 
organisms when tested with standard bioactivity assays. Those compounds may have other functions, 
e.g. such as myxochelin which is a siderophore and helps iron acquisition by chelating iron, or they are 
involved in signaling pathways, or they are simply not active in the limited collection of assays that are 
available.25 The metabolic effort to produce secondary metabolites is significant and it is considered 
unlikely that they would be produced without being directly or indirectly beneficial for the producer.4,26 
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This should be considered when a new compound is characterized that lacks activity on first sight. Not all 
secondary metabolites are per se bioactive under pharmaceutically relevant conditions and for many of 
them the type of bioactivity needs to be elucidated first.26 In light of this, it is noteworthy that the 
combination of new assays and a tight collaboration between research groups is beneficial for finding 
more promising activities.  
Research of the last decades has revealed that myxobacterial secondary metabolites often have 
uncommon or previously undescribed modes of actions, making them particularly interesting for 
pharmaceutical research.10 Among the myxobacteria screened so far, the most proficient sources for 
natural products are strains of Sorangium cellulosum, Myxococcus, and Chondromyces.22 Strains of S. 
cellulosum are classified in the family Polyangiaceae of the suborder Sorangiineae. These cellulose 
degrading strains are usually terrestrial isolates derived from decaying plant material. Some of these 
strains are moderately thermophilic and grow at 42-44 °C while the majority is culturable at 30 °C.11,27 
Many potent natural products were isolated from strains of the Sorangiineae suborder, e.g. ambruticin28, 
epothilon29, ripostatin30, sorangicin31, soraphen32, and thuggacin33 (Figure 3). The majority of 
myxobacterial secondary metabolites reported to date are derived from huge protein complexes of the 
polyketide synthase (PKS) type, the nonribosomal peptide synthetase (NRPS) type, or hybrids thereof (see 
Chapter 1.3). In addition, current research reveals an increasing number of ribosomally produced natural 
products (RiPPs).34 However, their overall number is still moderate with one possible reason being that 
RiPP biosynthetic gene clusters circumvent a straightforward detection by genome mining approaches.  
Over the last decades, research with myxobacteria yielded around 900 compounds of 140 
compound classes isolated and characterized at the Helmholtz Center for Infection Research, 
Braunschweig, Germany and at the Helmholtz Institute for Pharmaceutical Research, Saarbrücken, 
Germany (as of 01/2014). The overall number of myxobacterial natural products is quite remarkable in 
light of the rather small number of strains screened (< 10,000), especially when compared to the 
screening efficiency in actinomycetes research.35 However, myxobacterial natural products still account 
for only a low percentage of all published microbial natural products. Most of these are derived from 
actinomycetes, fungi, and bacilli strains;22 a fact owing to the long-standing research in these fields in 
combination with extensive screening programs conducted by industrial and academic research groups. 
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Figure 3: Selection of bioactive secondary metabolites isolated from Sorangium cellulosum strains. 
1.2.1 Discovery of New Secondary Metabolites from Myxobacteria  
The current notion of how to exploit myxobacterial secondary metabolism comprises several 
fundamental ideas, i.e. (1) isolation of new myxobacterial strains, (2) using state-of-the-art instrumental 
analytics in combination with (3) a versatile screening for bioactivity against a panel of representative 
indicator strains and (4) applying the full range of advanced genome-related techniques such as genome 
mining, directed mutagenesis, and heterologous expression of biosynthetic pathways in alternative hosts. 
Ongoing efforts to sequence myxobacterial genomes continue to reveal a huge potential for 
secondary metabolite production.36 So far, numerous loci within each sequenced genome harbor genes 
that belong to secondary metabolite biosynthetic gene clusters. The number of such clusters varies from 
around 10 to > 20 clusters per strain. On the contrary, only a subset of the corresponding compound 
classes is usually found in a crude extract. This mismatch may be attributed in part to the cultivation 
conditions, which hardly resemble a natural environment. Some compounds may be not produced at all, 
e.g. until an unknown signal initiates transcription of the responsible genes. Others may be produced in 
very low amounts and missed in typical screening approaches. However, at least one analysis of the 
proteome of M. xanthus DK1622 revealed that proteins for 17 out of 18 secondary metabolite gene 
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clusters were expressed.37 In terms of cultivation conditions it was recently shown, that a strict control of 
the CO2 and O2 partial pressures during fermentation can influence productivity of different 
compounds.38 Such effects are not considered if shaking flask cultures are prepared. After all, the reason 
why so many potential secondary metabolites are still not found remains elusive and achievements to 
induce production by different cultivation conditions were merely serendipitous. An interesting approach 
towards altering the secondary metabolome is co-cultivation of bacterial strains and fungi in order to 
induce unforeseen effects.39,40 With respect to myxobacteria the effects of co-cultivation are to date still 
underexploited. 
Table 1: Overview of some myxobacterial genome sizes, secondary metabolite clusters found in silico, and the 
number of clusters that were already linked to a secondary metabolite. 
Strain 
Genome 
[Mbp] 
Secondary 
metabolite 
cluster overall 
Secondary 
metabolite 
cluster assigned 
Ref.  
Myxococcus xanthus DK1622 9.2 Mbp 18 11 
41
  
Sorangium cellulosum So ce56 13.0 Mbp 13 4 
15
  
Stigmatella aurantiaca DW4/3-1 10.3 Mbp 14 5 
42
  
Sorangium cellulosum So ce38 
a
 14.5 Mbp 8 2 this work  
Sorangium cellulosum So ceGT47 
a
 10.9 Mbp 9 3 this work  
a 
unpublished results      
 
For M. xanthus DK1622 eleven out of 18 compound classes were identified under culture conditions 
so far. For S. cellulosum So ce56 compound classes were assigned to only 4 out of 8 gene clusters 
identified by genome sequencing. The projects of this thesis deal with two S. cellulosum strains, So ce38 
and So ceGT47, which were sequenced at the starting point of this work. Table 1 lists assigned and 
unassigned secondary metabolite clusters of different genome-sequenced myxobacteria. 
Several approaches address the apparent discrepancy between observed metabolite profiles and 
the genetic capacity for the production of secondary metabolites by introducing new methods for 
identifying secondary metabolites and new ways of using the genomic information. Among the genomics-
based methods, perhaps the most straightforward is to create knock-out mutants by targeted disruption 
of a biosynthetic gene. This approach has been used with both site-directed and random transposon 
mutagenesis techniques for genetic manipulation of the organism under investigation.43–45 Upon 
successful knock-out of a biosynthetic gene cluster the corresponding natural product cannot be 
produced anymore. Careful comparison of a wildtype strain’s LC-MS chromatogram with the knock-out 
strain’s chromatogram can help to identify the signals representing the compound produced by the 
inactivated gene cluster. However, this method requires first of all that the secondary metabolite is 
produced in the wildtype strain and demands at the same time for the development of a genetic 
manipulation method, a challenging undertaking with some myxobacteria. Moreover, the knock-out of a 
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biosynthetic gene cluster that is not expressed in the wild-type strain will obviously not result in an 
informative change between the metabolite profiles of wildtype and knock-out mutant.  Even if all 
prerequisites are fulfilled it is tedious and error-prone to identify differential signals in complex LC-MS 
datasets by manual comparison. Peak intensities of metabolites and matrix components can be subject to 
strong variation among replicate cultivations, and unforeseeable changes may occur when cultivating the 
knock-out strain in the presence of an antibiotic to maintain the selection marker introduced for gene 
inactivation. Less abundant compound peaks are easily missed under such circumstances. This problem 
can be overcome by employing software-aided data evaluation e.g. by making use of principal 
component analysis (PCA) to highlight differences between two sample sets (see chapter 1.4).46  
A gene cluster can be linked to a secondary metabolite by approaching the analysis from the 
opposite way, i.e. starting from a characterized secondary metabolite. Retrobiosynthetic considerations 
help to create a draft biosynthesis gene cluster that, in theory, could hold responsible for synthesizing the 
core structure of the metabolite. In a next step, all biosynthetic gene clusters of a producer strain’s 
genome are compared to this draft in order to identify the one that fits best. This type of analysis was 
done for all compounds of this thesis as well as for the identification of other myxobacterial compounds, 
e.g. gephyronic acid and althiomycin.47,48 This metabolite-to-genes approach can also be applied in a very 
early stage research when LC-MS/MS data of crude extracts is acquired. Here, indicative fragmentation 
patterns can highlight amino acid building blocks, which are then in turn mapped to the adenylation 
domains found within the genome, a method which was recently named peptidogenomics.49  
Another method to discover and study new secondary metabolites uses heterologous expression of 
secondary metabolite gene cluster in suitable hosts, e.g. Pseudomonas putida or Myxococcus xanthus.50,51 
However, the size of NRPS or PKS gene clusters demands new techniques for working with large DNA 
fragments.52,53 In addition, the number of suitable host organisms is limited owing to the high GC content 
of myxobacteria and the fact that some host organisms may lack metabolic pathways for the biosynthesis 
of uncommon precursors and for the post-translational activation of multi-domain biosynthetic 
enzymes.36 Nevertheless, heterologous expression provides an opportunity to evade the weak point of 
several other approaches, with regard to low productivity of unknown metabolites as a consequence of 
inappropriate cultivation conditions, unforeseen regulation, and genetic inaccessibility.36 However, 
similarly to the knockout- and comparative profiling approach, heterologous expression also requires the 
sensitive detection of potentially subtle differences between LC-MS samples. 
Finally, when the assignment of a new metabolite to a biosynthetic gene cluster could be 
accomplished, the next challenge is to improve yield in order to enable compound isolation and full 
characterization, since newly discovered compounds may be initially produced in very low yields only. A 
good option is to isolate alternative strains that are better producers of a target compound. While the 
diversity of metabolite profiles to date has not been comprehensively revealed at large scale in terms of 
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spanning a large group of organisms, the analysis of increasing numbers of strains nevertheless seems to 
indicate for myxobacteria that profiles from related genera exhibit a certain overlap. However, 
production rates for specific compounds may differ by several orders of magnitude between the 
producing strains.54 Obviously, a newly identified metabolite is easier to isolate if a good producer is 
available. Effectively using alternative producers from a wide choice of sources does however depend on 
availability of a large-scale analytical framework, capable of generating and handling quantitative 
information on production profiles and ideally covering an entire strain collection.  
With respect to these requirements, a screening project for myxobacteria was initiated. The large 
collection of myxobacterial strains and compounds at the Helmholtz Center for Infection Research, 
Braunschweig, Germany and at the Helmholtz Institute for Pharmaceutical Research, Saarbrücken, 
Germany was the perfect starting point to establish a comprehensive screening platform. All known 
compounds as well as approximately 2500 crude extracts of carefully selected myxobacterial strains were 
measured with standardized conditions using this analytical platform (LC-MS) and furthermore checked 
for bioactivities. All information is gathered in our proprietary data base, the Mxbase, which allows a 
convenient access to all information that is available to any strain or compound. Such a framework, which 
aims for comprehensiveness, facilitates dereplication of known compounds and identification of new 
compounds as well as the above mentioned search for alternative producers. 
1.3 The Rationale behind NRPS- and PKS-based Natural Product 
Biosynthesis 
Many natural products are derived from nonribosomal peptide synthetases (NRPS) and polyketide 
synthases (PKS). Both biosynthetic systems use rather large, multi-modular protein complexes, which 
have been heavily studied for the last 20 years. In contrast, another source of natural products based on 
the ribosomal formation of short genome-encoded precursor peptides and extensive post-translational 
modification has been increasingly investigated only since a couple of years. These ribosomally produced 
natural products (RiPPs) play a steadily increasing role in natural product research.34 However, RiPP 
biosynthetic genes are not as easy identified by genome mining approaches as NRPS or PKS clusters; 
hence, it is currently still challenging to predict the genetic capabilities of a given strain in this respect, 
apart from the previously reported RiP pathways. In the following paragraphs the discussion of 
biosynthetic logic for the production of myxobacterial natural products will focus on NRPS and PKS 
biosynthesis, since RiPPs are not within the scope of this work..  
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1.3.1 Polyketide Synthases – PKS 
The name polyketide reflects the structural basis common to this type of natural product. A 
polyketide chain can be described as a regular polymer consisting of C2 units with a ketone at every 
second carbon. This holds true for the most basic type of polyketides s derived solely from a sequence of 
elongation steps without further reductive processing. There is essential similarity between polyketide 
chains and fatty acid chains and indeed, the proteins forming polyketide synthases (PKSs) are homologues 
of the fatty acid synthase (FAS) machinery. Progress in FAS research was of great benefit to understand 
the principles of PKSs,55–57 although a PKS was not identified or characterized on genome or protein level 
for a long time.58 Finally, around the beginning of the 1990s – almost 40 years after the first biosynthetic 
proposal by Birch et al. – it was evident that all polyketides are produced by the same biosynthetic 
principles as found in fatty acid synthesis.59–61 Today it is proven that PKSs are huge megasynthases (up to 
> 1 MDa in size) of a homodimeric, twisted structure that share catalytic domains within the dimer.62,63 
Both FAS and PKS systems use a pool of simple precursors such as an acetyl-ester of coenzyme A (acetyl-
CoA) and a malonate-ester of coenzyme A (malonyl-CoA) to build up carbon chains by C-C bond 
formation. Several distinct enzymes are necessary to perform all the steps of precursor acquisition, chain 
initiation, elongation, and further reductive processing. 58,64 The central biosynthetic principle is a Claisen 
condensation when the enzyme-bound malonate decarboxylates whereupon the electron pair undergoes 
a nucleophilic attack to the enzyme-bound acetyl moiety (Figure 4 A). 
 
Figure 4: A Central condensation step as observed in fatty acid and polyketide biosynthesis. B Structure of the 
phosphopantetheine arm attached to a serine of the acyl carrier protein. KS, ketosynthase; ACP, acyl carrier protein.
The acetyl-CoA is used as a starter and delivered as an acetyl group onto the ketosynthase (KS). More 
precisely, an acyl transferase (AT) gathers the acetyl by transesterification of the coenzyme A ester with 
the hydroxyl group of a serine as depicted in Figure 5. This serine-bound acyl group is now transferred to 
the cysteine of the KS domain.  Following the same principles, the malonyl group is attached to a thiol of 
the acyl carrier protein (ACP) via an acyl transferase. This thioester is formed with the terminal thiol of a 
phosphopantetheine moiety that is posttranslationally attached to a serine of the acyl carrier protein 
(Figure 4B). The phosphopantetheine (ppant) has the function of a flexible arm, which carries the growing 
chain to the different catalytic domains that act on the biosynthetic intermediate.65 Hence, the 
intermediates can reach close proximity to the active centers of the assembly line, which plays an 
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important role for the efficiency of the whole process. After condensation of both units, the ACP-bound 
intermediate is further processed starting by reduction of the β-keto ester to form a β-hydroxyl ester, 
catalyzed by a keto reductase domain (KR). Following dehydration by a dehydratase domain (DH) and 
reduction of the double bond by an enoyl reductase domain (ER) the chain is ready for another round of 
elongation (Figure 5). For a fatty acid synthase, these subsequent steps are repeated until a certain chain 
length is reached upon which the product is cleaved off the ACP by a thioesterase (TE).  
 
Figure 5: Schematic reaction steps for one elongation step as found in FAS and PKS type I. The additional AT-ACP 
module is not found in FAS but usually present as loading module in PKS type I. (1) Loading of an activated precursor; 
(2) Transfer to a acyl carrier protein (ACP) by transesterification with ppant; (3) The starter unit is forwarded to a 
ketosynthase (KS); (4) Condensation reaction mediated by the KS domain; (5) Ketoreduction, dehydration, and enoyl 
reduction of the ACP-bound product; (6) Fully reduced chain extended by a C2 unit. 
While these basic enzymatic steps are the same for FAS and PKS type I, the way how enzymatic domains 
act together is different. A fatty acid synthase does always contain the same domains (KS, ACP, AT, KR, 
DH, ER, TE) performing iteratively as described above, whereas the biosynthetic logic of polyketide 
synthases is more flexible. PKS “assembly lines” are usually built up by single modules that often perform 
only one specific round of chain elongation. A PKS module is thereby defined as a set of enzymatic 
domains needed to extend the chain by a C2 unit. Hence, the minimal module is given by the domain set 
ACP-KS-AT, which will afford a β-keto ester. In addition to these essential domains a PKS module may 
contain further processing domains like KR, DH, and ER domains in order to further reduce the enzyme-
bound β-keto moiety to a β-hydroxy ester, an α-β-unsaturated ester, or finally a saturated ester.66 
Moreover, there are various starter and extender units possible as a consequence of AT domain substrate 
specificity. The most common extender unit substrates are malonyl- (M-CoA) and methylmalonyl-CoA 
(mM-CoA). But also extender units based on ethylmalonyl-CoA, hydroxymalonyl, methoxymalonyl, and 
aminomalonyl have been reported.67–71 The latter building blocks are not available from primary 
metabolic pathways, and thus are usually produced by specialized enzymes. To increase the repertoire, 
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several starter units such as propionate, isovalerate, phenylacetate, benzoate, cinnamic acid, amino 
acids, and many more be incorporated as reviewed by Moore and Hertweck.72 The different specificities 
for starter unit or extender unit are governed by conserved motifs found in AT domains.73 Directed 
modification of these motifs by genetic engineering in principle opens up the possibility to alter AT 
domain substrate specificity.74,75 
Polyketide synthases are historically classified in three major groups: type I, II and III.76 The initial 
constraints of the three groups did not last for long as more and more exceptions were found. As a result 
of the ongoing research, there are many “PKS type I” known that act iteratively, which was initially only 
attributed to type II PKSs (Chapter 1.3.4). PKSs of trans-AT type are another example that does not fit into 
the classification scheme. Hence, it is now deemed rather inappropriate to force PKS systems into these 
groups.77 Indeed, PKSs are very versatile megasynthases made from a pool of different functions that 
allow numerous combinations and thereby bring about an impressive diversity of assembly line 
architectures. The flexibility of multimodular PKS architecture in turn gives rise to a plethora of 
polyketides. Moreover, PKS assembly lines may be extended beyond the basic set of enzymatic functions 
by additional enzymes, such as methyl transferases acting on carbon, nitrogen, and oxygen or 
aminotransferases just to name two classes. Those additional enzymes may be located inside modules, or 
alternatively be distinct enzymes that are encoded by genes downstream or upstream in respect to the 
PKS cluster.  
1.3.2 Nonribosomal Peptide Synthetases – NRPS 
An alternative way of enzymatic peptide synthesis apart from the ribosomal system was not known 
until the work of Lipmann et al.in 1971.78 Today, nonribosomal peptide synthetases (NRPS) are a well-
studied system that is found in many bacteria and fungi. Like PKSs, NRPSs are megasynthases producing a 
wide variety of peptide-derived secondary metabolites by a sequence of chain elongation and 
modification events. Each elongation step is again performed by a single module, which minimally a 
condensation domain (C), an adenylation domain (A), and a peptidyl carrier domain (PCP). From a general 
point of view, the minimal NRPS module resembles the domain triad AT-KS-ACP of PKS systems (Chapter 
1.3.1), but the distinct biochemical steps catalyzed by NRPS domains are different. The biosynthetic logic 
of a NRPS is based on an activation of monomers by conversion of the free amino acid to the respective 
AMP-conjugate (AMP = adenosine monophosphate). This reaction is catalyzed by the A domain, 
consuming one equivalent of ATP (adenosine triphosphate) in presence of magnesium ions. Activated 
amino acids are then transferred to the adjacent PCP domain by forming a thioester with the terminal 
thiol of a phosphopantetheine (ppant) moiety. The amino acid building block is thereby attached to the 
flexible ppant arm, which directs the amino acid toward the condensation domain (C). At the same time 
another PCP domain, located downstream within the megasynthase, sequesters a second PCP-bound 
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amino acid. The condensation domain can now catalyze the amide bond formation between both PCP-
bound amino acids (Figure 6).64,79  
With respect to possible extender units, NRPS systems are more flexible than ribosomal peptide 
biosynthesis, as adenylation domains can accept a variety of substrates apart from the proteinogenic 
amino acids. Stachelhaus et al. identified ten key amino acid residues responsible for the substrate 
specificity of A domains. This so-called Stachelhaus code is derived from a crystal structure of an 
adenylation domain having an amino acid bound to the active site.80 The side chains that form the cavity 
around the active site hold responsible for the selectivity of the adenylation domain. This set of side 
chains is referred to when the Stachelhaus code is mentioned. Using this knowledge, bioinformatics 
methods have been devised in order to predict an A domain’s substrate specificity from its amino acid 
sequence.81,82 
 
Figure 6: Principle biosynthetic step leading to peptide bond formation in NRPS. Active domains of each step are 
highlighted in red. The reaction cycle starts with the activation of an amino acid by an adenylation domain (A) that is 
specific for the respective amino acid (1). A peptidyl carrier protein (PCP) gathers the activated amino acid by 
transesterification using the terminal thiol of a phosphopantetheine group (2). The scheme features a loading unit 
(A-PCP) which frequently provides the initial amino acid in NRPS clusters. 
In addition to common L-amino acids, many NRPS-derived natural products incorporate unusual building 
blocks such as D-configured amino acids in their scaffold. Besides the direct activation of D-amino acids 
by an adenylation domain,83 epimerization from L to D-configured amino acids is frequently employed to 
generate D-amino acid moieties in NRPS products.64 In particular, most D-amino acids are usually not 
available from primary metabolism, and thus their direct loading appears less favorable. The 
stereochemical inversion on the assembly line is mediated by dedicated epimerization domains (E) that 
are integrated into NRPS modules, usually showing the domain order C-A-PCP-E. The proximate module 
to the E domain is special as its C domain is specific for using a D-configured substrate. For this reason, 
this C domain is named as DCL domain in contrast to the conventional 
LDL domain.
84 Incorporation of D-
amino acids plays a role for the peptide’s metabolic stability, as proteases may not be able to cleave the 
backbone.85 Furthermore, the incorporation of non-proteinogenic building blocks contributes to the large 
structural diversity of NRPS-derived structures, and can contribute to special modes-of-action.86  
The biosynthetic potential of NRPS is further extended by special C domains (Cy or HC) that are able 
to cyclize serine, threonine and cysteine to 5-membered heterocycles. These heterocycles can be further 
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oxidized to form aromatic systems by additional oxidation domains (Ox), which are often found in Cy-
containing modules. Modifications like heterocyclization or cross-linking of side chains leads to increased 
rigidity and stability of NRPS metabolites, and heterocycles are important structural features for chelating 
metal ions or interacting with nucleotides.87 Release of PCP-bound intermediates is usually catalyzed by a 
terminal thioesterase (TE) domain, similar to that found in PKS systems. However, release mechanisms 
apart from typical TE domains are reported as well.88 After all, the different types of release mechanisms 
are the origin of a variety of structural features found in natural product. Depending on whether the 
NRPS template is released by hydrolysis, intramolecular cyclization, or reductive cleavage the resulting 
structural feature are lactames, lactones, free acids, imines, or aldehydes.79,88 
1.3.3 NRPS-PKS Hybrid Pathways 
Although NRPS and PKS use different monomeric substrates, their compatible mechanism of chain 
elongation using ppant-bound intermediates allows the evolution of hybrid systems. PCP and ACP 
domains have analogous functions but show rather low homology on protein level. Interestingly, their 
solvent structure is similar with the main difference being the surface charge, which is acidic for ACPs and 
less polar for PCPs.79,89 Notwithstanding these differences, true translational hybrids of PKS and NRPS 
have been known since 1999.90 The overall diversity of natural products is heavily expanded by this 
additional option of literally combining NRPS and PKS modules like building blocks. In light of the 
structures of PKS and NRPS complexes, this possibility is remarkable on first sight as PKS systems have 
been revealed to act as dimers, whereas the structure of NRPS megasynthases seems to be monomeric.91 
However, a homodimeric NRPS structure has been reported for VibF, a subunit of the vibriobactin 
cluster.92 These reports fuel speculation about the true NRPS quaternary structure and raise the question 
how PKS and NRPS modules can interact in terms of forwarding the PCP/ACP-bound templates at the 
interface. A recent study gives strong hints that the NRPS part of a NRPS-PKS hybrid is homodimeric, thus 
allowing a reasonable interaction with the homodimeric PKS part.93 In particular, the NMR-derived 
solution structure of the N-terminal docking domain from the NRPS module TubC (tubulysin) turned out 
to be a homodimer featuring a new type of protein fold amongst docking domains. It turned out that 
there are different types of docking domains between the different combinations of NRPS and PKS 
systems, which could reflect a separate evolutionary path for these systems.94 
1.3.4 Deviations from Textbook Biosynthetic Logic 
As increasing numbers of PKS and NRPS systems were characterized it became evident that many of 
these do not follow strict textbook biosynthetic logic, e.g. the co-linearity rule of modular extension.95,96 
Some of these deviations are also found in microsclerodermin biosynthesis which is topic of chapter 3 but 
also referred to in this chapter. A commonly observed exception is the iterative use of single modules in 
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PKS assembly lines, as found e.g. in the biosynthesis of stigmatellin or myxochromid.97,98 
Microsclerodermin biosynthesis features two iteratively acting PKS modules as can be seen in Figure 7 
(module 1 and 3). There is no hint on how to predict the frequency of iteration. Hence, such iterative type 
I PKS systems add another level of natural product diversity and complexity to PKS and PKS-NRPS hybrid 
systems.99 First direct evidence for an iteratively acting single module is reported for the natural product 
borellidin.100 Fortunately, it turned out that iteratively acting PKS modules can be distinguished from 
modular acting ones by alignment of the protein sequence of KS domains.101,102 Such in silico predictions 
help to characterize the modules of a given biosynthetic gene cluster in an early stage. In contrast to the 
repeated use of a module, module skipping or domain skipping is another observed deviation from 
textbook logic that was found in both, PKS and NRPS systems.103,104 In particular, skipping is also observed 
for the intact catalytic domains MscB and MscD of the microsclerodermin biosynthesis (Figure 7, module 
2 and 6). However, it is not evident that this is a real skipping as these intact modules are not 
translationally fused to the other modules. The exact mechanism on how the ppant-bound templates are 
forwarded under such conditions is not yet fully understood. One proven mechanism, at least, is the 
direct transfer from one ppant moiety to another.105 This is the most obvious and energetically favorable 
way as the thioester bond persists during the process. 
 
Figure 7: Modules and domains of the biosynthetic gene cluster responsible for microsclerodermin production in S. 
cellulosum So ce38. The cluster comprises several deviations from textbook biosynthetic logic for NRPS and PKS 
systems. 
Some PKS systems that were identified seemed to be incomplete since they lack an appropriate number 
of acyl transferases (AT).106,107 More precisely, there are PKS clusters with just one or two AT domains that 
hold responsible for furnishing the whole set of modules with monomers. Such clusters are called trans-
AT cluster as the AT domain can load all KS domains an thereby acts “in trans” in respect to the whole 
cluster.108 The expression cis-AT clusters, which would comprise typical PKS modules with the complete 
domain set to perform an elongation step, is rarely used. Evolution of PKS clusters apparently resulted in 
a PKS architecture (trans-AT) that is intrinsically different to the PKS textbook example (cis-AT). A 
phylogenetic analysis of KS domains of trans-AT and cis-AT clusters results in two distinct clades for both 
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types, indicating that both systems evolved independently from an ancient FAS system.109 Numerous 
clusters were characterized, which ultimately enabled a sequence-based analysis of trans-AT related KS 
domains and permitted the development of a predictive model for KS domain specificity.110,111  
In addition, some biosynthetic clusters contain additional enzymatic functions such as 
aminotransferases112,113, oxidases114,115, prenyltransferases116–118, or even enzymes of currently unknown 
effect, which further increase the variety of chemical entities that can be produced. Moreover, post-
assembly line modifications like sulfation or glycosylation were observed among secondary 
metabolites.119,120 Most of biosynthetic gene clusters reveal an uncommon architecture and/or functions. 
In light of this, it is quite obvious that there is still more variation to be observed in the future.  
1.4 Analytical Techniques for Natural Product Research 
Analytical techniques have always been of importance for natural product research. The advent of 
liquid chromatography and related separation techniques was a milestone for identification and 
purification of natural products out of crude biological extracts. Advances in these techniques in 
combination with the progress in the field of mass spectrometry and DNA sequencing opened up new 
possibilities of natural product research.121 Together with the growing number of available genomes and 
biosynthetic gene clusters, the basis for bioinformatic analysis increases and allows further optimization 
of the models behind bioinformatics predictions.  
1.4.1 Instrumental Analytics in Natural Product Research 
Steadily improving techniques in instrumental analytics play a tremendous role in identifying natural 
products.122 Modern LC-MS instrumentation has the potential to detect compounds that were missed 
before, e.g. such that previously evaded detection due to their weak UV absorbance. In line with this, 
many natural products discovered in the past show a characteristic UV/Vis absorption spectrum; a 
circumstance based on the fact that UV/Vis detectors were the matter of choice for a long time. 
Nowadays, mass spectrometric detection is improving the value of chromatographic data by adding 
highly resolved, accurate m/z information that supports the calculation of sum formula.123 Several types 
of mass spectrometers can combine wide dynamic range alongside with mass errors of around 1 ppm, 
e.g. FT-ion traps and modern time-of-flight machines. As a consequence, the problem of coeluting peaks 
is not that pronounced anymore as high resolution mass spectra allow identification of distinct 
compounds. At the same time chromatographic separation improved dramatically when stationary 
phases of the sub-2µm class were introduced to the HPLC market. Highly efficient separations of complex 
samples became achievable using very short run times. These advances set the stage for reliable chemical 
screening programs for small molecules, in particular secondary metabolites.  
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In a similar fashion, progress in proteomics helps to study biosynthetic processes using digested as 
well as intact proteins of biosynthetic pathways.124,125 Of special interest amongst the proteomics 
applications is the ppant ejection assay as introduced by the Kelleher group.126,127 This methodology 
opens up the possibility to identify ppant moieties that still harbor biosynthetic intermediates. In 
particular, the complete ppant moiety is dissociated from an intact protein or from a respective peptide 
after digestion. This was shown to be applicable very specific by means of infrared multiphoton 
dissociation (IRMPD). Aside of this important contribution to the field of biosynthesis research, 
measurement of ACP and PCP domains enabled monitoring of extender unit loading in vitro.128–130 For 
more aspects of proteomics-linked natural product research the reader is referred to review articles.124,125  
1.4.2 Genome Mining and in silico Analysis of Biosynthetic Gene Cluster 
A milestone in natural product research, especially for microbial secondary metabolites, was the 
access to whole genome sequences. Versatile high-throughput sequencing techniques recently reached 
an affordable cost level alongside with high speed and accuracy. The domains of PKS and NRPS clusters 
have a remarkable sequence similarity on protein level, which facilitates the in silico identification. 
Several bioinformatics tools emerged that take advantage of this circumstance to identify putative 
secondary metabolite cluster.131–133 The most convenient tool in this field is likely antiSMASH 2.0 which 
was made freely available in 2013.134 It offers automated genome-wide analysis of bacteria, fungi, and 
archaea for the presence of biosynthetic gene clusters, eventually creating annotated genomes. The 
genetic potential of an organism is thereby revealed within a short time, which allows numerous ways to 
proceed towards discovery of the metabolites connected to the predicted pathways, e.g. by mutagenesis, 
heterologous expression, regulation studies, or by proposals for the putative secondary metabolite 
structure derived from a given cluster.36 This knowledge allows focusing on clusters that feature 
uncommon enzymes or domain organizations as this may be a hint for new chemical moieties. With an 
organism that is amenable to genetic modifications, such “interesting” clusters should be preferably 
addressed when thinking about disrupting genes for functional characterization.  
Another important aspect deals with prediction of enzyme specificities amongst PKS and NRPS 
related domains. Biochemical studies and crystal structures of domains led to an understanding of the 
amino acid residues that govern the specificity or stereochemical course of single biosynthetic steps. A 
prominent example is the Stachelhaus code which comprises 10 amino acid residues in adenylation (A) 
domains responsible for the amino acid specificity of the A domain.80,135 This was further improved by 
Rausch et al. by taking an 8 Å space around the substrate into account.81 These findings enabled several 
bioinformatics tools to predict the A domain specificity,136,137 whereupon the NRPSpredictor2 is most 
widely used. The substrate prediction is however not equally accurate for the different substrates known 
so far. While cysteine incorporation is usually predicted without any doubt, prediction of some amino 
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acids such as tryptophan and lysine relies on an insufficient bioinformatics model.136 However, the 
prediction is usually successful to reveal certain substrate classes such as aliphatic side chains with H-
bond-donor, aromatic side chains, side chains with hydroxyl groups et cetera.  
Condensation and ketosynthase domains can be functionally assigned by using the NaPDoS tool in a 
convenient way.138 In NRPS systems, different types of C domains have been reported, e.g. C domains 
incorporating D-amino acids, cyclization domains, epimerization domains, and some mixed mode 
domains.81 Among the PKS, Ketosynthase (KS) domains are grouped into cis-acting, trans-acting, 
iteratively acting domains. Based solely on genome analysis it is also possible to distinguish a KS domain 
of a NRPS-PKS interface from a PKS-PKS interface. The specificity of trans-AT related KS domains is also 
matter of recent research.110,111 Other KS domains that are involved in special types of products are 
distinguishable as well, i.e. those involved in poly-unsaturated fatty acid and enediyne biosynthesis.96 
Furthermore, the configuration of the hydroxyl group that is created upon reduction of a polyketide 
extender unit by means of a ketoreduction domain (KR) is also predictable. Caffrey et al. proposed two 
types of KR domains.139 An A-type KR domain leads to a (S)-3-OH-intermediate and the B-type to an (R)-3-
OH-intermediate bound to the assembly line. The assigned stereochemistry implies that the priority of C2 
is higher than of C4. The main discriminant between both types is an conserved LDD motif, which is solely 
found in B-type domains.139 This model was further improved by Keatinge-Clay based on the crystal 
structure for both KR types.140 Interestingly, the stereogenic center at C3 does have an effect in the next 
reaction cycle when the DH domain eliminates water. Based on a crystal structure it is proposed that (S)-
3-OH-intermediates result in Z-configured double bonds.141 Unfortunately, there were not enough DH 
sequences available at the time of publication to fully prove this. Finally, reduction of the double bond by 
an enoyl reductase (ER) yields a fully reduced polyketide extender unit. The new stereogenic center, 
which is set upon enoyl reduction, can be predicted as well.142  
In conclusion, genome-related techniques are powerful in predicting secondary metabolite clusters 
together with the putative specificity of single domains and the stereochemistry of structural units. 
However, it should be clear that results are based on a statistical model derived from all the biosynthetic 
pathways known so far.  This implies that some models are still error-prone as they are based on an 
underrepresented set of references. On the contrary, other models such as those predicting A-domain 
specificities are already very good. Fortunately, the models will improve when more biosynthetic 
pathways are elucidated and published. After all, a full prediction of the compound’s structure that is 
derived from a biosynthetic pathway is not possible as genome mining tools are not able to predict 
whether a biosynthesis follows the co-linearity rule or whether unforeseen modifications of the 
compound take place. Hence, in silico techniques to predict secondary metabolites just based on a given 
genome are still error-prone although yet highly beneficial in the process of biosynthetic cluster 
characterization. 
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1.4.3 Secondary Metabolome Mining 
Mining the secondary metabolomes of microbial producer benefits from both, the instrumental 
advances of mass spectrometry, and the genome mining techniques by additionally combining them with 
bioinformatics tools.143 Secondary metabolomics is often divided in two fields, namely the targeted and 
the untargeted approach. A targeted approach aims towards identification of known secondary 
metabolites, also referred to as dereplication.144 Dereplication is of high importance when dealing with 
microbial extracts as chances are that different bacterial strains may produce the same metabolite. 
Obviously, isolation of already known compounds must be avoided to save time and resources, which are 
better invested when focusing on new chemical scaffolds. This was a very demoralizing insight in 
actinomycetes research where thousands of screened strains turned out to produce the same 
compounds and a plethora of strains had to be screened to finally find some new secondary 
metabolites.35  
Aside of a careful selection of the strains that are going to be screened, a proper dereplication 
process is key to success. A straight forward dereplication strategy is based on a standardized LC-MS 
screening platform with analytical information available for all known compounds. Samples of unknown 
composition (e.g. crude extracts prepared from new strains) are compared to the analytical reference like 
it is commonly done in pesticide analysis or forensics. A typical way to annotate known compounds 
within such a sample is based on retention time, accurate m/z, isotope pattern fit, and occasionally 
MS/MS data. The comparison of fragment spectra adds another level of confidence. A reliable 
dereplication is advantageous when a screening project aims towards identification of good producer 
strains for a distinct compound, such as reported by Krug et al. for a set of 98 different strains of 
Myxococcus xanthus.54 The targeted query amongst the strains allowed the comparison of production 
rates for cittilin A to eventually identify the best producer for further downstream processes.  
When searching for unknown compounds, the situation is more complicated. Especially when 
dealing with very complex crude extracts it is laborious to determine which signals in a LC-MS 
chromatogram are related to interesting compounds and which are simply components of the complex 
nutrition broth. With decreasing relative intensity of a signal of interest, identification of the respective 
signal gets more complicated. To overcome this problem, statistical tools such as multivariate analysis can 
be used to highlight differences between distinct sample groups. An interesting application of principal 
component analysis (PCA) is the analysis of knock-out mutants. After disrupting a biosynthetic gene 
cluster that is not linked to a known metabolite, it is easier to track the difference between a knock-out 
mutant and a wild type sample by statistical evaluation rather than by manual inspection.145,146 It was also 
shown that strain prioritization as well as sorting of strains according to their secondary metabolome is a 
suitable application for PCA. 147,148 It should be noted here, that such untargeted analyses request a 
suitable data processing prior to use in downstream tools. This is usually termed as feature extraction, 
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which is basically the very first step that aims to extract reasonable information out of raw data on the 
spectral level. In particular, all m/z values are checked for a chromatographic intensity change (i.e. 
resembling a peak) as only those m/z values are likely to represent a real compound eluting from the 
column. A feature is in terms of LC-MS analysis defined as the triad [m/z, retention time, intensity]. It 
represents the minimal information that is necessary to identify and quantify a compound in a LC-MS 
measurement. Features from several measurements can be further processed by time alignment or 
transformed using different mathematical operations.149–152 Data that is processed this way are subjected 
to multivariate analysis. In conclusion, multivariate analysis has the potential to highlight differences in 
secondary metabolome analyses. This is of special importance when changes are not obvious like often 
experienced for knock-out mutants or differences in regulation.153 
More specific approaches for the characterization of nonribosomal peptides were devised as well. In 
particular, the characteristic fragmentation of peptidic bonds enables a de novo sequencing strategy for 
cyclic NRPS. 154,155 However, this holds only true for NRPS compounds that are not highly modified and do 
not comprise too many structural features apart from NRPS units, i.e. PKS units, alkyl chains, 
glycosylations et cetera. Aside of these de novo sequencing techniques, Ibrahim et al. developed a library-
based screening that is capable of comparing MS/MS fragment spectra of NRPS to known NRPS fragment 
spectra, thereby adding another way of NRPS dereplication.156 Another promising approach is linking the 
genome mining information to mass spectrometric data. Information about a short sequence of amino 
acids within an unknown compound can facilitate the search for a set of NRPS modules within the 
respective genome, which encode the proper A-domains.49 A similar approach is applicable for 
glycosylations, although the identification of a glycosylation may be not that indicative for a natural 
product as it is just a post-assembly modification.157  
In conclusion, mass spectrometric analysis, genome mining, and bioinformatics initiated a new era of 
natural product discovery by combining the strengths of all methods. However, there are still more 
problems that need to be addressed and the methods mentioned herein are far from being easily 
applicable. It became clear that many of these methods rely on MS/MS data. Interestingly, acquisition of 
MS/MS spectra is still highly biased by the abundance of the secondary metabolites. A fact that is – to the 
best of my knowledge – not tackled in literature up to now. Chapter 4 of this thesis is basically trying to 
overcome this drawback by presenting a method that enables targeted MS/MS in an untargeted 
secondary metabolomics approach.  
  
 1.5  Outline of this Work 33 
 
1.5 Outline of this Work 
This thesis comprises several aspects of natural product research. The first part aims toward the 
discovery and characterization of new secondary metabolites using analytical techniques and methods of 
genome mining to fully characterize the biosynthetic machinery. Here, the work on pellasoren follows a 
more traditional “structure-first” approach of isolation and structure elucidation with subsequent 
characterization of the underlying biosynthesis. The work on microsclerodermin, a previously reported 
sponge metabolite, features a comprehensive review of this secondary metabolite and its biosynthesis 
with respect to different sources producing the same compound class thereby extending analysis to 
various myxobacterial producers. The second part of this thesis deals with the development of analytical 
methods, including the evaluation and improvement of a LC-MS system that is used for a large screening 
program together with the development of new methods for untargeted secondary metabolomics. 
The myxobacterial strain S. cellulosum So ce38 showed promising antimicrobial and cytotoxic activity 
which led to an in-depth analysis of its metabolite profile in order to find the new secondary metabolites 
responsible for this bioactivity. In the course of this screening a high abundant peak was identified as 
pellasoren, a myxobacterial compound previously reported from another S. cellulosum strain but at that 
time not fully characterized. Full structure elucidation of pellasoren was achieved by NMR and MS/MS 
analyses and the first insight into its biosynthesis was based on bioinformatic analyses of the So ce38 
genome. The assigned gene cluster was finally confirmed by creating a knock-out mutant which resulted 
in abolishment of pellasoren production. Pellasoren biosynthesis incorporates the rare extender unit 
methoxy-malonyl-CoA that gives rise to an enol ether moiety in the final structure. Interestingly, two 
slightly different pathways have been proposed for this precursor biogenesis and the genes involved in 
pellasoren biosynthesis combine aspects of both pathways. A detailed analysis of the biosynthetic 
domains predicted substrate specificities and stereochemical outcomes of each biosynthetic step. At the 
same time the total synthesis of this compound was accomplished in the group of Prof. Kalesse 
(Hannover, Germany), revealing that the in silico prediction for one stereochemical center was incorrect. 
This discrepancy underlined the importance of interdisciplinary approaches in natural product research. 
The work on microsclerodermin took advantage of a large-scale screening platform which allowed 
the analysis of approximately 2000 myxobacterial extracts aimed at identifying distinct compounds. Using 
this technology, the microsclerodermin compound class was identified in 16 different myxobacterial 
strains. Moreover, it was shown that the marine-derived metabolite microsclerodermin D is also 
produced by four different myxobacteria. Thus, microsclerodermin is one of the few examples where an 
identical natural product is derived from a marine and a terrestrial producer. The finding fueled 
speculation on whether production in the marine habitat is related to myxobacteria that exist in 
symbiosis with the sponges. This notion is in agreement with recent results from 16s rRNA analyses of 
sponge holobioms. In the course of this work, two groups of microsclerodermin producing myxobacteria 
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were identified comprising 12 and 4 members, respectively. Derivatives of both groups feature an 
identical core structure but differ in some structural moieties such as hydroxylation, methoxylation, 
halogenation, or overall length of the side chain. Whole genome sequencing of a representative of both 
groups provided access to two biosynthetic gene clusters. As a result, group-specific variations of the 
derivatives were linked to different tailoring enzymes found in both gene clusters. 
An additional major part of this work deals with an improved workflow for untargeted secondary 
metabolomics in natural product research. In particular, development was focused on a more reasonable 
selection of precursor ions for subsequent acquisition of fragment spectra. The latter is of interest as 
current developments of computational tools critically rely on fragment spectra for the classification of 
compounds based on calculated spectra similarities. In the approach taken here, statistical methods are 
used to create a precursor list reflecting the signals related to bacterial metabolism, thereby increasing 
the content of LC-MS/MS runs by forwarding only signals of potential interest to MS/MS analysis. This is 
contrary to classical auto-MS² approaches where precursors are usually selected based on signal 
intensity. As complex biological samples do frequently cover many signals, the most intense signals do 
not necessarily represent signals of interest. Hence, such a shot gun-like data acquisition is prone to a 
bias toward unwanted MS/MS scans while important signals may be missed. In line with this, the method 
described here achieves improved MS/MS scan coverage for precursor ions of low abundance that are 
usually not covered by an auto-MS² experiment. Performance evaluation and assessment of the above 
method including the effect of ion suppression in crude myxobacterial extracts are examined in order to 
quantify the effect of matrix components on the detection of known natural products in complex 
samples.  The newly established analytical method was successfully applied to identify the lipothiazole 
compound class in S. cellulosum So ceGT47. 
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2 Pellasoren 
2.1 Introduction 
Myxobacteria are efficient producers of numerous secondary metabolites, and the genus 
Sorangium is frequently described as an proficient source for new, biologically active natural 
products.[1-3] We report here the discovery and complete structure elucidation of pellasoren from the 
myxobacterium Sorangium cellulosum. Identification of the corresponding pel gene cluster from S. 
cellulosum So ce38 allowed us to establish a model for pellasoren biosynthesis, providing evidence for 
an unusual route to glycolate extender unit generation. Moreover, we present the first total synthesis of 
pellasoren and thereby confirm the absolute configuration of this natural product. 
2.2 Results and Discussion 
Pellasoren (1) was initially isolated from S. cellulosum So ce35 in the course of an activity-guided 
discovery program.[4] Additionally, we recently identified 1 in relatively high amounts in extracts from 
strain S. cellulosum So ce38 using LC-MS analysis. Here we determine its cytotoxicity against HCT-116 
human colon cancer cells at a concentration of 155 nM (IC50). Full structural elucidation by NMR and 
ESI-MS analysis was performed and confirmed the identity of pellasoren from both sources (Supporting 
Figures 1 to 3 and Table 1). 
 
Figure 1: Structure of pellasoren A (1a) and B (1b). 
The pellasoren scaffold features an unusual enol ether moiety, also known from a small number of 
other natural products, which was corroborated by specific HMBC correlations between a methoxy 
signal and sp2 hybridized carbon atoms (Supporting Figure 1).[5-7] The lactone moiety was identified 
through HMBC correlation between C1 and C5 and characteristic shifts for H-5 and C5 of 4.02 and 
90.3 ppm, respectively. The position of the amide bond was assigned on the basis of indicative 
fragments in CID spectra. Efforts were made to establish the molecule’s relative configuration by using 
NOE spectroscopy: ROESY interactions together with molecular modelling suggest an anti-configuration 
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of the substituents at C4 and C5, as well as a syn-configuration of the methyl groups at C2 and C4 
(Supporting Figure 2). The stereogenic centre at C14 maintains the configuration derived from the 
incorporation of an L-alanine building block during biosynthesis. Stereochemical assignments which 
could initially not be validated by NOE analysis, such as the configuration at C6, were later established 
following total synthesis (see below). Additionally, two isomeric pellasorens differing at the C10-C11 
double bond configuration were isolated from S. cellulosum extracts. Pellasoren A (1a) represents the 
(E)-C10-C11 configuration while the B derivative 1b has (Z)-C10-C11 configuration which can be 
rationalized by isomerization of the corresponding double bond. 
Following the structural elucidation of pellasoren, we set out to identify the underlying 
biosynthetic machinery using fragmentary whole-genome sequence information for strain S. cellulosum 
So ce38. Assuming that pellasoren is most likely the product of a hybrid PKS/NRPS biosynthetic 
pathway,[8] the full complement of putative PKR/NRPS-related domains encoded in the So ce38 
genome was annotated using bioinformatic tools.[9] Using the presumed incorporation of alanine into 
pellasoren as a guide, we identified a genomic region ~ 57,500 bp in size, containing seven characteristic 
PKS modules organized as an apparent operon which also encodes one adenylation (A) domain 
exhibiting the required predicted substrate specificity for alanine (Figure 2a). Insertion by single-
crossover homologous recombination of a plasmid conferring hygromycin resistance into module 7 led 
to the abolishment of pellasoren production and thus ultimately confirmed involvement of the pel locus 
in pellasoren biosynthesis (Supporting Figure 5). 
 According to common PKS- and NRPS biosynthetic logic, we reasoned that pellasoren formation 
starts with the condensation between an ACP-bound propionate and a rare glycolate-derived extender 
unit by module 1, followed by extension with alanine in module 2. Biosynthesis then continues via 
elongation with two methylmalonyl-CoA units (mM-CoA, modules 3 and 4), one malonyl-CoA (M-CoA, 
module 5) and another three mM-CoA extender units (modules 6 to 8), and finally the full-length 
intermediate undergoes lactone ring formation and is released by the terminal TE domain in module 8 
(Figure 2a). The order and function of domains encoded by genes pelA to pelF is pleasingly colinear with 
the proposed biosynthetic route. 
Furthermore, both the predicted substrate specificities of AT and A domains (Supporting Table 5 
and Figure 4) and the presence of KR, DH and ER domains necessary to achieve the appropriate 
reduction of extender units agree well with the pellasoren 1 scaffold. Modules 2 and 7 encode 
seemingly superfluous ketoreductase (PelA-KR2) and dehydratase domains (PelE-DH), respectively; 
however, these domains are likely inactive as judged on the basis of sequence analysis, revealing 
deviations inside otherwise highly conserved amino acid motifs (Supporting Tables 4 and 6). 
 
44 Pellasoren 
 
 
Figure 2: A) The pel biosynthetic gene cluster in Sorangium cellulosum So ce38 and the proposed biosynthetic route 
to pellasoren. B) Putative biosynthetic pathway to the glycolate extender unit, allowing for alternative loading of 
phosphoglycerate onto the PelG-ACP by PelK or PelG-AT. A: adenylation domain, ACP: acyl carrier protein, AT: 
acyltransferase domain, C: condensation domain, DH: dehydratase domain, ER: enoylreductase domain, KR: 
ketoreductase domain, KS: ketosynthase domain, TE: thioesterase domain. 
Pellasoren (1) features several chiral centres (C2, C4, C5, C6, C14) of which the configuration is set 
during its biosynthesis. The absence of an epimerization domain within the NRPS module 2 in PelA 
indicates an S-configured C14 for the alanine-derived building block. The configuration at C4 and C5 
results from extender unit reduction by PelE-KR in module 7, whereas stereocentres at C2 and C6 are 
generated by the ER domains PelD-ER (module 6) and PelF-ER (module 8, Figure 2a). All active KR 
domains are of B-type[10] which is in agreement with the 4R,5R configuration of pellasoren. Kwan et al. 
highlighted several key amino acid residues in ER domains which appear to exert a crucial influence on 
the stereochemical outcome of the reduction resulting in either 2R or 2S configuration of the 
intermediary building block.[11] A tryptophan residue at position 52 has been shown to direct the 
conformation to 2S, whereas absence of Trp52 favours the 2R conformation. In pellasoren biosynthesis, 
both ER domains should produce 2R centres since they lack Trp52. Nevertheless, they appear to 
establish converse stereogenic centres during biosynthesis: 2S (by PelD-ER) and 2R (by PelF-ER). The 
conflict between the bioinformatics prediction and the proposed NMR-based configuration of 
pellasoren (1) could only be solved by total synthesis of the NMR-based structure. We therefore decided 
to approach the synthesis of pellasoren A (1a). 
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Figure 3: Retrosynthetic analysis of pellasoren A. 
Our retrosynthetic analysis divides pellasoren into two key building blocks (2 and 3) which are 
supposed to be connected by an olefination reaction in order to install the sensitive triene at a late 
stage during the synthesis (Figure 3). In synthetic direction, the western fragment 2 is accessible by a 
sequence of eight steps, starting from L-alanine (9). The eastern fragment 3 contains the lactone subunit 
and it was planned to be generated by an intramolecular stereoselective protonation of an aldehyde-
derived enolate as the key step. This particular transformation takes advantage of conjugate reduction 
of an ,-unsaturated aldehyde by Stryker’s reagent[12] and its subsequent protonation through an 
internal alcohol.[13] The synthesis of the required enal 4 is achieved via vinylogous Mukaiyama aldol[14] 
reaction (VMAR) of the chiral vinylketene silyl N,O-acetal 5 an aldehyde 6 affording the anti aldol 
product 7 (Figure 4).  
 
Figure 4: Synthesis of aldehyde 3 and postulated mechanism of the stereoselective intramolecular protonation. 
a)TiCl4, CH2Cl2, –78 °C to –30 °C, 18 h, 61% (two steps), d.r. 17:1; b) LiBH4, THF, MeOH, 0 °C, 3 h, 90%; c) MnO2, 
CH2Cl2, RT, 2 h, quant.; d) Stryker’s reagent, benzene, RT, 15 h, 65%, d.r. 20:1; e) TPAP, NMO, MS 4 Å, CH2Cl2, RT, 
14 h, 90%; f) O3, CH2Cl2, –78 °C, 10 min, then PPh3, RT, 1 h, quant. Stryker’s reagent= [{(PPh3)CuH}6], TPAP
[15]
 = 
Tetrapropyl-ammonium perruthenate, NMO= N-Methylmorpholine-N-oxide, MS= molecular sieve. 
The western fragment 2 could be synthesized starting from Boc-protected amino alcohol 9 (Figure 
5). Swern[16] oxidation established the aldehyde functionality required for the following sequence of two 
olefination reactions. The first olefination yielded aldehyde 10 which was used in the next 
transformation to generate ester 11. The aldehydes were used immediately in the next steps to avoid 
racemization, yielding ester 11 in 80%ee. Liberating the amine with TFA/CH2Cl2 at 0 °C and peptide 
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coupling with acid 12 (generated from 2-oxovaleric acid in two steps[17]) gave access to compound 13. 
The synthesis continued by reducing the ester functionality of 13 to the alcohol which was submitted to 
an Appel reaction to provide corresponding bromide.[18] Reaction with tributylphosphine provided 
phosphoniumbromide 2 and completed the synthesis of this key building block.  
 
Figure 5: Synthesis of fragment 2. Reagents and conditions: a) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C to 0 °C, 2 h; b) 
Ph3P=C(CH3)CHO, toluene, 90 °C, 14 h, 65% (two steps); c) Ph3P=C(CH3)CO2Et, CH2Cl2, RT, 16 h, 85%, 80%ee
a
; d) TFA, 
CH2Cl2, 0 °C, 30 min; e) 12, EDC, HOBt, CH2Cl2, 0 °C, RT, 14 h, 82% (two steps); f) DiBAlH, CH2Cl2, –78 °C, 2 h, 87%; g) 
CBr4, PPh3, CH2Cl2, RT, 5 min, 76%; h) PBu3, MeCN, RT, 3 h, quant. TFA= Triflouroacetic acid, EDC= 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride, HOBt= 1-Hydroxybenzotriazole, DiBAlH= 
Diisobutylaluminiumhydride. 
a 
Determined by chiral GC. 
With both building blocks in hand we were able to complete the synthesis of pellasoren A (1a) by 
connecting both segments through an E-selective Wittig olefination between C8 and C9. Comparison of 
the 1H-NMR data of synthetic and authentic pellasoren confirmed the relative configuration of 
pellasoren as shown in structure 1a (see Supporting Information). Additionally, the two chromophores 
joined by carbon C14, should provide the desired CD data to distinguish between both enantiomers. In 
order to compare both isomers, additionally the unnatural diastereomer (14R)-pellasoren was 
synthesized following the same strategy as described for 1a. Gratifyingly, comparison of the NMR and 
CD spectra of pellasoren (1a), (14R)-pellasoren and the authentic sample validated the absolute and 
relative configuration of this natural product as shown for 1a (Figure 1). 
 
Figure 6: Completion of pellasoren (1a). Reagents and conditions: a) KOtBu, THF, –78 °C to RT, 15 h, 46%. 
Validation of the pellasoren configuration by total synthesis confirms the above-described 
deviations from bioinformatic analysis, and thus underpins the current limits of ER sequence-based 
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stereochemistry prediction. When seeking to improve bioinformatic tools, the pellasoren ER domains 
may provide a useful starting point for future biochemical and structural studies, as they show 92.4 % 
identity spanning 315 aa residues where Arg43 from PelF-ER is substituted to Leu43 in PelD-ER. We 
hypothesize here that Arg43 could be another important amino acid to govern the stereochemistry of 
the reduced extender unit. 
The genes involved in biosynthesis of the rarely observed glycolate extender unit are located 
upstream of pelA-F. Specifically, we propose that PelG to PelK generate the unusual "glycolate" extender 
unit believed to be incorporated by module 2, because these proteins show high similarity to proteins 
responsible for synthesis of glycolate precursors in the soraphen-, ansamitocin- and FK-520 pathways 
(Table 1). Unfortunately and despite serious efforts, our attempts to prove the gene cluster analysis 
based hypothesis by incorporation studies using isotopically labelled precursors and employing MS/MS 
analysis were not conclusive due to heavy metabolism of fed compounds (Supporting Figure 7).[7] 
However, the above mentioned similarity to known glycolate pathways strongly supports the 
biosynthesis as shown in Figure 2.  
Table 1: Comparison of proteins involved in biosynthesis of glycolate extender units. 
protein aa 
proposed function of the homologous 
protein 
identity/similarity to  
soraphen biosynthetic  
genes 
FK-520 
biosynthetic 
genes 
 
PelG 794 
Acyl transferase (28-355) 57/65 % (SorC - AT part) 18/26 % (FkbH)  
Ppant attachment site (427-480) 22/28 % (SorC - ACP part) 21/29 % (FkbJ)  
FkbM methyltransferase (589-744) 39/48 % (SorC - OMT part) 8/15 % (FkbG)  
PelH 283 Hydroxyacyl-CoA dehydrogenase 74/82 % (SorD) 36/51 % (FkbK)  
PelI 93 Acyl carrier protein 57/67 % (SorX) 27/44 % (FkbJ)  
PelJ 384 Acyl-CoA dehydrogenase  49/60 % (SorE) 33/48 % (FkbI)  
PelK 376 HAD superfamily phosphatase not present 41/57 % (FkbH)  
 
It is assumed that 1,3-bisphosphoglycerate is loaded to an ACP and according to soraphen 
biosynthesis, PelG-ACP binds 1,3-phosphoglycerate loaded by the PelG-AT domain. Methylation could 
then be catalysed by the internal SAM-dependent PelG-MT domain. These functions are usually 
facilitated by discrete proteins rather than a multifunctional protein. Moreover, the presence of the pelK 
gene is fairly unexpected. PelK shows homology to FkbH, a protein that is assumed to load 1,3-
bisphosphoglycerate to FkbJ in FK-520 pathway.[5] Since PelG-AT is supposed to catalyse this loading 
step during pellasoren biosynthesis, PelK seems to be redundant. The pel gene cluster actually 
represents the first finding with this specific gene arrangement. However, when speculating about a 
hypothetical function for PelK in pellasoren biosynthesis it has to be pointed out that the precise 
mechanism for loading of phosphoglycerate has to date not been experimentally proven for any of the 
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known biosynthetic pathways which employ glycolate extender units. Thus, the presence of two 
proteins potentially able to catalyse the same loading reaction in the pellasoren pathway raises more 
questions concerning the biosynthesis of this extender unit. The involvement of pelK in the latter using 
targeted inactivation is not straight-forward due to the pel operon organization, but will be the subject 
of future studies. 
Pellasoren A is cytotoxic against human colon cancer cells of the HCT-116 cell line with an IC50 of 
155 nM. Interestingly, pellasoren B is around one magnitude less active against HCT-116 with an IC50 of 
2.35 µM, emphasizing the importance of the linear nature of an all-(E)-configuration. Furthermore, both 
pellasorens show a strong effect on lysosomes. Upon incubation with osteosarcoma cells (U-2 OS) using 
an acridine orange assay, the pH of the lysosomes changed from acidic to neutral values (Supporting 
Figure 10). This is related to an apoptotic mechanism that remains elusive at the current state of 
research.[19] 
This report features a new cytotoxic compound from Sorangium cellulosum. We present the first 
total synthesis of pellasoren and thereby validated the molecule's stereochemistry. A Wittig reaction in 
the last step of the synthesis was used to install the sensitive polyene system. The key steps include a 
vinylogous Mukaiyama aldol reaction of a chiral vinylketene silyl N,O-acetal and a stereoselective 
intramolecular protonation, which was shown to be an efficient and practical protocol in natural 
products total syntheses for the first time. Identification of the biosynthetic machinery nicely 
complements this work by enabling bioinformatics and chemical analyses including an unusual pathway 
to the glycolate extender unit. 
2.3 Supporting Information 
2.3.1 Structure  
Pellasoren A and B are isobaric compounds having the same constitution and a sum formula of 
C26H41NO4. The corresponding [M+H]
+ ion is easily detectable by ESI-MS analysis at 432.31007 m/z 
(Δm/z = -1.7 ppm). The [M+H]+ ion fragments partially during the ESI process which results in the major 
fragment ion of 303.23008 m/z. The structure of pellasoren A was elucidated by NMR spectroscopy and 
high resolution MS/MSn analysis. The derivative pellasoren B differs by the 1H-NMR shifts of H-8, H-9, H-
11, and H-13 while coupling constants of H-9 and H-13 remained constant, indicating some changes in 
the double bond system. Same exact masses and identical fragmentation behavior of both compounds 
proved furthermore the conclusion of Z/E isomerism. Prolonged storage (2 weeks at room temperature) 
of pure pellasoren A or B samples leads to conversion between both constitutional isomers to end up 
with a mixture in both cases. A photochemical mechanism is the most reasonable explanation for this 
effect. 
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Supporting Table 1: NMR spectroscopic data of pellasoren A and B. NMR spectra for structure elucidation were 
recorded in MeOH-d4 at 700 MHz conducting an Ascend 700 using a cryogenically cooled triple resonance probe 
(Bruker Biospin, Rheinstetten, Germany). 
Position Pellasoren A     Pellasoren B   
  δH δC   δH δC 
1 - 
177.6 
(Cquat)  
- n.a. 
2 2.54 m 37.4 (CH) 
 
2.53 m 37.2 (CH) 
3a 1.39 m 38.6 (CH2) 
 
1.38 m 38.1 (CH2) 
3b 1.91 m 38.6 (CH2) 
 
1.94 m 38.1 (CH2) 
4 1.98 m 31.6 (CH) 
 
1.94 m 31.7 (CH) 
5 
4.02 dd (10.2, 
1.4) 
90.3 (CH) 
 
4.01 dd (10.5, 
1.4) 
90.0 (CH) 
6 1.92 m 36.1 (CH2) 
 
1.94 m 35.9 (CH2) 
7a 2.21 m 38.4 (CH2) 
 
2.19 m 38.3 (CH2) 
7b 2.30 m 38.4 (CH2) 
 
2.28 m 38.3 (CH2) 
8 
5.67 dt (15.6, 
7.3) 
128.5 (CH) 
 
5.74 dt (15.3, 7.4) 130.1 (CH) 
9 6.14 d (15.4) 138.7 (CH) 
 
6.6 d (15.5) 131.8 (CH) 
10 - 
135.4 
(Cquat)  
- n.a. 
11 5.81 s 134.1 (CH) 
 
5.74 s 132.2 (CH) 
12 - 
135.3 
(Cquat)  
- n.a. 
13 5.34 d (8.7) 132.7 (CH) 
 
5.28 d (8.6) 132.7 (CH) 
14 - 
150.2 
(Cquat)  
- n.a. 
15 4.86 44.8 (CH) 
 
4.59 44.6 (CH) 
16 - 
164.8 
(Cquat)  
- n.a. 
18 6.04 t (7.6) 126.1 (CH) 
 
6.05 t (7.7) 125.8 (CH) 
19 2.24 m 19.8 (CH2) 
 
2.24 m 19.5 (CH2) 
20 1.05 t (7.6) 13.9 (CH3) 
 
1.05 t (7.6) 13.8 (CH3) 
21 3.59 s 61.0 (CH3) 
 
3.60 s 60.8 (CH3) 
22 1.26 d (6.7) 21.5 (CH3) 
 
1.28 d (6.9) 21.2 (CH3) 
23 1.83 s 17.3 (CH3) 
 
1.79 s 17.3 (CH3) 
24 1.90 s 13.9 (CH3) 
 
1.86 s 21.2 (CH3) 
25 0.91 d (6.6) 12.6 (CH3) 
 
0.91 d (6.7) 12.2 (CH3) 
26 0.97 d (6.6) 17.4 (CH3) 
 
0.97 d (6.5) 17.3 (CH3) 
27 1.24 d (7.3) 17.6 (CH3)   1.23 (6.9) 17.1 (CH3) 
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Supporting Figure 1: HMBC (arrows) and 1H,1H-COSY (bold) correlations for pellasoren A. 
 
Supporting Figure 2: NOE correlations (arrows) as identified by ROESY. Model generated with Chem3D Pro 12.0 
running MM2 calculation to minimize energy. The bond angle H(5)-C(5)-C(6)-H(6) was fixed to 90° according to the 
very small coupling constant of 1.4 Hz between these two protons. 
 
Supporting Figure 3: Fragmentation pattern of pellasoren A with some of the fragment ions assigned. Collision 
induced dissociation of the [M+H]
+
 ion (upper part) and the main fragment 303.2301 m/z (lower part). The main 
fragment 303.2301 m/z is readily formed in the ESI process. Thus both fragmentations are in MS² stage for better 
S/N values in the resulting spectra. 
2.3.2 Analysis of the gene cluster in So ce38 
The pellasoren gene cluster sequence was deposited in the EMBL database with the accession no 
HE616533. The region of interest as well as 20 kb flanking region on both sides was searched for open 
reading frames (ORFs) using Glimmer 3.0 and subsequently subjected to an automatic annotation by the 
CLUSEAN software tool[1;2]. The pel locus is 57,502 bp in size and covers eight modules within the genes 
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pelA to pelK with a GC content of 72.1 %. An ABC transporter gene is located at the very beginning of the 
cluster. 
Supporting Table 2: Genes involved in pellasoren biosynthesis as annotated in the cluster of the Sorangium 
cellulosum So ce38 genome. 
Gene Start End  Length Function  
pelT 1478 3736 2259 ABC transporter  
pelG 4808 7192 2385 AT-ACP-MT  
pelH 7189 8040 852 3-OH-acyl-CoA-dehydrogenase  
pelI 8044 8325 282 ACP  
pelJ 8375 9529 1155 Acyl-CoA-dehydrogenase  
pelK 9581 10711 1131 AT functionality  
pelA 10735 22728 11994 ACP-KS-AT-AT-DH-KR-ACP-C-A-KR-PCP  
pelB 22730 28303 5574 KS-AT-DH-KR-ACP  
pelC 28317 33929 5613 KS-AT-DH-KR-ACP  
pelD 33926 45976 12051 KS-AT-DH-KR-ACP-KS-AT-DH-ER-KR-ACP  
pelE 45973 51621 5649 KS-AT-DH-KR-ACP  
pelF 51618 58979 7362 KS-AT-DH-ER-KR-ACP  
 
Supporting Table 3: Proteins involved in pellasoren biosynthesis in the strain Sorangium cellulosum So ce38. 
NRPS/PKS part of the S. cellulosum so ce38 pellasoren biosynthetic machinery 
Protein aa Protein domains and their position in the sequence[1] 
PelA 3997 
NRPS/PKS: ACP' (9-74), KS (97-521), ATL (618-911), AT (1059-1354), DH (1421-1591), KR' (1954-
2131), ACP'' (2233-2299), C (2393-2831), A (2836-3352), KR'' (3607-3784) 
PelB 1857 PKS: KS (34-451), AT (556-851), DH (921-1091), KR (1454-1631), ACP (1734-1799) 
PelC 1870 PKS: KS (36-454), AT (562-857), DH (925-1096), KR (1469-1646), ACP (1749-1814) 
PelD 4016 
PKS: KS' (38-456), AT' (563-858), DH' (920-1089), KR' (1436-1613), ACP' (1716-1782), KS'' (1809-
2183), AT'' (2339-2637), DH'' (2705-2875), ER (3256-3571), KR'' (3596-3772), ACP'' (3875-3940) 
PelE 1882 PKS: KS (25-443), AT (550-845), DH (914-1082), KR (1470-1647), ACP (1753-1818) 
PelF 2453 
PKS: KS (39-459), AT (566-861), DH (930-1100), ER (1477-1791), KR (1817-1993), ACP (2095-2161), 
TE (2208-2439) 
     
Non-NRPS/PKS proteins of the So ce38 pellasoren biosynthetic machinery (putative conserved domains) 
Protein aa 
Proposed function of the homologous 
protein 
Identity/similarity to 
soraphen biosynthesis 
Identity/similarity to 
FK-520 biosynthesis 
PelG 794 
Acyl transferase (28-355) 57/65 % (SorC - AT part) 18/26 % (FkbH) 
Phosphopantetheine attachment site (427-
480) 
22/28 % (SorC - ACP part) 21/29 % (FkbJ) 
FkbM methyltransferase family (589-744) 39/48 % (SorC - OMT part) 22/32 % (FkbM) 
PelH 283 Hydroxyacyl-CoA dehydrogenase 74/82 % (SorD) 36/51 % (FkbK) 
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PelI 93 Acyl carrier protein 57/67 % (SorX) 27/44 % (FkbJ) 
PelJ 384 Acyl-CoA dehydrogenase  49/60 % (SorE) 33/48 % (FkbI) 
PelK 376 HAD superfamily phosphatase 
not present in 
 soraphen cluster 
41/57 % (FkbH) 
[1] A: adenylation domain, AT: acyltransferase, C: condensation domain, DH: dehydratase, ER: enoylreductase, KR: 
ketoreductase, KS: ketosynthase, TE: thioesterase. 
 DH domains 2.3.2.1
According to the structur of pellasoren we can conclude that PelE-DH is an inactive domain. Within 
the consensus sequence of PelE-DH we observed two substitutions compared to the other DH domains, 
more precisely Arg38 and an Asp42 are substituted by alanine (Supp. Table 4). This replacement leads 
obviously to a change in local charge distribution within the consensus region and thus to the 
inactivation of the domain.  
Supporting Table 4: Active site analysis of the dehydratase domains (DH) involved in pellasoren biosynthesis.  
Consensus L x x H x x x G x x x x P  
PelA-DH L S D H R V Q G E V V F P  
PelB-DH L A D H R V Q G E V V F P  
PelC-DH L A D H R V L G E V V F P  
PelD-DH1 L A D H R V Q G E M V F P  
PelD-DH2 L S D H R V Q G E V V F P  
PelE-DH* L K D H A V Q G A V L F P  
PelF-DH L A D H R V F G E V V M P  
 
 AT domains 2.3.2.2
Substrate specificity of acyl transferase (AT) domains was identified by conserved site analysis by 
aligning the AT domains to a reference AT from E.coli FAS, 1MLA (PDB 1MLA, UniProtKB P0AAI9). The 
main discriminant between loading of a methylmalonyl-CoA (mm-CoA) or malonyl-CoA (m-CoA) is the 
amino acid position 200 in 1MLA, whereas Ser200 supports mm-CoA and Phe200 supports m-CoA. The 
AT specificity is correct for the standard AT domains while the loading domain PelA-AT1 and PelA-AT2 
(methoxymalonyl) were wrongly assigned, just as expected. The starter unit in pellasoren biosynthesis is 
a propionate although genetic analysis of PelA-AT1 predicts an arginine at position 117 of the AT domain 
(Supp. Table 5). Yadav et.al. draw the conclusion that Arg117 is a highly conserved amino acid involved 
in the discrimination between mono- and dicarboxylic acid substrates.[3] This circumstance may lead to 
the assumption that PelA-AT1 loads a methylmalonyl-CoA to the ACP domain which is then 
decarboxylated by the first KS, PelA-KS1, resulting in a propionate bound to the ACP. On the contrary, 
such a biosynthetic pathway would need another KS domain within module PelA catalyzing the claisen 
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condensation instead. This is not the case; hence, the selectivity for monocarboxylic extender/starter 
units of AT domains is not solely governed by the absence of an Arg117.  
Supporting Table 5: Active site analysis of the acyl transferase domains (AT) according to Yadav et.al.
[3]
 
Domain observed predicted 11 63 90 91 92 93 94 117 200 201 231 250 255 15 58 59 60 61 62 70 72 197 198 199 
PelA-AT1 propionate - Q Q G Q S M G R S H T N V W D T A R I Q A D Y A 
PelA-AT2 MeO-M MM Q Q G H S M G R S H T N V W E I D V A E A D V A 
PelB-AT MM MM Q Q G H S M G R S H T N V W A I D V V E A D V A 
PelC-AT MM MM Q Q G H S M G R S H T N V W E I D V V E A D V A 
PelD-AT1 M M Q Q G H S V G R F H T N V W E T I V A E A N Y A 
PelD-AT2 MM MM Q Q G H S M G R S H T N V W E I D V V E G D V A 
PelE-AT MM MM Q Q G H S M G R S H T N V W E I D V V E G D V A 
PelF-AT MM MM Q Q G H S M G R S H T N V W E I D V V E G D V A 
 
 KR domains 2.3.2.3
The KR domain of module 7, PelE-KR, is responsible for the stereochemistry at C4 and C5. An 
alignment of KR domains allows no obvious discrimination between A- and B-type domains (Supp. Table 
6).[4] The conformation as generated during biosynthesis is 2R,3R and thereby indicates a B1-type 
domain (Figure 2a, module 7). However, the conserved LDD motif of B-domains is substituted by an FDN 
motif in PelE-KR[5]. This finding shows that the three amino acid motif is again just a rule of thumb when 
discriminating A- and B-type KR domains.  
Supporting Table 6: (a) Active site analysis of the ketoreductase domains (KR) involved in pellasoren biosynthesis. 
(b) Discrimination between A- and B-type KR domains according to Caffrey et.al. (2003).
[5]
 The LDD sequence in 
motif I is an indicator for B-type KR domains while Pro144 and Asn148 are conserved in motif II.
[4;5]
  
active consensus G x G x x G x x x A  
Pel-KR1 G L G G L G I A L A  
Pel-KR2 G L G R L G L A L S  
Pel-KR3 G L G G L G L S L A  
Pel-KR4 G L G G L G L S L A  
Pel-KR5 G L G A L G L R V A  
Pel-KR6 G L G G L G L S L A  
Pel-KR7 G L G G L G L T V A  
Pel-KR8 G L G G L G L S L A  
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 region 88 - 103  region 134 -  149  
Pel-KR1 H A A A V L D D H T L L E L D E 
 
Y S S A L S L F G S P G Q A N Y  
Pel-KR2* H A A G V A D D H P L L D L D E 
 
C S S S A S L F G A P G E A S S  
Pel-KR3 H A A A V L D D H T L L E Q S E 
 
Y S S G A S L F G S P G Q G N Y  
Pel-KR4 H A A A V L D D H T L L E Q S E 
 
Y S S A S A L F G A P G Q G N Y  
Pel-KR5 H A A G V L D D G V L V E Q S A 
 
F S S L S S V L G S G G Q G N Y  
Pel-KR6 H A A A V L D D H T L L E Q S E 
 
Y S S A A S L F G S P G Q G N Y  
Pel-KR7 H T A V N F D N H P V L G L S E 
 
Y S S V S V L L G L P G L G N Y  
Pel-KR8 H A A A V L D D H T L L E Q S E 
 
Y S S A S A L F G S P G Q G N Y  
 
 ER domains 2.3.2.4
 Kwan et.al. proposed the responsible amino acid motif in an enoyl reductase’s active site.[6] Kwan 
states several key residues to be representative when trying to discriminate between 2R and 2S 
stereocenters. The active site was identified by aligning both ER domains to the E.coli quinone 
oxidoreductase (PDB 1QOR, UniProtKB 28304) which holds a tryptophan at position 52 that directs the 
conformation to 2S, whereas absence of Trp52 favors 2R conformation (Supp. Table 7). Pellasoren 
biosynthesis is not following this rule of thumb. Moreover, PelD-ER and PelF-ER, both with Leu52 lead to 
the synthesis of a 2S (PelD-ER) and a 2R (PelF-ER) stereocenter, respectively. Both ER show 92.4 % 
identity within 315 aa while Arg43 is substituted to Leu43 for PelD-ER within the consensus sequence. 
Up to now, the amino acid at position 43 was not shown to be important although this result speaks for 
a certain influence. 
Supporting Table 7: Active site analysis of the enoyl reductase domains (ER) by comparison to ER domains of 
known stereoselectivity.
[6]
 The second to last amino acid of the consensus is putatively directing the 
stereochemistry of the sp³ carbon atom during reduction. Tryptophan at this position favors a 2S-configured 
product. The E.coli quinone oxidoreductase (PDB 1QOR, UniProtKB 28304) was used as alignment outgroup 
according to Kwan et.al.
[6]
 
Consensus G X X F X43 D X L X X X X X X52 X  
PelD-ER (2S) G L N F L D V L L A L G M L P  
PelF-ER (2R) G L N F R D V L L A L G V L P  
Nan_ER_4_2S G I N F R D V L I V L G M Y P  
Nig_ER_2_2S G V N F R D A L I V L G M Y P  
Mer_ER_6_2S G V N F R D V L L A L G M Y P  
Nan_ER_2_2S G L N F R D A L I A L D M Y P  
Mon_ER_4_2S G M N F R D V L I A L G M Y P  
Ole_ER_4_2S G V N F R D V L L A L G M Y P  
Fkb_ER_6_2S G L N F R D V L I A L G T Y P  
Rap_ER_7_2S G L N F R D V L I A L G T Y P  
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Nan_ER_14_2S G V N F R D V L I A L G M Y P  
Fkb_ER_7_2S G L N F R D V L I A L G T Y T  
Tyl_ER_5_2S G V N F R D A L I A L G M Y P  
Hbm_ER_2_2S G Q N F R D V L I A L G M Y E  
Myc_ER_5_2S G L I F R D T L I A L G V Y P  
mon_ER_2_2S G V N F R D V L I A L G M Y P  
Rap_ER_3_2S G L N F R D V L I A L G T Y P  
Ery_ER_4_2S G V N F R D V L L A L G M Y P  
Pik_ER_4_2S G L N F R D V L I A L G M Y P  
Tmc_ER_6_2S G L N F R D V L N A L G M Y P  
Nig_ER_4_2S G M N F R D A L I A V G M Y P  
Gdm_ER_2_2S G Q N F R D V L I A L G M Y E  
Meg_ER_4_2S G V N F R D V L L A L G M Y P  
Chm_ER_5_2S G L N F R D T L I A L G M Y P  
 
 Adenylation Domain Specifictiy 2.3.2.5
 
Supporting Figure 4: Output of A-domain specificity prediction using antiSMASH.
[7]
 The results clearly indicate 
specificity for alanine. 
2.3.3 Knockout of pellasoren production in So ce38 
Genetic modification of the So ce38 strain was accomplished according to a previously described 
protocol.[8] Putative single cross-over knockout mutants were grown in M-Medium (1 % papaic digest of 
soybean meal, 1 % maltose, 0.1 % CaCl2 ·2 H2O, 0.1 % MgSO4·7H2O, 8 mg/l FeEDTA, 50 mM HEPES, 
adjusted to pH 7.2 using 10N KOH) supplemented with hygromycin (100 µg/ml) and 1% adsorber resin 
56 Pellasoren 
 
(XAD-16, Rohm & Haas) for at least 5 days at 180 rpm and 30°C. Methanolic extracts of the XAD resin 
were analyzed by LC-MS and compared with WT extracts. For isolation of chromosomal DNA the mutant 
strain was grown in M-medium containing hygromycin. The integration of the plasmid at the right 
position in the genome was verified by PCR as shown in figure 4 in which mutant and wild-type DNA 
were used as template.  
Supporting Table 8: Primers used for amplification and verification of the pellasoren knock-out mutant in 
Sorangium cellulosum So ce38. 
oligonucleotide sequence 5`-3`  
pelAT7_fwd GGC GAT CCC GAA GAA CCT GCA  
pelAT7_rev ACT CGC CCT CGC GGA GGT TCT  
pSUPHyg_fwd ATG TAG CAC CTG AAG TCA GCC  
pSUPHyg_rev ACG CAT ATA GCG CTA GCA GC  
pelAT7_check_up TCT TCG ATC CAG TAC CGC TC  
pelAT7_check_down ACA TCG GGT ACG TGG AGA CG  
 
 
Supporting Figure 5: Verification of KO-mutant by PCR and due to abolishment of pellasoren production as 
detected by LC-MS analysis of WT and mutant. 
2.3.4 Isolation 
Pellasoren was produced by the Sorangium cellulosum strain So ce38 in shaking flask cultures using 
M medium (10 g/l soy peptone, 10 g/l maltose, 1 g/l CaCl2*2H2O, 1 g/l MgSO4*7H2O, 11.9 g/l HEPES, 8 
mg/l NaFeEDTA, adjusted to pH 7.2 using 10 N KOH). Six liters (distributed over three 5 l flasks) of M-
Medium were inoculated with 600 ml of a 7-day-old So ce38 culture. After four days of incubation, 80 ml 
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of aqueous adsorber resin slurry (Amberlite XAD-16, 50 % (w/v)) were added to each flask. Incubation at 
30° C and 150 rpm was maintained for another ten days. The cultivation broth was centrifuged at 
6000 x g to separate the XAD from liquid medium and cells. 120 g XAD was washed with 2 x 500 ml of 
ethyl acetate followed by 2 x 500 ml of methanol/chloroform (50:50 v/v) to obtain extracts that are both 
equally rich in pellasoren. Extracts were combined to give 5.31 g crude extract. The dry extract was 
purified using silica chromatography. The column was packed with hexane and elution of pellasoren was 
achieved using 400 ml hexane followed by 2 l of CHCl3/MeOH (95:05). The fraction of interest eluted 
within the early second elution step. After evaporating to dryness 366 mg of pellasoren crude extract 
was obtained. After dilution in 2 ml of methanol the dissolved sample was centrifuged and the 
supernatant applied to preparative HPLC. Preparative HPLC was performed with a Waters Autopurifier 
system equipped with a Waters XBridge C18 150 x 19 mm, 5 µm dp column running at 25 ml/min flow 
rate using (A) water + 0.1 % FA and (B) methanol + 0.1 % FA as solvent system. Separation of a 300 µl 
injection was done under isocratic conditions at 73 % B within 16 min. Fraction collection was triggered 
by a mass trigger set to 432.2 m/z, resulting in collection of two peaks. Corresponding fractions of seven 
consecutive runs were combined and evaporated to dryness. Pellasoren A (1a) eluted at 8.0 min and 
yielded 13.8 mg. Pellasoren B (1b) eluted at 10.2 min and yielded 9.0 mg. 
2.3.5 HPLC-MS analysis 
All measurements were performed on an Ultimate 3000 RSLC system (Dionex, Germering, 
Germany) using a Waters BEH C18, 100 x 2.1 mm, 1.7 µm dp column. Two µl of methanolic sample was 
injected. Separation was achieved by a linear gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a 
flow rate of 550 µl/min and 45 °C. The gradient was initiated by a 0.39 min isocratic step at 5 % B 
followed by an increase to 95 % B in 18 min to end up with a 1.60 min flush step at 95 % 
B before reequilibration using the initial conditions.  Coupling the HPLC to a MS was supported by an 
Advion Triversa Nanomate nano-ESI system attached to an Orbitrap (ThermoFisher, Schwerte, 
Germany). Mass spectra were acquired in centroid mode ranging from 200 – 2000 m/z at a resolution of 
R = 30000 using positive electrospray ionization. Alternatively, the same HPLC setup was hyphenated to 
a maXis time-of-flight mass spectrometer (Bruker Daltonics, Bremen, Germany) using a mass range from 
150 – 2000 m/z with positive electrospray ionization. 
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Supporting Figure 6: Pellasoren production compared to cell growth. Growth state is represented by OD600 values. 
Amount of pellasoren is a relative value according to the peak height observed in HPLC-MS analysis. 
2.3.6 Feeding with labeled precursor 
25 ml of M medium was inoculated with 2.5 ml so ce38 culture (OD600,init = 0.3) and incubated at 30 
°C and 140 rpm using a 100 ml shaking flask. After two days of incubation, 0.5 ml of aqueous adsorber 
resin slurry (Amberlite XAD-16, 50 % (w/v)) was added. Labeled precursor was dissolved in 4 ml water, 
sterile filtered, and added over 4 days to end up with a final concentration of 2 mM 13C-glycerol or 20 
mM 13C-acetate, respectively. The culture was incubated for 6 days (OD600 = 2.7) before extraction of the 
XAD resin. A reference culture was prepared the same way. Figure 7 indicates the use of labeled 
precursor in primary metabolism since we observe M+1 enrichments although doubly labeled 
precursors were fed.  
 
Supporting Figure 7: Isotopic distribution of natural (upper part), glycerol-fed (middle part), and acetate-fed 
pellasoren (lower part). The glycerol-fed pellasoren is enriched in the M+1 isotope as well. A strict incorporation as 
glycerate cannot be proven from these patterns. 
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2.3.7 Cytotoxicity Assay 
Human HCT-116 colon carcinoma cells were seeded at 6 x 103 cells per well of 96-well plates 
(Corning CellBind) in 180 μl complete medium (McCoys5A /10% FBS) and directly treated with varying 
concentrations of pellasoren diluted in methanol. Each derivative was tested in duplicate as well as the 
internal methanol control. After 5 d incubation, 20 μl of 5 mg/ml MTT (Thiazolyl blue tetrazolium 
bromide) in PBS was added per well and it was further incubated for 2 h at 37 °C. The medium was then 
discarded and cells washed with 100 μl PBS before adding 100 μl 2-propanol/10 N HCl (250:1 v/v) in 
order to dissolve formazan granules. The absorbance at 570 nm was measured using a microplate 
reader (EL808, Bio-Tek Instruments Inc.) and cell viability was expressed as percentage relative to the 
respective methanol control. 
 
Supporting Figure 8: Cytotoxicity assay using HCT-116 cells.  
  
Supporting Figure 9: Effect of pellasoren on U-2OS cells in an acridine orange assay. The acidic compartments 
(lysosomes) result in an orange fluorescence of the dye whereas neutral pH gives green fluorescence. Incubation 
with pellasoren shows an evident effect on lysosomes.  
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2.3.8 Synthetic procedures: 
All non-aqueous reactions were carried out using flame-dried glassware under argon atmosphere. 
Solvents for non-aqueous reactions were dried as follows prior to use: THF was distilled from 
sodium/benzophenone, CH2Cl2 was distilled from CaH2. All commercially available reagents and 
reactants were used without purification unless otherwise noted. Reactions were monitored by thin 
layer chromatography (TLC) using Merck Silica Gel 60 F245-plates and visualized by fluorescence under 
UV-light. In addition, TLC-plates were stained using a cerium sulfate/phosphomolybdic acid or KMnO4 
stain. Chromatographic purification of products was performed on Merck Silica Gel 60 (40-60 µm) using 
a forced flow of eluents. NMR-spectra were recorded on a Bruker AVS-400 or RX500 at room 
temperature. Chemical shifts are reported in ppm with the solvent resonance as internal standard. Data 
are reported as follows:   s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad signal. 
High–resolution mass spectra using electrospray ionization (ESI-hrMS) were recorded with a Waters 
Micromass LCT spectrometer with a Lock-Spray unit. Optical rotations [α] were measured on a 
Polarimeter 341 (Perkin Elmer) at a wavelength of 589 nm and are given in 10-1 deg cm2 g-1. Chiral GC 
experiments were carried out on a HP 5890-II device (Hewlett-Packard) with a flame ionisation detector 
and hydrogen as carrier gas in constant flow modus. A Hydrodex-® PM capillary column (50 m, 0.25 
mm, 723370, Macherey-Nagel) was used for separation of enantiomers. 
 
• Ester 14 
 
To a solution of Boc-L-alanine (5.00 g, 26.4 mmol) in DMF (40 mL), Na2CO3 (6.05 g, 57.1 mmol) and 
methyl iodide (7.00 mL, 1.12 mmol) were added. The solution was stirred for 15 h and diluted with 
EtOAc (20 mL). The organic layer was washed with water (30 mL) and brine (30 mL), dried over MgSO4 
and concentrated in vacuo. The residue was used directly in the next steps without further purification. 
Ester 14 (4.62 g, 22.7 mmol, 99%) was obtained as white solid. 1H-NMR (400 MHz, CDCl3) δ 5.01 (s, 1H), 
4.29-4.26 (m, 1H), 3.70 (s, 3H), 1.40 (s, 9H), 1.34 (d, J = 7.2 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 173.8, 
155.1, 79.8, 52.3, 49.1, 28.3, 18.6; HRMS (ESI): calculated for C9H17NO4Na 226.1055, found 226.1055; 
[α]20589:   –3.8 (c 1.0, CHCl3).
  
 
  
  5.1 Predicting Secondary Metabolite Structures 61 
 
• Alcohol 9 
 
LiAlH4 (1.13 g, 30.0 mmol) in THF (50 mL) was cooled to 0 °C. To this suspension, ester 14 (4.06 g, 
20.0 mmol) in THF (5 mL) was added. The solution was stirred for 30 min, warmed to room temperature 
and stirred for additional 10 min. The mixture was quenched with water (2.80 mL), NaOH (2.80 mL, 
2 mol/L) was added and the solution was stirred for 15 min. MgSO4 was added, the solution was filtered 
and concentrated under reduced pressure. The residue was purified by flash chromatography (PE/EtOAc 
3:1) and alcohol 9 (2.87 g, 16.4 mmol, 82%) was obtained as white crystals. 1H-NMR (400 MHz, CDCl3) δ 
4.71-4.65 (m, 1H), 3.75 (br. s, 1H), 3.62 (dd, J = 10.9, 3.8 Hz, 1H), 3.49 (dd, J = 10.9, 6.2 Hz, 1H), 2.59 (br. 
s, 1H), 1.43 (s, 9H), 1.13 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 156.3, 79.7, 67.3, 48.6, 28.4, 
17.3; HRMS (ESI): calculated for C8H17NO3Na 198.1106, found 198.1104; [α]
20
589: –9.6 (c 1.0, CHCl3). 
 
• Aldehyde 15  
 
(COCl)2 (1.70 mL, 19.5 mmol) in CH2Cl2 (42 mL) was cooled to –78 °C and DMSO (2.20 g, 30.2 mmol) 
was added. After 15 min, alcohol 9 (2.66 g, 15.4 mmol) in CH2Cl2 (16.5 mL) was added and the mixture 
was stirred for 30 min. NEt3 (10.5 mL, 75.7 mmol) was added dropwise and after 15 min at    –78 °C, the 
solution was warmed to 0 °C and stirred for 30 min. The reaction mixture was diluted with water (20 mL) 
and layers were separated. After extraction with CH2Cl2 (2x 20 mL) the organic layer was washed with 
HCl (2x 30 mL, 2 mol/L) and sat. NaHCO3 (30 mL). The solution was dried over MgSO4, filtered and 
evaporated. The crude aldehyde was used directly in the next step. 1H-NMR (400 MHz, CDCl3) δ 9.53 (s, 
1H) 5.15 (s, 1H), 4.21-4.18 (m, 1H), 1.42 (s, 9H), 1.30 (d, J = 7.3 Hz, 3H), 13C-NMR (100 MHz, CDCl3) δ 
199.8, 155.3, 80.0, 55.5, 28.2, 14.7; HRMS (ESI): calculated for C8H15NO3Na 196.0950, found 196.0951; 
[α]20589: +40.8 (c 1.0, CHCl3). 
 
• Aldehyde 10  
 
To a solution of aldehyde 15 (125 mg, 0.731 mmol) in toluene (5 mL) was added 2-
(triphenylphosphoranylidene)propanal (580 mg, 1.82 mmol) and the solution was stirred at 90 °C 
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overnight. The solution was diluted with PE (5 mL), filtered and evaporated. The residue was purified by 
flash chromatography (PE/EtOAc 3:1) and the product 10 (100 mg, 469 mmol, 65% over 2 steps) was 
obtained as white solid. 1H-NMR (400 MHz, CDCl3) δ 9.39 (s, 1H) 6.25 (dd, J = 8.3, 1.3 Hz, 1H), 4.66 (br. 
s/m, 2H), 1.81 (s, 3H), 1.42 (s, 9H), 1.27 (d, J = 6.6 Hz, 3H), 13C-NMR (100 MHz, CDCl3) δ 195.0, 155.0, 
154.5, 144.8, 79.9, 28.3, 20.3, 9.2; HRMS (ESI): calculated for C11H19NO3Na 236.1263, found 236.1263; 
[α]20589: +9.6 (c 1.0, CHCl3). 
 
• Ester 11  
 
Aldehyde 10 (639 mg, 3.00 mmol) was solved in CH2Cl2 (12 mL) and ethyl 2-
(triphenylphosphoranylidene)propanoate (2.31 g, 6.31 mmol) was added. The solution was stirred at 
room temperature overnight. PE (10 mL) was added, the resulting yellow solid was filtered, the solution 
was evaporated and the residue was purified by flash chromatography (PE/EtOAc 5:1). Ester 11 
(758.3 mg, 2.55 mmol, 85%) was obtained as white solid. The enantiomeric excess was determined to be 
80% ee by chiral GC using Hydrodex®-PM capillary column (120-200 °C, 0.5 °C/min) by comparison of the 
peaks at 84.1 min and 84.7 min.  1H-NMR (400 MHz, CDCl3) δ 7.06 (s, 1H) 5.36 (d, J = 7.9 Hz, 1H), 4.47 
(br. s/m, 2H), 4.20 (q, J = 7.1 Hz, 2H), 1.98 (s, 3H), 1.89 (s, 3H), 1.44 (s, 9H), 1.30 (t, J = 7.1 Hz, 3H), 1.21 
(d, J = 6.1 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 168.8, 154.9, 141.9, 136.6, 126.9, 121.1, 79.4 60.7, 44.7, 
28.4, 21.4, 16.6, 14.3, 14.0; HRMS (ESI): calculated for C16H27NO4Na 320.1838, found 320.1834; [α]
20
589: -
30.2 (c 1.0, CHCl3). 
 
• Amine 16 
 
Ester 11 (200 mg, 0.673 mmol) in CH2Cl2 (3 mL) was cooled to 0 °C and TFA (1.5 mL) was added. 
After stirring at 0 °C for 30 min, the solution was reduced in vacuo. The free amine (16) was directly used 
without further purification. 1H-NMR (400 MHz, CDCl3) δ 7.42 (br. s, 2H), 7.02 (s, 1H), 5.48 (d, J = 8.6 Hz, 
1H), 4.34-4.25 (m, 1H), 4.22 (q, J = 7.1 Hz, 2H), 1.95 (s, 3H), 1.89 (s, 3H), 1.48 (d, J = 6.0 Hz, 3H), 1.32 (t, 
J = 7.1 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 169.2, 140.4, 138.2, 129.0, 128.2, 125.3, 61.5, 46.7, 21.5, 
19.4, 16.5, 14.1, 13.7; HRMS (ESI): calculated for C11H20NO2Na 198.1494, found 198.1491; [α]
20
589: –3.5 
(c 1.0, CHCl3). 
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• Ester 13 
 
Amine 16 (394 mg, 2.00 mmol) and acid 12 (400 mg, 3.08 mmol) were solved in CH2Cl2 (20 mL). 
HOBt (400 mg, 2.10 mmol) was added and the mixture was cooled to 0 °C. EDC (500 mg, 2.61 mmol) and 
DIPEA (0.371 mL, 2.10 mmol) were added and the reaction mixture was stirred at room temperature 
overnight. HCl (10 mL, 0.1 mol/L) was added and the solution was diluted with CH2Cl2 (10 mL). The 
aqueous layer was extracted with CH2Cl2 (2x 20 mL), the organic layer was then washed with sat. NH4Cl 
(30 mL), dried over MgSO4, filtered and concentrated under reduced pressure. After flash 
chromatography (PE/EtOAc 5:1) compound 13 (488 mg, 1.64 mmol, 82% over 2 steps) was yielded as 
colourless oil. 1H-NMR (400 MHz, CDCl3) δ 7.06 (s, 1H), 6.43 (d, J = 7.6 Hz, 1H), 6.19 (t, J = 7.7 Hz, 1H), 
5.41 (d, J = 8.8 Hz, 1H), 4.97-4.78 (m, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.59 (s, 3H), 2.24-2.17 (m, 2H), 1.96 (s, 
3H), 1.91 (s, 3H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 (d, J = 6.9 Hz, 3H), 1.03 (t, J = 7.5 Hz, 3H); 13C-NMR 
(100 MHz, CDCl3) δ 168.7, 162.5, 148.1, 141.7, 135.5, 134.0, 127.1, 125.4, 60.7, 43.2, 21.3, 19.0, 16.7, 
14.2, 13.9, 13.5; HRMS (ESI): calculated for C17H27NO4Na 332.1838, found 332.1841; [α]
20
589: –24.8 (c 
1.0, CHCl3). 
 
• Alcohol 17 
 
Compound 13 (140 mg, 0.497 mmol) in CH2Cl2 (9 mL) was cooled to –78 °C and DiBAl-H (1.20 mL, 
1.17 mmol, 1.0 mol/L in CH2Cl2) was added dropwise. After stirring for 90 min, the solution was diluted 
with MTBE (10 mL), warmed to room temperature and quenched with water (0.110 mL). The resulting 
gel was stirred and NaOH (0.40 mL, 2 mol/L) was added. After stirring for additional 10 min, MgSO4 was 
added, the solution was filtered and reduced in vacuo. The residue was purified by flash 
chromatography (PE/ EtOAc 1:1) and alcohol 17 (109 mg, 0.432 mmol, 87%) was yielded as colourless 
oil. 1H-NMR (400 MHz, CDCl3) δ 6.40 (d, J = 7.3 Hz, 1H), 6.21 (t, J = 7.7 Hz, 1H), 5.88 (s, 1H), 5.21 (d, 
J = 8.8 Hz, 1H), 4.86-4.79 (m, 1H), 4.04 (s, 2H), 3.60 (s, 3H), 2.26-2.18 (m, 2H), 1.84 (s, 3H), 1.80 (s, 3H) 
1.62 (br. s, 1H), 1.27 (d, J = 6.6 Hz, 3H), 1.04 (t, J = 7.5 Hz, 3H), 13C-NMR (100 MHz, CDCl3) δ 162.4, 148.2, 
135.9, 134.7, 131.0, 128.2, 125.3, 69.1, 60.7, 43.3, 21.7, 19.0, 17.4, 15.3, 13.5; HRMS (ESI): calculated for 
C15H25NO3Na 290.1732, found 290.1732; [α]
20
589: -31.3 (c 1.0, CHCl3). 
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• Allyl bromide 18  
 
To a solution of alcohol 17 (20.0 mg, 74.5 µmol) in CH2Cl2 (5 mL) was added successively PPh3 
(39.0 mg, 0.149 mmol), NEt3 (21.0 µL, 0.149 mmol) and CBr4 (50.0 mg, 0.149 mmol). The yellow solution 
was stirred for 5 min, PE (5 mL) was added, the resulting solid was removed and the residue was 
concentrated under reduced pressure. Flash chromatography yielded bromide 18 (18.8 mg, 56.6 µmol, 
76%) as yellow oil which was used directly in the next step. HRMS (ESI): calculated for C15H25NO2 
330.1069, found 330.1069. 
 
• Phosphoniumbromide 2 
 
To a solution of allyl bromide 18 (15.0 mg, 45.6 µmol) in acetonitrile (1 mL), PBu3 (56.0 µL, 
0.227 mmol) was added. The mixture was stirred for 3 h, evaporated and used directly in the olefination 
reaction to generate pellasoren. 
 
• Ester 19 
 
To NaH (1.03 g, 25.8 mmol) in DMF (5 mL) was added 2-oxovaleric acid (500 mg, 4.31 mmol) 
dropwise. The resulting foam was stirred for 90 min at room temperature. The solution was cooled to 
0 °C and methyl sulfate (3.27 mL, 34.5 mmol) was added carefully over 60 min by syringe pump. The 
solution was stirred at room temperature for 3 h. Afterwards, the reaction was quenched with water 
(6 mL), the aqueous layer was extracted with diethylether (3x 10 mL). The organic layers were dried over 
MgSO4, filtered and evaporated at room temperature. The residue was purified by flash 
chromatography (pentane/Et2O 10:1) and product 19 (447 mg, 3.31 mmol, 72%) was obtained as slight 
yellow oil. 1H-NMR (400 MHz, CDCl3) δ 6.24 (t, J = 7.6 Hz, 1H), 3.76 (s, 3H), 3.64 (s, 3H), 2.28-2.20 (m, 
2H)., 1.02 (t, J = 7.6 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 164.3, 145.5, 130.7, 60.1, 51.7, 18.9, 13.2.  
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• Acid 12 
 
Compound 19 (100 mg, 0.69 mmol) was solved in a THF/H2O/MeOH (2 mL, 1 mL, 0.5 mL, 4:2:1) and 
aq. LiOH (1 mL, 0.5 mol/L) was added. The solution was stirred for 16 h and aq. HCl (0.5 mL, 2 mol/L) was 
added. After extraction with Et2O (3x 10 mL), the organic layer was dried over MgSO4, filtered and 
concentrated under reduced pressure. Acid 12 (92.0 mg, 69.2 µmol, 100%) was obtained as colourless 
oil. 1H-NMR (400 MHz, CDCl3) δ 11.34 (br. s, 1H), 6.43 (t, J = 7.7 Hz, 1H), 3.68 (s, 3H), 2.32–2.25 (m, 2H), 
1.06 (t, J = 7.6 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 168.9, 145.0, 133.4, 60.3, 19.2, 13.2. 
 
• Compound 20 
 
(E)-Methyl-2-pentenoic acid (0.36 mL, 3.09 mmol) in THF (80 mL) was cooled to  –78 °C and NEt3 
(0.80 mL, 6.19 mmol) was added. After 5 min, PivCl (0.45 mL, 3.72 mmol) was added and the solution 
was warmed to room temperature and stirred for 60 min. LiCl (427 mg, 9.29 mmol) and (S)-4-
isopropyloxazolidin-2-one (400 mg, 3.09 mmol) were added successively and the mixture was stirred for 
15 h. Water (20 mL) was added, layers were separated and the aqueous layer was extracted with MTBE 
(3x 20 mL). The organic layer were washed with brine (2x 20 mL), dried over MgSO4, filtered and 
evaporated. The residue was purified by flash chromatography (PE/EtOAc 6:1) and product 20 (585 mg, 
2.59 mmol, 84%) was obtained as colourless oil. 1H-NMR (400 MHz, CDCl3) δ 6.05 (t, J = 7.2 Hz, 1H), 4.57-
4.45 (m, 1H), 4.29 (t, J = 8.9 Hz, 1H), 4.15 (dd, J = 9.0, 5.5 Hz, 1H), 2.42-2.30 (m, 1H), 2.22-2.13 (m, 2H), 
1.88 (s, 3H), 1.03 (t, J = 7.6 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H); 13C-NMR (100 MHz, 
CDCl3) δ 171.9, 153.6, 141.1, 130.2, 63.3, 58.2, 28.2, 21.61, 17.8, 15.0, 13.4, 12.7; HRMS (ESI): calculated 
for C12H19NO3Na 248.1263, found 248.1260; [α]
20
589: +84.2 (c 1.0, CHCl3). 
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• Vinylketene silyl N,O-acetal 5 
 
To a solution of compound 20 (275 mg, 1.22 mmol) in THF (12 mL) was added at  –78 °C NaHMDS 
(1.22 mL, 1.83 mmol, 1.5 mol/L in THF). The solution was stirred for 90 min, TBSCl (551 mg, 3.66 mmol) 
was added and the reaction mixture was stirred additional 90 min. The reaction was quenched with sat. 
NH4Cl (10 mL) and the aqueous layer was extracted with MTBE (3x 10 mL). The organic layers were 
washed with water (20 mL) and brine (20 mL), dried over MgSO4, filtered and reduced in vacuo. The 
resulting residue was purified by flash chromatography (PE/ EtOAc 8:1) and product 5 (339 mg, 
1.00 mmol, 82%) was yielded as white solid. 1H-NMR (400 MHz, CDCl3) δ 6.22 (d, J = 15.4 Hz, 1H), 5.72-
5.57 (m, 1H), 4.35-4.31 (m, 1H), 4.16-4.11 (m, 1H), 4.03-3.00 (m, 1H), 1.99-1.91 (m, 1H), 1.79 (s, 3H), 
1.80-1.78 (m, 3H), 0.99 (s, 9H), 0.94 (d, J = 6.9 Hz, 6H), 0.17 (d, J = 20.0 Hz, 6H); 13C-NMR (100 MHz, 
CDCl3) δ 155.9, 134.6, 128.1, 124.3, 114.9, 64.4, 59.3, 29.3, 28.3, 26.4, 25.6, 18.7, 18.3, 16.3, 12.3, -3.6, -
4.4; HRMS (ESI): calculated for C18H29NO4Na 346.1994, found 346.1992; [α]
20
589: –30.2 (c 1.0, CHCl3). 
 
• Aldehyde 6  
 
To a solution of (S)-2-methylpent-4-en-1-ol (60.0 mg, 0.591 mmol) in DMSO (3 mL) was added IBX 
(250 mg, 0.891 mmol) and the solution was stirred for 2 h. Water (2 mL) was added, the resulting solid 
was filtered, the aqueous layer was extracted with Et2O (20 mL), the organic layer was washed 
intensively with NaHCO3 (3x 10 mL, 4 mol/L), dried over MgSO4, filtered and carefully concentrated. The 
crude aldehyde was used directly in the next step without further purification. 
 
• Aldol product 7  
 
A solution of aldeyhde 6 (20.0 mg, 0.204 mmol) in CH2Cl2 (2 mL) was cooled to –78 °C and TiCl4 
(0.204 mL, 0.204 mmol, 1 mol/L in CH2Cl2) was added dropwise. Vinylketene silyl N,O-acetal 5 (104 mg, 
0.306 mmol) was added and the solution was warmed to –30 °C. After stirring for 14 h, sat. sodium 
  5.1 Predicting Secondary Metabolite Structures 67 
 
tartrate (5 mL) and sat. NaHCO3 (5 mL) were added and the mixture was warmed to room temperature. 
The resulting slurry was stirred until the solution was nearly clear, the aqueous layer was extracted with 
CH2Cl2 (2x 10 mL), The organic phase was washed successively with water (10 mL) and brine (10 mL), 
dried over MgSO4, filtered and evaporated. The residue was purified by flash chromatography (PE/EtOAc 
5:1). Product 7 (40.3 mg, 124 µmol, 61% over 2 steps, d.r. 17:1) was obtained as colourless oil. 1H-NMR 
(400 MHz, CDCl3) δ 5.87-5.80 (m, 1H), 5.79-5.76 (m, 1H), 5.07, 4.98 (m, 1H), 4.60-4.55 (m, 1H), 4.34 (t, 
J = 9.0 Hz, 1H), 4.18 (dd, J = 9.1, 2.5 Hz, 1H), 2.76-2.70 (m, 1H), 2.37-2.31 (m, 1H), 2.26-2.21 (m, 1H), 
2.15-2.08 (m, 1H), 1.95 (d, J = 1.5 Hz, 3H), 1.78-1.73 (m, 1H), 0.94-0.91 (m, 12H); 13C-NMR (100 MHz, 
CDCl3) δ 171.6, 154.5, 142.3, 137.9, 131.2, 115.7, 76.6, 63.4, 58.1, 39.1, 37.4, 34.1, 28.4, 17.9, 15.6, 15.2, 
13.9, 11.9; HRMS (ESI): calculated for C18H29NO4Na 346.1994, found 346.1993; [α]
20
589: +20.4 (c 1.0, 
CHCl3). 
 
• Diol 21  
 
To a solution of compound 7 (80.0 mg, 0.242 mmol) in THF (20 mL) and MeOH (0.4 mL) which was 
cooled to 0 °C, LiBH4 (0.10 mL, 0.371 mmol, 4 mol/L in THF) was added and the mixture was stirred for 
3 h. Afterwards, NaOH (10 mL, 1 mol/L) was added, the mixture was stirred for 10 min at room 
temperature, water (10 mL) was added and the aqueous layer was extracted with CH2Cl2 (2x 20 mL). The 
organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified by flash chromatography (PE/EtOAc 2:1) and diol 21 (42.8 mg, 0.221 mmol, 90%) was obtained 
as colourless oil. 1H-NMR (400 MHz, CDCl3) δ 5.84-5.74 (m, 1H), 5.31 (d, J = 9.8 Hz, 1H), 5.07-4.99 (m, 
2H), 4.03 (s, 2H), 3.26 (dd, J = 8.2, 3.3 Hz, 1H), 2.62-2.53 (m, 1H), 2.22-2.16 (m, 1H), 2.09-2.02 (m, 1H), 
1.71 (s, 3H), 1.55 (bs, 2H), 0.92 (d, J = 2.3 Hz, 3H), 0.90 (d, J = 2.4 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 
137.5, 136.8, 128.4, 115.9, 77.5, 68.5, 38.9, 35.9, 34.4, 17.0, 14.2, 12.3; HRMS (ESI): calculated for 
C12H22O2Na 221.1517, found 221.1517; [α]
20
589: –7.9 (c 1.1, CHCl3). 
 
• Aldehyde 4  
 
To alcohol 21 (76.0 mg, 0.382 mmol) in CH2Cl2 (9 mL) was added MnO2 (1.00 g, 11.5 mmol) and the 
suspension was stirred for 2 h. The mixture was filtered through celite® and the solution was 
concentrated in vacuo. Aldehyde 4 (74.2 mg, 0.381 mmol, 99%) was obtained as colourless oil.         1H-
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NMR (400 MHz, CDCl3) δ 9.44 (s, 1H), 6.51 (d J = 9.8 Hz, 1H), 5.83-5.73 (m, 1H),  5.08-5.03 (m, 2H), 3.49-
3.45 (m, 1H), 2.93-2.87 (m, 1H), 2.21-2.14 (m, 1H), 2.06-1.99 (m, 1H), 1.79 (s, 3H), 1.78-1.74 (m, 1H), 
1.06 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 195.4, 156.6, 139.5, 136.7, 
116.5, 77.5, 38.5, 37.0, 35.3, 16.5, 13.0, 9.6; HRMS (ESI): calculated for C12H20O2Na 219.1361, found 
219.1360; [α]20589: +0.9 (c 1.0; CHCl3) 
 
• Lactol 8  
 
Stryker’s reagent (268 mg, 0.136 mmol) in degassed benzene (7.5 mL) was stirred for 40 min under 
argon atmosphere. Aldehyde 7 (75.0 mg, 0.381 mmol) in degassed benzene (4 mL) was added and the 
solution was stirred for 14 h. The reaction was quenched by adding sat. NH4Cl (10 mL) and the mixture 
was stirred for 45 min exposed to air. The resulting blue solution was extracted with CH2Cl2 (3x 10 mL). 
The organic layer was dried over MgSO4, filtered and evaporated. The residue was purified by flash 
chromatography (PE/EtOAc 10:1). Lactol 8 (18.1 mg, 0.911 mmol, 65%) was yielded as a mixture of both 
isomers. 
• Lactone 22  
 
To activated molecular sieve (55 mg, 4 Ǻ) in CH2Cl2 (2 mL) were added successively hemiacetal 8 
(22.0 mg, 0.112 mmol) and NMO (31.5 mg, 0.269 mmol) The solution was stirred for 30 min, TPAP 
(2.00 mg, 5.50 μmol) was added and the solution was stirred for additional 14 h. The solution was 
concentrated under reduced pressure and the residue was purified by flash chromatography (PE/EtOAc 
8:1). Lactone 22 (19.4 mg, 100 μmol, 90%, d.r. 20:1) was generated as colourless oil.       1H-NMR 
(400 MHz, CDCl3) δ 5.74-5.70 (m, 1H), 5.09-5.01 (m, 2H), 3.95 (d, J = 10.2 Hz, 1H), 2.51-2.44 (m, 1H), 
2.31-2.23 (m, 1H), 2.19-2.12 (m, 1H), 1.93-1.87 (m, 2H), 1.81-1.79 (m, 1H), 1.40-1.31 (m, 1H), 1.27 (d, 
J = 7.16 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 174.7, 
136.8, 116.6, 88.4, 38.0, 37.6, 36.3, 34.2, 30.9, 17.2, 17.0, 12.0; HRMS (ESI): calculated for C12H20O2Na 
219.1361, found 219.1359; [α]20589: +39.8 (c 1.0; CHCl3) 
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• Aldehyde 3  
 
Lactone 22 (25.0 mg, 0.127 mmol) in CH2Cl2 (5 mL) was cooled to –78 °C and ozone was bubbled 
through the solution until blue colour occured. PPh3 (100 mg, 0.407 mmol) was added and the solution 
was warmed to room temperature and stirred for 60 min. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography (PE/EtOAc 1:1) to afford aldehyde 3 
(25.7 mg, 0.127 mmol, quant.) as colourless oil. 1H-NMR (400 MHz, CDCl3) δ 9.79 (s, 1H), 3.94 (dd, 
J = 10.3, 1.6 Hz, 1H), 2.79 (dd, J = 18.5, 6.7 Hz, 1H), 2.58 (dd, J = 18.5, 6.7 Hz, 1H), 2.52-2.44 (m, 2H), 
1.97-1.86 (m, 2H), 1.41-1.29 (m, 1H), 1.26 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.8 Hz, 
3H); 13C-NMR (100 MHz, CDCl3) δ 201.5, 174.4, 88.6, 48.0, 37.6, 36.3, 30.9, 28.4, 17.2, 16.8, 12.2; HRMS 
(ESI): calculated for C11H18O3Na 221.1154, found 221.1154; [α]
20
589: –5.8 (c 1.0; CHCl3) 
 
• (14S)-Pellasoren 1a 
 
Phosphoniumbromide 2 (0.111 mmol) was solved in THF (1 mL) and cooled to –78 °C. KOtBu 
(0.133 mL, 0.133 mmol, 1 mol/L in THF) was added dropwise, the solution was warmed to 0 °C and 
stirred for 45 min. Aldehyde 3 (22.0 mg, 0.111 mmol) in THF (1 mL) was added and the mixture was 
stirred at room temperature for 15 h. The reaction was quenched with water (2 mL), extracted with 
CH2Cl2 (2x 5 mL), the organic layer was washed with brine (10 mL), dried over MgSO4, filtered and 
evaporated. The residue was purified by flash chromatography (PE /EtOAc 5:1) and (14S)-Pellasoren 1a 
(21.8 mg, 50.6 µmol,46%) was obtained as a white solid. 1H-NMR (500 MHz, MeOD) δ 6.16 (d, 
J = 15.5 Hz, 1H), 6.06 (t, J = 7.7 Hz, 1H), 5.83 (s, 1H), 5.69 (dt, J = 15.1, 7.4 Hz, 1H), 5.35 (d, J = 8.9 Hz, 1H), 
4.89-4.85 (m, 1H), 4.04 (dd, J = 10.5, 1.5 Hz, 1H), 3.61 (s, 3H), 2.60-2.52 (m, 1H), 2.35-2.28 (m, 1H), 2.27-
2.22 (m, 2H), 2.23-2.18 (m, 2H), 2.04-1.97 (m, 1H), 1.97-1.92 (m, 2H), 1.91 (s, 3H), 1.85 (s, 3H), 1.41 (dd, 
J = 25.0, 12.4 Hz, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.26 (d, J = 7.1 Hz, 3H), 1.07 (t, J = 7.6 Hz, 3H), 0.99 (d, 
J = 6.5 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 177.7, 164.8, 150.1, 138.7, 135.3, 
134.1, 132.7, 128.5, 126.1, 90.3, 61.0, 44.8, 38.6, 37.4, 36.1, 32.0, 21.5, 19.8, 17.7, 17.4, 17.3, 14.3, 13.9, 
12.6; HRMS (ESI): calculated for C26H41NO4Na 454.2933, found 454.2926; [α]
20
589:     –96.0 (c 0.105; 
MeOH)  
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•  Authentic pellasoren 
 1H-NMR (500 MHz, MeOD) δ 6.16 (d, J = 15.5 Hz, 1H), 6.06 (t, J = 7.7 Hz, 1H), 5.83 (s, 1H), 5.69 (dt, 
J = 15.1, 7.4 Hz, 1H), 5.35 (d, J = 9.1 Hz, 1H), 4.89-4.85 (m, 1H), 4.04 (dd, J = 10.5, 1.5 Hz, 1H), 3.61 (s, 
3H), 2.59-2.52 (m, 1H), 2.35-2.28 (m, 1H), 2.27-2.22 (m, 2H), 2.23-2.18 (m, 1H), 2.04-1.97 (m, 1H), 1.97-
1.92 (m, 1H), 1.91 (s, 3H), 1.85 (s, 3H), 1.41 (dd, J = 25.0, 12.3 Hz, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.26 (d, 
J = 7.1 Hz, 3H), 1.07 (t, J = 7.6 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H); 13C-NMR (125 MHz, 
CDCl3) δ 177.6, 164.8, 150.2, 138.7, 135.3, 134.1, 132.7, 128.5, 126.1, 90.3, 61.0, 44.8, 38.5, 37.4, 36.1, 
32.0, 21.5, 19.8, 17.6, 17.4, 17.3, 14.3, 13.9, 12.6; HRMS (ESI): calculated for C26H41NO4Na 454.2933, 
found 454.2933; [α]20589: –86.0 (c 0.109, MeOH)  
 
• (14R)-Pellasoren  
 
1H-NMR (400 MHz, MeOD) δ 6.15 (d, J = 15.3 Hz, 0.5H), 6.11 (d, J = 15.4 Hz, 0.5H) 6.04 (t, J = 7.7 Hz, 
1H), 5.81 (s, 1H), 5.71-5.63 (m, 1H), 5.33 (d, J = 8.8 Hz, 1H), 4.89-4.83 (m, 1H), 4.04 (dd, J = 10.4, 1.7 Hz, 
0.5H), 4.02 (dd, J = 10.6, 1.5 Hz, 0.5H), 3.59 (s, 3H), 2.76-2.69 (m, 0.5H), 2.57-2.51 (m, 0.5H), 2.32-2.28 
(m, 1H), 2.27-2.23 (m, 2H), 2.23-2.18 (m, 1H), 2.04-1.97 (m, 1H), 1.97-1.92 (m, 1H), 1.89 (s, 3H), 1.83 (s, 
3H), 1.77-1.61 (m, 1H), 1.41 (dd, J = 24.9, 12.3 Hz, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.24 (d, J = 7.1 Hz, 1.5H), 
1.16 (d, J = 7.1 Hz, 1.5H), 1.05 (t, J = 7.6 Hz, 3H), 0.99 (d, J = 6.8 Hz, 1.5H), 0.98 (d, J = 6.5 Hz, 1.5H) 0.93 
(d, J = 6.9 Hz, 1.5H), 0.91 (d, J = 6.8 Hz, 1.5H); 13C-NMR (125 MHz, MeOH) δ 178.2, 177.7, 163.0, 150.3, 
138.8, 138.8, 135.4, 134.2, 132.8, 132.8, 128.6, 128.5, 126.2, 90.5, 86.8, 61.1, 44.9, 38.8, 38.7, 38.5, 
37.5, 36.4, 36.2, 35.8, 33.7, 32.2, 29.8, 21.6, 19.9, 17.7, 17.7, 17.5, 17.4, 17.0, 14.4, 14.0, 12.7, 12.6; 
HRMS (ESI): calculated for C26H41NO4Na 454.2933, found 454.2930; [α]
20
589: +92.0 (c 0.103; MeOH). 
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2.3.9 CD Spectra 
 
 
Supporting Figure 11: CD spectra of a) synthetic pellasoren: MeOH, RT, 7.88·10
-5
 mol/L; b) authentic pellasoren: 
MeOH, RT, 8.6·10
-5
 mol/L; c) (14R)-pellasoren: MeOH, RT, 7.95·10
-5 
mol/L. 
2.3.10 Enantiomeric Excess of Ester 11 
 
Supporting Figure 12: Racemic mixture of ester 11. 
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Supporting Figure 13: Enantiomeric excess of 11. 
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3 Microsclerodermin 
3.1 Abstract 
The microsclerodermins are unusual peptide natural products exhibiting potent antifungal activity 
reported from marine sponges of the genera Microscleroderma and Theonella. We here describe a 
variety of microbial producers of microsclerodermins and pedeins among myxobacteria along with the 
isolation of several new derivatives. A retro-biosynthetic approach led to the identification of 
microsclerodermin biosynthetic gene clusters in genomes of Sorangium and Jahnella species, allowing 
for the first time insights into the intriguing hybrid PKS/NRPS machinery required for microsclerodermin 
formation. This study reveals the biosynthesis of a “marine natural product” in a terrestrial 
myxobacterium where even the identical structure is available from both sources. Thus, the newly 
identified terrestrial producers provide access to additional chemical diversity; moreover, they are 
clearly more amenable to production optimization and genetic modification than the original source 
from the marine habitat. As sponge metagenome data strongly suggest the presence of associated 
myxobacteria, our findings underpin the recent notion that many previously described “sponge 
metabolites” might in fact originate from such microbial symbionts. 
3.2 Introduction 
Natural products have a longstanding tradition as leads for the development of new medicines.1 In 
addition to well-established and extensively investigated plant, fungal, and bacterial producers of 
secondary metabolites, newer screening campaigns increasingly include organisms from less studied 
taxa and previously underexploited habitats such as terrestrial myxobacteria and marine sponges.2–5 
Their potential as sources of novel chemical scaffolds has been clearly demonstrated and despite the 
impressive structural diversity originating from these organisms, the overall picture has emerged that 
structural types obtained from phylogenetically distant producers usually show little overlap.6 However, 
as an exception to this general notion the production of several strikingly similar compounds by 
unrelated species has also been reported. Some of these findings are parallel discoveries of initially 
sponge-derived metabolite classes from microbial sources, leading to the assumption that the 
respective natural products might in fact be produced by bacterial sponge symbionts.7–9 Support for this 
theory comes from the identification of filamentous bacteria growing within intercellular space inside 
the sponge.8,10 However, studies which unambiguously prove the production of a “sponge metabolite” 
by a symbiotic bacterium are exceedingly rare.10,11 The same holds true for marine natural products of 
other host organisms.12–14 This shortcoming may be attributed to difficulties with isolation and 
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cultivation of symbiotic microbes under laboratory conditions. Notably, the ability to independently 
cultivate the "real" producer of a specific secondary metabolite holds great promise, not only for 
sustained production but also for improving yields using both biotechnological and genetic engineering 
approaches. These opportunities present an invaluable advantage when further investigating a 
compound of interest, as the marine organism itself usually faces critical supply limitations and is poorly 
amenable to genetic manipulation. Moreover, access to a microbial producer facilitates the 
identification of biosynthetic genes underlying the formation of the metabolite of interest - a crucial 
prerequisite for understanding the biosynthetic machinery and a promising step toward transferring 
these genes into a suitable heterologous expression host.15  
 
Figure 1: The microsclerodermin scaffold with an overview of the different residues identified so far. Groups R1-R4 
are related to the presence of tailoring enzymes during biosynthesis whereas the side chain R5 is derived by the PKS 
part of the biosynthetic machinery. The pyrrolidone is reported to have R,R- or S,S-configuration, respectively. 
Looking at those natural products from marine sources having apparent microbial counterparts, 
several cases exist where structures of myxobacterial secondary metabolites are indeed strikingly similar 
to previously discovered sponge-derived compounds. For example, the cyclodepsipeptide jaspamide 
(jasplakinolide) isolated from the marine sponge Jaspis.16,17 is closely related to the structure of 
chondramides produced by the myxobacterium Chondromyces crocatus Cm c5, suggesting that the 
biosynthetic pathways responsible for production of these molecules should be largely similar.18 The 
same holds true for renieramycin and saframycin MX1, isolated from a Reniera sponge and a 
myxobacterium of the genus Myxococcus.19,20 Moreover, the macrolides salicylihalamide and apicularen 
were isolated from a Halicona sp. sponge and a Chondromyces species, respectively.21,22 Very recently, 
bengamides were described from a Jaspis sponge and a cultured myxobacterium.23,24 Adding to the list 
of "biosynthetic look-alikes", the structure of pedein from the terrestrial myxobacterium Chondromyces 
pediculatus Cm p3 closely resembles that of microsclerodermin,25 which was isolated in 1994 from 
Microscleroderma sp., a lithistid sponge harvested in New Caledonia.26 Upon their finding of pedeins in 
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myxobacteria, Kunze et al. suggested that the origin of microsclerodermins could be a bacterial sponge 
symbiont closely related to myxobacteria.25 Indeed, pedein and microsclerodermin are highly similar, 
and both exhibit potent antifungal activity. To date several new derivatives belonging to the 
microsclerodermin class of peptides have been identified from various Microscleroderma species as well 
as from a Theonella sponge.27–30 Nevertheless, the biosynthetic machinery behind this natural product 
remains so far elusive.  
Table 1: Overview of Different Microsclerodermins and Pedeins and Their Origin 
derivative R
1
 R
2
 R
3
 R
4
 R
5
 
pyrrolidone 
confign 
sum formula (M+H)
+
 [m/z] [a] [b] [c] [d] [e] ref. 
A H H COOH OH i S, S C47H62N8O16 995.4357 •     
26,29 
B H H COOH H i S, S C47H62N8O15 979.4407 •     
26,29 
C Cl CONH2 H H vii R, R C41H50N9O13Cl 912.3289 • •    
27 
D Cl H H H vii R, R C40H49N8O12Cl 869.3231 • • • •  
27, this 
study 
E H H COOH H iii R, R C45H54N8O14 931.3832 •     
27 
F + G 
f
 H H H H iv R, R C45H56N8O12 901.4090 •     
28 
H + I 
f
 H H H H ii R, R C46H58N8O12 915.4247 •     
28 
J H H H H i S, S C46H60N8O12 917.4403 •     
29 
K H H H OH i S, S C46H60N8O13 933.4353 •     
29 
L Cl H H OMe vii R, R C41H51N8O13Cl 899.3337   
• • 
 
this study 
M H H H H v R, R C44H54N8O12 887.3934     
• this study 
Pedein A
g
 Cl H H OMe vi R, R C43H53N8O13Cl 925.3493   
• • 
 
25, this 
study 
Pedein B 
g 
H H H OMe vi R, R C43H54N8O13 891.3883   
• • 
 
25, this 
study 
[a] Microscleroderma sp. (3 species) [b] Theonella sp. (1 species) [c] Chondromyces sp. (2 species) [d] Jahnella sp. (2 
species) [e] Sorangium sp. (11 species) [f] The tryptophan side chain is reduced to an α-β-unsaturated amino acid. 
[g] Based on their same biosynthetic origin, we implicitly include pedeins when referring to the microsclerodermin 
family in this study. 
 
In this study we present several terrestrial myxobacteria as alternative producers of 
microsclerodermins and pedeins. Our data show that Jahnella and Chondromyces species can produce 
the identical derivate also known from a Microscleroderma species. In addition, they produce new 
derivatives not previously reported from other sources. Access to genomic sequences for two 
myxobacterial producers allowed us to establish for the first time a biosynthetic model for 
microsclerodermin formation and also provided us with an opportunity to probe the molecular basis 
responsible for the structural diversity observed from microsclerodermins. Moreover, it was shown that 
the myxobacterial pedeins25 originate from the same biosynthetic machinery as the microsclerodermins; 
hence, they belong to the same compound family. Taken together with recent metagenomic studies 
providing evidence that myxobacterial taxa may even exist as sponge symbionts,31 our results underpin 
the assumption that a myxobacterium is the real biosynthetic source of the "marine" natural product 
microsclerodermin.  
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3.3 Experimental Section 
3.3.1 Bacterial Strains and Culture Conditions 
Sorangium cellulosum So ce38 was cultivated in H-medium (2 g/L soybean flour, 2 g/L glucose, 
8 g/L starch, 2 g/L yeast extract, 1 g/L CaCl2·2H2O, 1 g/L MgSO4·7H2O, 8 mg/L Fe-EDTA, 50 mM HEPES, 
adjusted to pH 7.4 with 10 N KOH). Mutants of S. cellulosum So ce38 were cultivated in H-medium 
supplemented with hygromycin B (100 µg/mL) and 1 % (w/v) adsorber resin (XAD-16, Rohm & Haas) at 
180 rpm and 30 °C. Jahnella sp. MSr9139 was cultivated in buffered yeast broth medium VY/2 (5 g/L 
baker`s yeast, 1 g/L CaCl2·2H2O, 5 mM HEPES pH 7.0 with 10 N KOH) at 180 rpm and 30 °C.
32 The 
Escherichia coli strains DH10B and ET12567 harboring the plasmids pUB307 and pSUPmscH_KO for 
conjugation purposes were cultivated in Luria-Bertani (LB) medium at 37°C. Transformation of strains 
was performed according to the standard methods described elsewhere.33 Antibiotics were added with 
the following final concentrations: chloramphenicol (25 µg/mL), kanamycin sulfate (25 µg/mL) and 
hygromycin B (100 µg/mL). 
3.3.2 Disruption of the mscH Locus in So ce38 
Gene disruption in So ce38 using biparental mating was carried out according to a previously 
established protocol.34 For construction of the plasmid pSUPmscH_KO a homologous fragment with the 
size of 2472 bp was amplified from genomic DNA using the oligonucleotides mscH_KO_for (GAT CCA 
GCG CTG GTT CCT CG) and mscH_KO_rev (ACG AGG CTG TCG AAG AGC G) and cloned into pCR-TOPO II-
vector, resulting in the plasmid pTOPO_mscH_KO. The genomic segment was subsequently recovered 
from this plasmid using the restriction enzymes HindIII and EcoRV and further integrated into the 
prepared vector pSUPHyg.  
3.3.3 Isolation of  Microsclerodermin M from So ce38 
The production medium for So ce38 was P38X medium (2 g/L peptone, 2 g/L glucose, 8 g/L starch, 
4 g/L probion, 1 g/L CaCl2 ·2H2O, 1 g/L MgSO4·7H2O, 8 mg/L Fe-EDTA, 50 mM HEPES, adjusted to pH 7.5 
with 10 N KOH). A 100 L fermenter with 2 % (w/v) XAD-16 adsorber resin (Rohm & Haas) was harvested 
after 14 days of fermentation. The cells were removed from the XAD before extraction with 3 x 3 L of 
methanol followed by 1 x 3 L of acetone. The combined fractions yielded 47.2 g dry weight of crude 
extract. Five grams of this extract was suspended in cold water, the suspension was centrifuged 
immediately, and the remaining pellet was dissolved in DMSO/MeOH (1:1, v/v) to give a product-
enriched solution which was subjected to preparative HPLC using a Waters Autopurifier System 
equipped with a Waters XBridge C18, 150 x 19 mm, 5 µm dp column operated at room temperature. The 
gradient started at 30 % B, increased to 50 % B in 2 min and to 51 % B in another 2 min before increasing 
to 95 % B in 4 min for column flushing. The combined fractions of interest were lyophilized, dissolved in 
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DMSO/MeOH (1:1, v/v), and forwarded to a semipreparative Dionex HPLC system (P680 pump, TCC100 
thermostat, and PDA100 detector) equipped with a Phenomenex Fusion C18, 250 x 4.6 mm, 4 µm dp 
column. Separation was achieved by a linear gradient using (A) H2O and (B) ACN at a flow rate of 
5 mL/min and 30 °C. The gradient started at 10 % B and increased to 30 % B in 3 min, followed by an 
increase to 38 % B in 15 min (0.9 % B/column volume). UV data were acquired at 316 nm. A maximum of 
100 µL of the sample was manually injected before fraction collection, yielding 8.1 mg of 
microsclerodermin M. Microsclerodermin M: white amorphous solid,      
   - 55.7 ° (c 0.10, 
DMSO/MeOH 8:2).  
3.3.4 Isolation of Microsclerodermins from MSr9139 
The strain MSr9139 was cultivated in 3 x 1 L shaking flasks containing 500 mL of buffered VY/2 
medium for 30 days. The medium was changed every 24 h by pipetting out the liquid broth. The cell 
pellet was harvested by centrifugation and lyophilized overnight, followed by extraction with 3 x 300 mL 
of methanol. The combined fractions yielded an orange-brown crude extract which was further 
partitioned between hexane and MeOH/H2O 7:3 (v/v) to yield 170 mg of crude extract out of the 
aqueous phase. Subsequently, the extract was purified by semipreparative HPLC using an Agilent 1260 
Infinity system (G1311C quaternary pump, G1330B thermostat, G1315D DAD detector and G1328C 
manual injector) equipped with a Phenomenex Jupiter Proteo, 250 x 10 mm, 4 µm dp column. 
Separation was achieved by a linear gradient using (A) H2O and (B) ACN at a flow rate of 2.5 mL/min and 
22 °C. The gradient started at 20 % B and increased to 50 % B in 35 min (5.7 % B/column volume). UV 
data were acquired at 280 nm. A maximum of 100 µL of the sample was manually injected before 
fraction collection yielding 0.7 mg of microsclerodermin D, 0.45 mg of microsclerodermin L, and 0.85 mg 
of pedein A. Microsclerodermin L: white amorphous solid,     
   - 77.7 ° (c 0.12, MeOH). 
3.3.5 LC-MS data acquisition 
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a BEH C18, 100 x 
2.1 mm, 1.7 µm dp column (Waters, Germany). Separation of 1 µL sample was achieved by a linear 
gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and 45 °C. The 
gradient was initiated by a 0.5 min isocratic step at 5 % B, followed by an increase to 95 % B in 18 min to 
end up with a 2 min step at 95 % B before reequilibration under the initial conditions. UV spectra were 
recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 75 µL/min before entering 
the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, Germany) using the Apollo II ESI source.  
Mass spectra were acquired in centroid mode ranging from 150 – 2500 m/z at 2 Hz scan rate. 
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3.3.6 16S rRNA Gene and Phylogenetic Analysis 
Extraction of the 16S rRNA gene was performed in representative microsclerodermin producing 
strains of Sorangium, Jahnella and Chondromyces. Sequences of other myxobacterial strains used in the 
analysis were obtained from GenBank. The 16S rRNA gene was amplified using a set of universal 
primers, and phylogenetic analysis was performed as described in a previous study, but using the 
MUSCLE alignment algorithm and Neighbor-Joining tree method (JC69) as implemented in the Geneious 
Pro program version 5.6.5.35  
3.3.7 Genome Data 
The msc gene cluster sequence was deposited in the GenBank with the accession no KF657738 for 
S. cellulosum So ce38 and accession no KF657739 for Jahnella sp. MSr9139. 
3.4  Results and Discussion 
3.4.1 Production of Microsclerodermins by Terrestrial Myxobacteria 
In the course of our screening for bioactive natural products from myxobacteria, we observed 
antifungal activity in extracts from strain MSr9139, a newly isolated Jahnella species. Subsequent HPLC-
based purification led to several fractions showing antifungal activity which contained compounds 
featuring an isotopic pattern typical for chlorination in MS analysis. Two compounds from these 
fractions could be assigned by their exact mass, fragmentation pattern, and retention time as pedein A 
(925.3493 m/z, [M+H]+) and pedein B (891.3883 m/z, [M+H]+), antifungal metabolites known from the 
myxobacterium Chondromyces pediculatus Cm p3.25 Full structure elucidation was carried out for a 
compound with 869.3231 m/z obtained from another bioactive fraction, and the data unambiguously 
revealed this candidate as the known marine natural product microsclerodermin D (Table 1 and Figure 
S1). In addition to this, analysis of the MSr9139 extract led to the isolation and structure elucidation of 
the new derivative microsclerodermin L, differing from microsclerodermin D by an additional methoxy 
group, which is also reported for the pedein structure (Table 1 and Figure S3). Notably, the 
microsclerodermins are the first family of compounds found in the unexplored genus Jahnella, a 
member of the notable secondary metabolite producer myxobacterial family Polyangiaceae.36 
Almost simultaneously, extracts from the myxobacterial strain Sorangium cellulosum So ce38 underwent 
biological profiling and HPLC fractionation, highlighting antifungal activity in the same chromatographic 
region as previously found from the MSr9139 extract. HPLC purification could narrow down the 
putatively active compounds to a candidate with 887.3934 m/z, and subsequent NMR analysis identified 
a peptide featuring the pyrrolidone moiety also known from microsclerodermins. NMR data revealed 
the presence of a new non-chlorinated derivative, microsclerodermin M (Table 1 and Figures 2, S4). It 
82 Microsclerodermin 
 
shares the typical cyclic core structure with other microsclerodermins but features an unbranched side 
chain with three double bonds in conjugation to a phenyl moiety. Like the known microsclerodermins, 
the newly identified derivatives show potent activity against Candida albicans (microsclerodermin M, 
MIC 0.16 µg/mL; microsclerodermin L, MIC 18 µg/mL, microsclerodermin D, MIC 6.8 µg/mL). The 
stereochemistry of the isolated microsclerodermins was identified by acetonide formation and chemical 
degradation experiments followed by advanced Marfey analysis (see supporting information). It is 
identical to that reported for the microsclerodermins C – I and pedeins.25,27,28 
Having discovered that myxobacteria from three different genera Jahnella, Sorangium, and 
Chondromyces are able to produce microsclerodermin congeners including even the exact same 
structure as previously described from two species of lithistid sponges (microsclerodermin D) was 
surprising for two reasons: examples of myxobacteria producing an identical scaffold also known from a 
phylogenetically distant organism are to date exceedingly rare (even when counting among the bacterial 
kingdom), and according to previous studies the secondary metabolite profiles from strains belonging to 
different myxobacterial genera usually exhibit little overlap.6 In order to shed light on the occurrence of 
microsclerodermins within the myxobacteria, we conducted a search across high-resolution LC-MS data 
sets measured from almost 800 extracts, thus covering a sufficiently representative sample including 
most known myxobacterial taxa (Figure S20). On the basis of the evaluation of exact masses, isotope 
patterns and retention times we could identify a panel of 15 strains from the suborder Sorangineae (no 
single producer was found within the Cystobacterineae) as producers of microsclerodermins. 
Interestingly, our comprehensive LC-MS survey of myxobacterial secondary metabolomes revealed that 
producers of microsclerodermins form two mutually exclusive groups: one group comprises 11 
Sorangium species producing solely the new microsclerodermin M, while the second group includes two 
strains of Jahnella sp. and two Chondromyces sp. that produce a variety of different derivatives: i.e. the 
“marine” microsclerodermin D in addition to the new microsclerodermin L and pedeins A/B (Figures S21 
and S22). The various microsclerodermins differ in side chain, tryptophan modification and oxidation 
state at the pyrrolidone ring, whereas the peptidic core structure is always identical (Figure 1).  
The fact that all microsclerodermins, irrespective of their origin, exhibit an identical macrocycle and 
in most cases even the same stereochemistry supports the idea of a shared biosynthetic origin or even a 
shared evolutionary ancestor. Moreover, the finding of a group of terrestrial myxobacteria producing 
exactly the same compound as found in lithistid sponges27 (microsclerodermin D) fuels speculation 
about the actual biosynthetic origin of marine microsclerodermins. We herein propose that the marine 
microsclerodermins actually originate from a myxobacterium phylogenetically related to the 
Sorangineae suborder – possibly a yet uncultured species of the Chondromyces, Jahnella, or Sorangium 
taxa living in symbiosis with the sponges from which microsclerodermins were previously isolated. 
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Figure 2: (A) Organization of the msc biosynthetic gene cluster in Jahnella sp. MSr9139 compared to Sorangium 
cellulosum So ce38. (B) Proposed biosynthetic route to microsclerodermin formation in So ce38. (C) Postulated 
biosynthetic steps leading to the amino group that is involved in macrolactam formation. A, adenylation domain; 
AMT, aminotransferase; ACP, acyl-carrier-protein domain; AT, acyltransferase; C, condensation domain; CoA-Lig, 
coenzyme A Ligase; DH, dehydratase; E, epimerase; KR, ketoreductase; KS, ketosynthase; MT, methyltransferase; 
MOX, monooxygenase; PCP, peptidyl-carrier-protein domain. 
In coincidence with this hypothesis, phylogenetic studies of sponge metagenomes recently 
identified δ-proteobacteria in the sponge holobiont.31 Indeed, the phylogenetic tree presented in the 
work of Simister et al. lists a clade containing nine myxobacterial species of terrestrial origin, including 
Sorangium cellulosum and Chondromyces pediculatus.31 These data underpin our assumption that an 
evolutionary link exists between microsclerodermin biosynthesis in terrestrial and marine producers. 
Notably, 13 out of 15 producers identified by our LC-MS metabolome survey belong to the genera 
Sorangium or Chondromyces. In addition, the new Jahnella sp. MSr9139 was isolated from a soil sample 
collected from the same Philippine island where the sponge Microscleroderma was initially found.27 This 
intriguing finding suggests that myxobacteria are possibly flushed to the ocean and adapted to an 
association with a sponge. The diversity and density of microbial flora present in sponges appears to be 
a good niche for a predator and proteo-bacteriolytic myxobacterium;7 thus it is expected that in the 
future myxobacteria will be isolated from this underexplored source.  
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Access to myxobacterial producers holds a remarkable benefit, as these bacteria may be cultivated 
in large-scale fermentations, thereby allowing efficient production of the compounds of interest. 
Microsclerodermin M is produced at 12 mg/L in S. cellulosum So ce38 without optimization of growth 
conditions or genetic modification of the strain. Moreover, it allows us to investigate their biosynthesis, 
which has not been elucidated from any marine source to date. Thus, we set out to mine genome 
sequences of the new terrestrial producers for the presence of putative microsclerodermin biosynthetic 
pathways, using a retrobiosynthetic analysis as the starting point. The genome sequence of the strain 
Sorangium cellulosum So ce38, producer of the new microsclerodermin M, was already available from a 
previous study.37 The newly isolated Jahnella sp. MSr9139 was selected for additional genome 
sequencing, as it produces the new microsclerodermin L in addition to known pedeins A and B and the 
“marine” microsclerodermin D.  
 
Figure 3: Neighbor-joining tree of myxobacteria inferred from 16S rRNA gene sequences showing the clades of 
microsclerodermin producing strains in suborder Sorangiineae. The numbers at branch points indicate percentage 
bootstrap support based on 1000 resamplings. GenBank accession numbers are indicated in parentheses. Bar = 
0.05 substitutions per nucleotide position. 
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3.4.2 Microsclerodermin Biosynthetic Machinery 
All microsclerodermins share the same cyclic peptide core but feature different lipophilic side 
chains and modifications of amino acid residues. On the basis of retrobiosynthetic considerations, the 
biosynthetic machinery for microsclerodermin formation was expected to consist of a multimodular 
PKS/NRPS system accompanied by a set of enzymes involved in side chain biosynthesis and post 
assembly line modification. The  core PKS/NRPS modules should be conserved between producers, while 
enzymes involved in side chain biosynthesis and additional tailoring enzymes – responsible for 
modifications such as halogenation or oxidation of the pyrrolidone ring – should occur differentially 
between the two producer groups, as a consequence of evolutionary diversification of the 
microsclerodermin pathway. 
Using S. cellulosum So ce38 and Jahnella sp. MSr9139 as representative strains from both 
microsclerodermin producer groups, we sought to identify microsclerodermin biosynthetic pathways in 
their genomes and subsequently elaborate on the molecular basis for the observed structural variations. 
The genome sequences of both strains were searched in silico for secondary metabolite gene clusters 
using the antiSMASH analysis pipeline.38 The assignment of a matching candidate cluster to 
microsclerodermin biosynthesis was verified in So ce38 via targeted gene disruption by single crossover 
integration using biparental conjugation (Figure S24). Sequence comparison on the protein and 
nucleotide level revealed high similarity between gene clusters from both strains (Table 2), and 
comparison of operons permitted the tentative assignment of cluster boundaries. The 
microsclerodermin cluster spans a region of 58 kbp (74.7 % GC) in So ce38 and 62 kbp (72.4 % GC) in 
MSr9139, respectively. In both strains, genes encoding a major facilitator superfamily transporter (mscK) 
followed by a type II thioesterase (mscJ) are located upstream to mscA. The core biosynthetic assembly 
line covers five NRPS modules and three PKS modules encoded on genes mscA to mscI. An additional 
halogenase is encoded by mscL near the downstream boundary of the cluster in MSr9139 (Figure 2 A). 
Microsclerodermin biosynthesis is initiated at the side chain to build up a phenyl group in 
conjugation to a double bond. An activated starter unit such as benzoyl-CoA or trans-cinnamoyl-CoA is 
usually recruited by the enzyme in such a case. However, a retrobiosynthetic proposal tells us that the 
observed double bond order of the side chain is likely different during biosynthesis (Figure 2, B). The 
biosynthetic logic requests the incorporation of C2 units, which is only possible if the double bonds are 
rearranged (Figure S23). A rearrangement of double bonds has already been reported for other natural 
products like bacillaen, rhizoxin, corallopyronin and ansamitocin where isomerization is likely catalyzed 
by a dehydratase domain.39–42 The reason for isomerization of the microsclerodermin side chain remains 
elusive; however, it is supported by an energetic benefit of a conjugated π-system. On the basis of this 
hypothesis, the only suitable starter unit is phenylacetyl-CoA, which has already been reported for other 
natural product biosynthesis.43 The incorporation of a phenylacetate starter unit was indeed verified by 
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feeding experiments using isotope-labeled precursors. Feeding ring-labeled 13C6-L-phenylalanine 
resulted in a mass increase of 6 Da, whereas the fully labeled 15N,13C9-L-phenylalanine led to a mass shift 
of 8 Da, indicating the incorporation of two side chain carbons (Figure S27). Feeding d5-benzoic acid or 
d7-trans-cinnamic acid resulted in no mass increase (Figure S25). We can conclude that the α and β 
carbon atoms of phenylalanine - but not the carboxyl carbon - is incorporated into microsclerodermin. 
Elongation of the phenylacetate unit is catalyzed by modules MscA and MscC using three times 
malonate and two times 3-hydroxymalonate as extender units in an iterative manner. Modules 2 (MscB) 
and 4 (MscD) do only exhibit a combination of a functional KS domain attached to an inactive AT domain 
as identified by consensus sequence analysis, likely a relic of a former PKS complex. 
Table 1: Proteins involved in microsclerodermin biosynthesis as identified in two myxobacterial strains. 
  
Sorangium cellulosum So ce38  Jahnella sp. MSr9139  
protein length 
[aa] 
domains and position in sequence length 
[aa] 
domains and position in sequence identity 
[%] 
MscA 3275 CoA-Lig (264-701), KR*(1034-1197), ACP 
(1348-1411), KS (1441-1828), AT (1976-
2286), DH (2342-2505), KR' (2870-3047), 
ACP' (3149-3214) 
3535 CoA-Lig (215-649), KR*(1032-1126), MT 
(1229-1509), ACP (1613-1676), KS (1712-
2147), AT (2244-2555), DH (2610-2774), 
KR*' (3132-3309), ACP' (3411-3476) 
65.4 
MscB 870 KS (27-451), AT* (548-772) 878 KS (39-464), AT* (561-792) 73.4 
MscC 1551 KS (36-460), AT (557-859), DH* (956-
1076), KR (1158-1336), ACP (1436-1505) 
1549 KS (39-464), AT (561-865), DH* (956-
1076), KR (1157-1335), ACP (1436-1499) 
75.0 
MscD 900 KS (36-461), AT* (565-678) 848 KS (36-461), AT* (564-675) 72.0 
MscE 446 Putative amidohydrolase 386 Putative amidohydrolase 82.9 
MscF 2273 PCP (27-98), AMT (329-660), MOX (828-
1127), C (1185-1529), A (1673-2082), 
PCP' (2169-2237) 
2189 PCP (4-75), AMT (280-614), MOX (758-
1057), C (1105-1397), A (1594-2000), 
PCP' (2088-2149) 
76.5 
MscG 1548 KS (14-439), AT (534-828), KR (1156-
1330), ACP (1441-1509) 
1511 KS (14-439), AT (531-850), KR (1136-
1312), ACP (1404-1472) 
72.1 
MscH 4141 C (76-377), A (564-966), MT (1037-1256), 
PCP (1469-1531), C' (1554-1850), A' 
(2037-2426), PCP' (2515-2574), E (2591-
2905), C'' (3074-3374), A'' (3558-3967), 
PCP'' (4054-4121) 
4106 C (48-346), A (534-936), MT (1007-1225), 
PCP (1442-1505), C' (1526-1827), A' 
(2013-2405), PCP' (2492-2551), E (2568-
2872), C'' (3043-3343), A'' (3527-3932), 
PCP'' (4019-4083) 
78.8 
MscI 2904 C (48-346), A (533-936), PCP (1023-
1087), KS (1111-1535), AT (1638-1936), 
KR (2266-2465), ACP (2549-2612), TE 
(2634-2888) 
2945 C (77-375), A (563-965), PCP (1053-
1116), KS (1150-1573), AT (1676-1970), 
KR (2309-2509), ACP (2597-2660), TE 
(2683-2945) 
77.8 
MscJ 257 thioesterase type II 263 thioesterase type II 43.5 
MscK 415 major facilitator superfamily (MFS) 
transporter 
450 major facilitator superfamily (MFS) 
transporter 
24.5 
MscL - - 535 Tryptophan halogenase - 
MscM - - 438 Fe(II)/α-ketoglutarate dependent 
oxygenase 
- 
MscN - - 277 methyltransferase - 
A, adenylation domain; AMT, aminotransferase; ACP, acyl-carrier-protein domain; AT, acyltransferase; C, 
condensation domain; CoA-Lig, coenzyme A Ligase; DH, dehydratase; E, epimerase; KR, ketoreductase; KS, 
ketosynthase; MT, methyltransferase; MOX, monooxygenase; PCP, peptidyl-carrier-protein domain. * inactive 
domain 
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The PKS-derived unit is forwarded to the first PCP domain of module MscF. This module harbors 
two additional domains of rather uncommon type showing high homology to the amino transferase 
family (AMT) and to the monooxygenase family, both located downstream to the PCP domain. A 
biosynthetic proposal to account for this domain order is based on oxidation of the β-hydroxyl group of 
the bound intermediate to the respective β-keto functionality followed by conversion to a β-amino 
moiety that undergoes macrocyclization (Figure 2, C). The use of an aminotransferase is known from 
other natural product biosynthetic pathways, however, not in combination with the initial oxidation 
step.44 
Thereafter, biosynthesis continues with a set of NRPS- and PKS-based reaction cycles. Analysis of 
the A domain specificities in silico is consistent with the amino acids incorporated.45 We propose the 
uncommon pyrrolidone moiety is built up by asparagine cyclization. To the best of our knowledge, such 
an asparagine-derived pyrrolidone system is only found in microsclerodermins and koshikamides, a 
natural product that was isolated from a Theonella species.46 Indeed, the A domain of MscF is specific 
for asparagine activation and we did a feeding experiment with fully labeled 15N2-
13C4-L-asparagine to 
prove this biosynthetic step. We observed a mass increase of 6 Da according to the incorporation of all 
carbon and nitrogen atoms of asparagine into the compound (Figures S26, S28). On the basis of this 
result, a plausible biosynthetic hypothesis requires the nucleophilic attack of the asparagine side chain 
to the backbone carbonyl atom. A suitable mechanism is known from the intein-mediated peptide 
cleavage, where intein initiates an intra-molecular asparagine cyclization, notwithstanding the poor 
reactivity of the side chain’s amide.47 In microsclerodermin biosynthesis, this reaction likely is 
accompanied by an inversion of the stereochemistry at the α-carbon of the former (S)-asparagine. The 
relative configuration of the pyrrolidone ring was identified by NOE correlations, whereas the absolute 
(R,R)-configuration is derived from degradation experiments (see supporting information). The 
stereochemistry at this position is thereby identical with that of microsclerodermins C – I. The protein 
MscE is most likely responsible for the cyclization step, as it is found in both microsclerodermin clusters 
and shows similarity to the amidohydrolase class, a fairly promiscuous enzyme family able to act on a 
variety of substrates. However, the exact mechanism involved in this biosynthetic step remains elusive 
at present.  
The forthcoming NRPS modules correspond to the observed structure of microsclerodermin in 
terms of domain order and predicted substrate specificity (Figure 2, B). For both new 
microsclerodermins an R-configured tryptophan was identified by means of the advanced Marfey 
method, which is in agreement with the epimerization domain found in module 8. The 
(3R)-configuration of the γ-amino butyric acid (GABA) subunit was identified by the same technique (see 
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Figures S13, S14). Both stereogenic centers have the same configuration as identified in all 
microsclerodermins so far. 
3.4.3 Genetic Basis for the Structural Diversity of Microsclerodermins  
The derivatives found in Jahnella sp. MSr9139 feature side chains with either one or two double 
bonds while the side chain in So ce38 comprises strictly three double bonds. As the number of PKS 
modules encoded in the gene cluster does not match the number of required elongation cycles, an 
iterative function of the type I PKS subunits MscA and MscC as described for the stigmatellin 
megasynthase may explain this finding.48 The KS domains of each module are highly identical for both 
strains and do not comprise any of the postulated sequence-based identifiers of iterative KS domains.49 
Nevertheless, MscB is grouping with iterative KS domains in a phylogenetic analysis (Figure S11). 
Comparing the entire module MscA of both clusters revealed the insertion of an additional methyl 
transferase-like domain into the first part of the protein in MSr9139. This domain is likely inactive on the 
basis of in silico analysis as judged by the presence of a corrupted SAM-binding motif (Table S13).50 
Currently, we cannot rule out the possibility that the presence of this additional methyl transferase may 
influence the iteration process within MscA. In addition to this difference, there is no obvious reason 
why biosynthesis in So ce38 results in a triene whereas MSr9139 is less strict in iteration. As another 
hint for a shared origin of the biosynthetic cluster, some of the sponge-derived derivatives exhibit a 
methyl-branched side chain which could be attributed to this methyl transferase being active in some of 
the marine producers. Eventually, the variable side chains of the microsclerodermin family are in 
agreement with the alternating PKS functionality. Halogenation of tryptophan as well as oxidation of the 
pyrrolidone ring is catalyzed by tailoring enzymes. The halogenase MscL is located downstream to the 
cluster in MSr9139 and is responsible for chlorination of the tryptophan. It shows 32 % identity on a 
protein level to a tryptophan halogenase from a Streptomyces species (PDB entry 2WET_A). There is no 
analogue of MscL found in So ce38, which is in agreement with the absence of chlorinated products in 
this strain. Supplementing KBr or NaBr to the MSr9139 cultivation broth led to the production of 
brominated microsclerodermins on the basis of LC-MS analysis.  Another difference is the inter-region 
between the main PKS and NRPS parts. In MSr9139 two additional proteins are found in this region. 
MscN is a member of the SAM-dependent methyl transferase family, and MscM shows homology to 
Fe(II)/α-ketoglutarate-dependent dioxygenases. On the basis of the structures produced by MSr9139, 
we conclude that MscM and MscN are responsible for oxidation and methylation of the pyrrolidone 
ring, respectively. Modifications at the tryptophan as known from some marine-derived 
microsclerodermins were not observed in this study. Such modifications are attributed to promiscuous 
acting enzymes that could be related to the producer strain or even to enzymes related to some sponge 
symbiont. 
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3.5 Conclusion 
The discovery of microsclerodermins/pedeins from several myxobacteria represents one of the few 
findings of identical compounds from marine organisms and terrestrial bacteria reported to date. This 
study thus strengthens the notion that certain natural products, which have been isolated from marine 
sources such as sponges or other invertebrates, actually originate from associated microbes. Notably, 
the identification of microsclerodermin-producing myxobacteria provides meaningful hints for future 
attempts to isolate the symbiotic microbe. This knowledge is considered particularly helpful because 
isolation success in many cases critically depends on methods well adapted to the requirements of the 
genus targeted for isolation, especially when aimed at the rather challenging isolation of slow-growing 
myxobacteria. Availability of an alternative microbial producer as a sustainable source is an advantage 
for realizing the potential of a marine natural product for therapeutic applications. Moreover, the 
myxobacterial producers come along with additional chemical diversity and are amenable to genetic 
manipulation, as demonstrated in this study. Finally, the identification of two slightly different 
microsclerodermin biosynthetic gene clusters from two myxobacteria allowed us to establish a 
conclusive model for microsclerodermin biosynthesis and provided insights into the molecular basis for 
structural diversity within this compound family. A detailed understanding of microsclerodermin 
biosynthesis is an important prerequisite for any future efforts toward engineering the pathway for yield 
improvement or for the production of new derivatives: whether in the native producer, by heterologous 
expression, or by using synthetic biology approaches. 
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3.6 Supporting Information 
3.6.1 Structure elucidation 
 NMR data of Microsclerodermin D  3.6.1.1
 
Figure S1: Structure and atom numbering of microsclerodermin D. Compound isolated from marine sponges of the 
genera Microscleroderma sp. and Theonella sp. and the myxobacterium Jahnella sp. MSr9139. 
Table S1: NMR chemical shifts of microsclerodermin D. 
Amino acid Assignment δC 
a
 δH (mult., J in Hz) 
b
 HMBC ROESY 
APTO 1 172.3    
 2 69.2 4.39 (d, 3.2)   
 3 53 4.13 (d, 11.3)   
 4 69.5 3.32 (m)   
 5 68.8 3.57 (m)   
 6 36.3 2.35 (m)    
 7 128.0 6.24 (m)   
 8 130.5 6.40 (d, 15.8)   
 9 137.2    
 10, 14 125.4 7.35 (d, 7.3)   
 11, 13 128.2 7.29 (t, 7.6)   
 12 126.5 7.19 (t, 7.3)   
 OH-2  6.58 (brs)   
 OH-4  4.17 (m)   
 OH-5  4.36 (d, 4.5)   
 NH-3  7.47 (d, 6.0)   
GABOB 15 172.3    
 16 40.7 2.43 (d, 14.0)   
   2.15 (d, 14.0)   
 17 66.8 3.72 (m)   
 18 44.7 3.39 (m)    
   2.61 (m)    
 OH-17  4.88 (d, 4.8)   
 NH-18  7.50 (m)   
Gly 19 168.5    
 20 42.3 3.75 (d, 7.0)   
   3.34 (d, 7.0)   
 NH-20  8.54 (t, 6.0)   
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6-Cl-Trp 21 171.5    
 22 55.1 4.17 (m)   
 23 25.8 3.10 (dd, 5.7, 14.7)   
   2.98 (dd, 5.7, 14.7)    
 24 124.6 7.26 (d, 1.8)   
 25 109.5    
 26 125.6    
 27 119.4 7.52 (d, 8.3)   
 28 118.4 7.00 (dd, 1.5, 8.3)   
 29 c    
 30 110.7 7.37 (s)   
 31 136.1    
 NH-22  8.64 (d, 4.3)   
 NH-24  11.04 (brs)   
N-Me-Gly 32 169.9    
 33 49.5 4.08 (d, 16.3)    
   3.84 (d, 16.3)    
 34 36.2 2.93 (s)   
Pyrrolidone 35 170.2    
 36 38.6 2.84 (d, 17.1)   
   2.69 (d, 17.1)   
 37 85.2    
 38 50.3 4.47 (m)    
 39 35.0 2.27 (m)   
 40 172.3    
 NH-37  7.96 (brs)   
 NH-38  7.56 (m)   
 OH-37  c   
a
 Recorded at 175 MHz, referenced to residual solvent DMSO-d6 at 39.51 ppm.  
b
 Recorded at 700 MHz, referenced to residual solvent DMSO-d6 at 2.50 ppm. 
 
c
 Not observed. 
ov 
overlapping signals. 
 
 
 
 NMR data of Dehydromicrosclerodermin D - acetonide 3.6.1.2
 
Figure S2: Structure and atom numbering of the acetonide of dehydromicrosclerodermin D. Derivative is based on 
microsclerodermin D as isolated from the myxobacterium Jahnella sp. MSr9139. 
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Table S2: NMR chemical shifts of dehydromicrosclerodermin D - acetonide. 
Amino acid Assignment δC 
a
 δH (mult., J in Hz) 
b
 
APTO 1 172.3  
 2 70.1 4.19 (d, 4.2) 
 3 55.4 4.11 (d, 10.0) 
 4 77.3 3.74 (ov) 
 5 78.7 4.02 (m) 
 6 37.1 
2.32 (m) 
2.55 (m) 
 7 126.5 6.24 (m) 
 8 131.3 6.43 (d, 16.0) 
 9 c  
 10, 14 125.4 7.38 (m) 
 11, 13 128.2 7.30 (t, 7.6) 
 12 126.5 7.20 (t, 7.2) 
 OH-2  6.23 (ov) 
 NH-3  7.09 (ov) 
GABOB 15 c  
 16 41.1 2.22 (d, 14.8) 
   2.01 (m) 
 17 65.6 3.89 (m) 
 18 44.7 3.23 (m)  
   2.82 (m)  
 OH-17  5.10 (d, 4.5) 
 NH-18  7.35 (t, 6.5) 
Gly 19 c  
 20 42.6 3.58 (m)) 
 NH-20  8.38 (t, 6.5) 
6-Cl-Trp 21 c  
 22 55.2 4.11 (m) 
 23 25.4 3.19 (ov) 
   3.01 (dd, 5.1, 10.0)  
 24 124.6 7.26 (d, 1.8) 
 25 109.5  
 26 125.6  
 27 119.4 7.52 (d, 8.3) 
 28 118.4 7.00 (dd, 1.5, 8.3) 
 29 c  
 30 110.7 7.37 (s) 
 31 136.1  
 NH-22  8.77 (d, 5.0) 
 NH-24  11.04 (brs) 
N-Me-Gly 32 c  
 33 50.5 3.44 (d, 15.7)  
   4.53 (d, 15.7)  
 34 36.8 3.06 (s) 
Pyrrolidone 35 c  
 36 88.0 5.25 (s) 
 37 c  
 38 45.4 5.21 (m)  
 39 33.7 
2.44 (m) 
2.74 (m) 
 40 c  
 NH-37  c 
 NH-38  8.36 (d, 8.8) 
a
 Recorded at 175 MHz, referenced to residual solvent DMSO-d6 at 
39.51 ppm. 
 
 Recorded at 700 MHz, referenced to residual solvent DMSO-d6 at 2.50 
ppm.  
c
 Not observed. 
ov 
overlapping signals. 
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 NMR data of Microsclerodermin L 3.6.1.3
 
Figure S3: Structure and atom numbering of microsclerodermin L. Compound isolated from the myxobacterium 
Jahnella sp. MSr9139. 
Table S3: NMR chemical shifts of microsclerodermin L. 
Amino acid Assignment δC 
a
 δH (mult., J in Hz) 
b
 HMBC ROESY 
APTO 1 172.9    
 2 69.2 4.43 (brs) 1  
 3 53 4.19 (d, 11.3) 4 4  
 4 69.7 3.32 (m)   
 5 68.7 3.59 (q, 6.5)   
 6 36.6 2.38 (m)  4, 5, 7, 8  
   2.33 (m)   
 7 128 6.26 (m) 6, 9  
 8 130.5 6.40 (d, 15.8) 6, 9, 10, 14 6 
 9 137.2    
 10, 14 125.6 7.36 (d, 7.0) 8, 12 7, 8 
 11, 13 128.3 7.29 (t, 7.6) 9, 10, 14  
 12 126 7.19 (t, 7.4) 10, 11, 13, 14  
 OH-2  6.57 (brs)   
 OH-4  4.85 (d, 4.9)    
 OH-5  4.30 (brs)   
 NH-3  7.42 (brs)  16 
GABOB 15 172.1    
 16 40.6 2.43 (d, 14.0) 15  
   2.12 (d, 14.0)   
 
17 66.6 3.77 (m) 16, 18 OH-17 
 
18 44.8 3.33 (m)  17  
   2.65 (m)    
 
OH-17  4.85 (brs)   
 
NH-18  7.43 (brs)  20 
Gly 19 168.5    
 
20 42.5 3.72 (d, 7.0) 19, 21  
 
  3.36 (d, 7.0)   
 
NH-20  8.51 (t, 6.0 )   22 
6-Cl-Trp 21 171.6    
 
22 55.2 4.17 (m)  NH-20 
 23 25.8 3.10 (dd, 5.7, 15.0) 21, 22, 24, 25, 26  
 
  2.98 (dd, 5.7, 15.0)    
94 Microsclerodermin 
 
 
24 124.7 7.26 (d, 2.0) 25, 31, 32  
 
25 109.3    
 
26 125.5    
 
27 119.4 7.52 (d, 8.5) 31  
 28 118.5 7.00 (dd, 1.8, 8.5) 30, 26  
 
29 c    
 
30 110.7 7.37 (s) 27  
 
31 136.3    
 
NH-22  8.68 (d, 4.3)  22, 23, 24, 33 
 
NH-24  11.03 (d, 2.0) 24, 25, 31, 26 24, 30 
N-Me-Gly 32 172.2    
 
33 49.6 4.28 (d, 16.4)  32, 34  
 
  3.69 (d, 16.4)    
 
34 35.9 2.92 (s) 33, 35  
Pyrrolidone 35 170.4    
 
36 38.6 2.83 (d, 16.9) 35, 37 38 
 
  2.61 (d, 16.9)   
 37 82.3    
 
38 55.8 4.44 (d, 9.0)  39 NH-38 
 
39 79.0 4.04 (d, 8.8) 40, 41 NH-38 
 
40 56.6 3.39 (s) 39  
 41 171.0    
 
NH-37  8.18 (brs) 37, 38, 39  
 
NH-38  7.61 (d, 9.6)  2, 39 
 
OH-37  c   
a
 Recorded at 175 MHz, referenced to residual solvent DMSO-d6 at 39.51 ppm. 
 
 Recorded at 700 MHz, referenced to residual solvent DMSO-d6 at 2.50 ppm.  
c
 Not observed. 
ov 
overlapping signals. 
 
 
 NMR data of Microsclerodermin M 3.6.1.4
 
Figure S4: Structure and atom numbering of microsclerodermin M. Compound isolated from the myxobacterium 
Sorangium cellulosum So ce38. 
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Table S4: NMR chemical shifts of microsclerodermin M. 
Amino acid Assignment δC 
a
 δH (mult., J in Hz) 
b
 HMBC ROESY 
APTD 1 172.5    
 2 69.3 4.38 (d, 5.4) 3 3, OH-2 
 3 53.0 4.11 (ov) 4, 5, 19 OH-5, NH-3 
 4 69.8 3.27 (ov) 2, 3 3, 7, OH-2, OH-3 
 5 68.8 3.52 (ov) 4, 6 7, 8 
 6 36.4 2.28 (ov) 4, 5, 7, 8 4, 5, 7, 8 
 7 133.0 5.74 (dt, 15.0, 7.4) 6, 9 4, 5, 6, 9 
 8 131.7 6.17 (dd, 10.0, 15.1) 9, 10 6, 11 
 9 133.7 6.34 (ov) 7, 8, 10, 11 7, 11 
 10 130.7 6.33 (ov) 8, 11, 12 12 
 11 129.2 6.92 (dd, 9.6, 15.6) 9, 10, 13 9, 18 
 12 131.3 6.56 (d, 15.6) 10, 14, 18, 13 10, 14 
 13 137.0    
 14, 18 125.7 7.44 (d, 7.6) 12, 16 11, 12 
 15, 17 128.4 7.31 (d, 8.3) 14, 18 14 
 16 127.1 7.21 (d, 7.1) 14, 15, 17, 18 14, 18 
 OH-2  6.25 (d, 5.6) 2, 3 2, 4, NH-42 
 OH-4  4.34 (d, 4.7) 5, 6 3, 5 
 OH-5  4.52 (d, 9.0) 3, 4, 5 3, 4 
 NH-3  7.43 (d, 12.6) 2, 3 4, 5, 20, OH-21 
GABOB 19 172.6 
 
  
 
20 40.7 2.44 (d, 14.0) 19, 21, 22  
   2.15 (ov)  NH-3 
 
21 66.9 3.73 (ov) 21, 23 20, 22, OH-21, NH-22 
 
22 44.8 3.37 (ov)  21, OH-21 
   2.64 (ov)   
 
NH-22 
 
7.49 (d, 6.7)  20, 21, 22 
 
OH-21 
 
4.86 (d, 5.0)  20, 21, 22 20, 21, 22, NH-3 
Gly 23 168.7 
 
  
 
24 42.4 3.76 (d, 7.6) 23, 25 NH-24 
   3.36 (d, 5.7)   
 
NH-24 
 
8.56 (t, 5.7)  24, 26, NH-22 
Trp 25 171.7 
 
  
 
26 55.2 4.19 (m) 25, 27, 29, 36 27, 30, NH-24 
 
27 26.2 3.11 (dd, 5.6, 14.6) 25, 26, 29 26, 28, 30, NH-26 
   2.98 (dd, 5.6, 14.6)   
 
28 123.5 7.21 (d, 6.6) 29, 34 26, 27, NH-26, NH-28 
 
29 109.6 
 
  
 
30 126.5 
 
  
 
31 118.0 7.52 (d, 7.7) 29, 32 26, 27, 32 
 
32 118.1 6.98 (t, 7.3) 33, 34 31, 34 
 
33 120.8 7.06 (d, 7.3) 30, 31, 35 31, 34 
 
34 111.1 7.32 (d, 7.9) 30, 32, 35 32 
 
35 135.9 
 
  
 
NH-28 
 
10.87 (brs) 28, 29, 35, 30 28, 34 
 
NH-26 
 
8.65 (d, 4.2) 26, 27 26, 27, 28, 37 
N-Me-Gly 36 169.9 
 
  
 
37 49.6 4.10 (d, 15.4) 39, 36 38, NH-26 
   3.82 (d, 15.4)   
 
38 36.2 2.94 (s) 39 37 
Pyrrolidone 39 170.4 
 
  
 
40 38.7 2.85 (d, 17.0)  39, 41, 42 42, OH-41, NH-41 
   2.70 (d, 17.0)   
 
41 85.5 
 
  
 
42 50.4 4.47 (ov) 40, 42, 43  40 
 
43 34.9 2.28 (ov) 41, 44 42, OH-41, NH-42 
 
44 172.9 
 
  
 
OH-41 
 
6.07 (s) 40, 42 40, 43, NH-41, NH-42 
 
NH-41 
 
7.97 (s) 41, 42, 43 40, 42, OH-41 
 
NH-42 
 
7.54 (ov) 42 42, 43, OH-41 
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a
 Recorded at 175 MHz, referenced to residual solvent DMSO-d6 at 39.51 ppm. 
 
 Recorded at 700 MHz, referenced to residual solvent DMSO-d6 at 2.50 ppm.  
c
 Not observed. 
ov 
overlapping signals. 
 
 NMR data of Dehydromicrosclerodermin M - acetonide 3.6.1.5
 
Figure S5: Structure and atom numbering of the acetonide of dehydromicrosclerodermin M. Derivative is based on 
microsclerodermin M as isolated from the myxobacterium Sorangium cellulosum So ce38. 
Table S5: NMR chemical shifts of microsclerodermin M - acetonide. 
Amino acid Assignment δC 
a
 δH (mult., J in Hz) 
b
 
APTD 1 172.5  
 2 69.9 4.17 (ov) 
 3 53.1 4.28 (m) 
 4 77.0 3.69 (dd, 7.0, 9.9) 
 5 78.6 3.96 (m) 
 6 36.7 2.47, 2.24 (ov) 
 7 133.0 5.75 (m) 
 8 131.7 6.17 (dd, 9.7, 15.0) 
 9 133.7 6.34 (ov) 
 10 130.7 6.33 (ov) 
 11 129.2 6.92 (dd, 9.6, 15.6) 
 12 131.3 6.56 (d, 15.6) 
 13 137.0  
 14, 18 125.7 7.44 (d, 7.6) 
 15, 17 128.4 7.31 (ov) 
 16 127.1 7.21 (t, 7.3) 
 45 c  
 46 26.6 1.35 (s) 
 47 26.6 1.35 (s) 
 OH-2  6.25  
 NH-3  7.43  
GABOB 19 172.6 
 
 
20 40.3 2.22 (ov) 
   2.00 (dd, 7.7, 10.8) 
 
21 65.2 3.87 (m) 
 
22 44.8 3.23 (ov) 
   2.82 (m) 
 
NH-22 
 
7.37  
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OH-21 
 
4.86  
Gly 23 168.7 
 
 
24 41.9 3.59 (m) 
 
NH-24 
 
8.40  
Trp 25 171.7 
 
 
26 54.8 4.14 (m) 
 
27 25.1 3.21 (dd, 3.3, 10.3) 
   3.00 (dd, 3.3, 10.3) 
 
28 123.5 7.21 (d, 5.3) 
 
29 109.6 
 
 
30 126.5 
 
 
31 118.0 7.52 (d, 7.7) 
 
32 118.1 6.98 (t, 7.3) 
 
33 120.8 7.06 (t, 7.3) 
 
34 111.1 7.32 (d, 7.9) 
 
35 135.9 
 
 
NH-28 
 
10.87 (brs) 
 
NH-26 
 
8.65  
N-Me-Gly 36 169.9 
 
 
37 49.7 4.54 (d, 11.5) 
   3.43 (ov) 
 
38 36.4 3.05 (s) 
Pyrrolidone 39 170.4 
 
 
40 87.3 5.23 (ov) 
 
41 c 
 
 
42 50.4 3.69 (m) 
 
43 33.1 2.45, 2.75 (ov) 
 
44 172.9 
 
 
NH-41 
 
8.35 
 
NH-42 
 
c 
a
 Recorded at 175 MHz, referenced to residual solvent DMSO-d6 at 39.51 
ppm.  Recorded at 700 MHz, referenced to residual solvent DMSO-d6 at 
2.50 ppm. 
c
 Not observed. 
ov 
overlapping signals. 
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3.6.2 Analytical data for microsclerodermins and pedeins 
 Microsclerodermin D 3.6.2.1
 
Figure S6: Accurate m/z measurement and CID fragmentation pattern of microsclerodermin D. 
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 Microsclerodermin L 3.6.2.2
 
Figure S7: Accurate m/z measurement and CID fragmentation pattern of microsclerodermin L. 
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 Microsclerodermin M 3.6.2.3
 
 
Figure S8: Accurate m/z measurement and CID fragmentation pattern of microsclerodermin M. 
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 Pedein A 3.6.2.4
 
Figure S8: Accurate m/z measurement and CID fragmentation pattern of pedein A. 
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 Pedein B 3.6.2.5
 
Figure S9: Accurate m/z measurement and CID fragmentation pattern of pedein B. 
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3.6.3 Analysis of the msc gene clusters in So ce38 and MSr9139 
The regions of interest as well as 20 kb flanking regions were searched for open reading frames 
(ORFs) using Glimmer 3.0 and subsequently subjected to an automatic annotation by the antiSMASH 
software tool1,2. The msc-locus in So ce38 (Table S6) spans 58,049 bp and covers nine modules within 
the genes mscA to mscI with a GC content of 74.7 % (EMBL accession no. XXXX). The 5’-end of the gene 
cluster covers a major facilitator superfamily transporter (MFS-type, mscK) and a type II-thioesterase 
(mscJ) located approximately 2.5 kb upstream to mscA.  
In the case of Jahnella sp. MSr9139 the cluster has a size of 62,268 bp and is thereby approximately 
4.2 kb larger. We find the same genes as in So ce38 starting from mscA to mscI (Table S6, EMBL 
accession no. XXXX). There are three additional auxiliary genes named mscL, mscM and mscN. The first 
one encodes a halogenase specific for tryptophan found at the end of the cluster. This is consistent with 
the observation that a chlorinated tryptophan residue is found for the microsclerodermins isolated from 
Jahnella specimen. The genes mscM and mscN are located within the cluster (between mscD and mscE). 
They are encoding two proteins with significant similarity to an α-ketoglutarate dependent dioxygenase 
and a methyltransferase, respectively. The pairwise similarity of both clusters is 74.2 % on DNA-level. 
Both msc clusters have a comparable GC content of around 72 %. 
Table S6: Genes involved in microsclerodermin biosynthesis as annotated in the strains Sorangium cellulosum So 
ce38 and Jahnella sp. MSr9139 
Sorangium cellulosum So ce38 Jahnella sp. MSr9139 
Gene Start End 
Length 
Function[1] 
 
Start End 
Length 
Function[1] 
pairwise 
[bp] [bp] identity 
mscA 3859 13686 9828 CoA-Lig-KR*-ACP-KS-AT-DH-KR-
ACP 
 4124 14731 10608 CoA-Lig-KR* -MT-ACP-KS-AT-DH-
KR-ACP 
74.7 
mscB 13709 16321 2613 KS-AT*  14718 17354 2637 KS-AT* 79.7 
mscC 16327 20982 4656 KS-AT-DH-KR-ACP  17341 21990 4650 KS-AT-DH-KR-ACP 81.5 
mscD 20995 23697 2703 KS-AT*  22000 24546 2547 KS-AT* 78.7 
mscE 23727 25067 1341 Putative amidohydrolase  27907 26747 1161 Putative amidohydrolase 83.9 
mscF 25335 32156 6822 PCP-ATT-MOX-C-A-PCP  28287 34856 6570 PCP-AAT-MOX-C-A-PCP 82.4 
mscG 32158 36804 4647 KS-AT-KR-ACP  34858 39393 4536 KS-AT-KR-ACP 80.9 
mscH 36844 49269 12426 C-A-M-PCP-C-A-PCP-E-C-A-PCP  39472 51792 12321 C-A-M-PCP-C-A-PCP-E-C-A-PCP 84.5 
mscI 49344 58049 8706 C-A-PCP-KS-AT-KR-ACP-TE  51789 60668 8880 C-A-PCP-KS-At-KR-ACP-TE 83.9 
mscJ 1473 2246 774 Thioesterase typeII  3006 3794 789 Thioesterase typeII 63 
mscK 1248 1 1248 MFS-transporter  1350 1 1350 MFS-transporter 55.9 
mscL - - - -  62268 60661 1608 Trp-halogenase - 
mscM - - - -  24583 25899 1317 Fe(II)/α-ketoglutarate 
dependent oxygenase 
- 
mscN - - - -   25881 26714 834 Methyltransferase - 
[1] A: adenylation domain, AAT: aminotransferase, ACP: acyl-carrier-protein domain AT: acyltransferase domain, C: condensation domain, CoA-
Lig: CoA-Ligase, DH: dehydratation domain, E: epimerase, KR: ketoreductase domain, KS: ketosynthase domain, MT: methyltransferase 
domain, MOX: monooxygenase, PCP: peptidyl-carrier-protein domain, TE: thioesterase domain, *: inactive domain 
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Table S7: Proteins involved in microsclerodermin biosynthesis in the strains Sorangium cellulosum So ce38 and 
Jahnella sp. MSr9139. 
 
 AT domains 3.6.3.1
Substrate specificity of acyl transferase (AT) domains was determined using conserved motif 
analysis by aligning the AT domains from both clusters to a reference AT from E.coli FAS, 1MLA (PDB 
1MLA, UniProtKB P0AAI9) (Table S8).3 This data shows that most of the listed AT-domains contain the 
GxSxG consensus motif with the catalytic residue in the center, except MscB in which the catalytic serine 
residue is replaced by a glycine. The MscD-AT domains are considered inactive as they are heavily 
truncated and do not align to the canonical motifs of AT domains. Active site analysis was used to 
predict which extender unit is recruited by a distinct AT domain. The main discriminant between using a 
methylmalonyl-CoA (mm-CoA) or malonyl-CoA (m-CoA) is the amino acid position 200 in 1MLA, where 
Ser200 supports mm-CoA and Phe200 supports m-CoA.  The in silico prediction for microsclerodermin 
production is in all cases m-CoA and thereby in agreement with the chemical structure observed. We 
were not able to predict the incorporation of a hydroxymalonyl-CoA substrate for MscC-AT.   
Sorangium cellulosum So ce38 Jahnella sp.  MSr9139 
Protein 
Length 
[aa] 
Domains and position in sequence[a] 
Length 
[aa] 
Domains and position in sequence[a] 
Identity 
[%] 
MscA 
3275 
CoA-Lig (264-701), KR*(1034-1197), ACP (1348-
1411), KS (1441-1828), AT (1976-2286), DH 
(2342-2505), KR' (2870-3047), ACP' (3149-3214) 
3535 
CoA-Lig (215-649), KR*(1032-1126), MT (1229-1509), 
ACP (1613-1676), KS (1712-2147), AT (2244-2555), DH 
(2610-2774), KR*' (3132-3309), ACP' (3411-3476) 
65.4 
MscB 870 KS (27-451), AT* (548-772) 878 KS (39-464), AT* (561-792) 73.4 
MscC 
1551 
KS (36-460), AT (557-859), DH* (956-1076), KR 
(1158-1336), ACP (1436-1505) 
1549 
KS (39-464), AT (561-865), DH* (956-1076), KR (1157-
1335), ACP (1436-1499) 
75.0 
MscD 900 KS (36-461), AT* (565-678) 848 KS (36-461), AT* (564-675) 72.0 
MscE 446 Putative amidohydrolase 386 Putative amidohydrolase 82.9 
MscF 
2273 
PCP (27-98), AMT (329-660), MOX (828-1127), 
C (1185-1529), A (1673-2082), PCP' (2169-2237) 
2189 
PCP (4-75), AMT (280-614), MOX (758-1057), C (1105-
1397), A (1594-2000), PCP' (2088-2149) 
76.5 
MscG 
1548 
KS (14-439), AT (534-828), KR (1156-1330), ACP 
(1441-1509) 
1511 
KS (14-439), AT (531-850), KR (1136-1312), ACP (1404-
1472) 
72.1 
MscH 
4141 
C (76-377), A (564-966), MT (1037-1256), PCP 
(1469-1531), C' (1554-1850), A' (2037-2426), 
PCP' (2515-2574), E (2591-2905), C'' (3074-
3374), A'' (3558-3967), PCP'' (4054-4121) 
4106 
C (48-346), A (534-936), MT (1007-1225), PCP (1442-
1505), C' (1526-1827), A' (2013-2405), PCP' (2492-2551), 
E (2568-2872), C'' (3043-3343), A'' (3527-3932), PCP'' 
(4019-4083) 
78.8 
MscI 
2904 
C (48-346), A (533-936), PCP (1023-1087), KS 
(1111-1535), AT (1638-1936), KR (2266-2465), 
ACP (2549-2612), TE (2634-2888) 
2945 
C (77-375), A (563-965), PCP (1053-1116), KS (1150-
1573), AT (1676-1970), KR (2309-2509), ACP (2597-
2660), TE (2683-2945) 
77.8 
MscJ 257 Thioesterase type II 263 Thioesterase type II 43.5 
MscK 415 Major Facilitator Superfamily (MFS) transporter 450 Major Facilitator Superfamily (MFS) transporter 24.5 
MscL - - 535 Trytophan halogenase - 
MscM - - 438 Fe(II)/α-ketoglutarate dependent oxygenase - 
MscN - - 277 Methyltransferase - 
[a] A: adenylation domain, AMT: aminotransferase, ACP: acyl-carrier-protein domain AT: acyltransferase domain, C: condensation domain, CoA-
Lig: coenzyme A Ligase, DH: dehydratation domain, E: epimerase, KR: ketoreductase domain, KS: ketosynthase domain, MT: methyltransferase 
domain, MOX: monooxygenase, PCP: peptidyl-carrier-protein domain, TE: thioesterase domain, *: inactive domain 
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Table S8: Active site analysis of the acyl transferase domains (AT) from S. cellulosum So ce38 and Jahnella sp. 
MSr9139 according to Yadav et al.
3
 
Domain observed predicted 11 63 90 91 92 93 94 117 200 201 231 250 255 15 58 59 60 61 62 70 72 197 198 199  
1MLA M M Q Q G H S L G R S H N Q V T K T W Q T S A S V P  
MscA-ATSo ce38 M M Q Q G H S V G R F H N H V Q R T E Y T E A S H A  
MscA-ATJahnella sp. M M Q Q G H S V G R F H N H V Q R T E Y T E A S H A  
MscB-ATSo ce38 inactive - E Q G Q G A G R - - S D D T Q T A F T Q A - - -  
MscB-ATJahnella sp. inactive - Q Q G L G V G R - - S Q D L Q A A F A E A - - -  
MscC-ATSo ce38 
Hydroxy 
malonate 
M Q Q G H S I G R F H N H V Q Q T A F T E A S H A  
MscC-ATJahnella sp. 
Hydroxy 
malonate 
M Q Q G H S I G R F H N H V F Q T A F A E A S H A  
MscG-ATSo ce38 M M Q Q G H S I G R F H N H V H D T A I A E A S H A  
MscG-ATJahnella sp M M Q Q G H S V G R F H N H V H D T A L A G A S H A  
MscI-ATSo ce38 M M Q Q G H S V G R F H N H V Y Q T R L T E A S H A  
MscI-ATJahnella sp M M Q Q G H S V G R F H N H V H Q T R L A E A S H A  
 
 KS domains 3.6.3.2
The ketosynthase (KS) domains of both msc biosynthetic gene clusters were extracted and 
analyzed using the NaPDoS web tool.4 The result is depicted as a phylogenetic tree in Figure S11 and 
allows easy annotation of the KS subtypes found in the msc cluster.  
The postulated iterative function of MscB is supported by grouping of these domains at the 
interface between modular (ochre) and iterative (green) domains. The remaining, functional domains 
MscA, MscG, and MscI are correctly grouped in the PKS/NRPS hybrid section. MscA is characterized as a 
hybrid domain because of its linkage to the first module with its uncommon starter unit. 
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Figure S11: Phylogenetic tree highlighting different KS domain types and the KS domains found in the msc 
biosynthetic gene cluster in So ce38 and MSr9139.  
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 DH domains 3.6.3.3
Both msc clusters contain two dehydration domains present in the proteins MscA and MscC. Based 
on the proposed biosynthesis of microsclerodermin the DH-domain in MscA must be active. However, it 
does not exhibit the common consensus-motif H(X3)G(X4)P of DH-domains as known from other modular 
PKS-systems (Table S9). Here, the central glycine is replaced by a valine. This substitution is obviously 
not affecting the enzyme function. The DH-domains from MscC are considered to be inactive as they do 
not contain a conserved motif at all. The domains are truncated with a protein length of around 100 
amino acids. 
Table S9: Active site analysis of the dehydratase domains (DH) of the msc biosynthetic gene cluster. 
Consensus H x x x G x x x x P  
MscA-DHSo ce38 H A E G V L V A R P  
MscA-DHJahnella sp H V E G V V V A R P  
 KR domains 3.6.3.4
The msc cluster from both myxobacteria encodes five ketoreductase domains. The KR domains may 
be classified as A- and B-type by analyzing the amino acid sequence of two regions within the amino acid 
sequence.5 However, it was shown that a reliable prediction of the stereogenic center that emerges 
upon KR reduction of a keto-function is governed by additional, unknown interactions.6 Nevertheless, 
we attempted to classify the domains in this work. The occurrence of a LDD motif is a good indicator for 
a B-type KR domain. This is sometimes supported by the presence of a Pro144 and an Asp148 according 
to the numbering based on the DEBS2 KR domain (GenBank #X62569.1). In case of A-type KR domains a 
highly conserved Trp141 is present. Moreover, a correct co-factor binding motif is mandatory for the 
enzyme function. Based on this, MscA-KR1 of both strains is predicted to be inactive as it does not 
exhibit the co-factor binding motif GxGxxGxxxA (Table S10). Additionally, the MscA-KR1 domain of 
MSr9139 is heavily truncated. The remaining KR domains feature the correct binding motif. 
 
Table S10: Analysis of the co-factor binding motif of the ketoreductase domains (KR) within the msc biosynthetic 
gene cluster. 
 Domain G x G x x G x x x A motif  
MscA-KR1 So ce38 D L G G V S L Q L L inactive  
MscA-KR1 MSr9139 A L G S Y E - - - - inactive  
MscA-KR2 So ce38 G L G A L G R R V A ok  
MscA-KR2 MSr9139 G L G A L G R R V A ok  
MscC-KRSo ce38 G T G A L G L H I A ok  
MscC-KRMSr9139 G I G A L G L H T A ok  
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MscG-KRSo ce38 G L G G A G L G I A ok  
MscG-KRMSr9139 G L G G V G L A I A ok  
MscI-KRSo ce38 G L G R I G L C L A ok  
MscI-KRMSr9139 G L G R I G L C L A ok  
 
The two amino acid regions for KR domain classification are shown in Table S11. MscA-KR2 and MscC-
KR1 can be classified as B-type and A-type, respectively. The LDD-motif together with an Asp148 is 
found in MscA-KR2 whereas the highly conserved Trp141 specifies MscC-KR. One stereogenic center 
originating from the A-type MscC-KR is still present in the final product and should exhibit S-
configuration. This is in agreement with the configuration of the last hydroxyl group reported for the 
microsclerodermin side chain. The KR domains of MscG do only feature a LDD-like motif but no 
additional identifier in the second region. It remains unclear whether this domain is active at all.  MscI-
KR produces an R-configured hydroxyl moiety as identified by advanced Marfey analysis of 
microsclerodermin (GABA subunit).  However, there is no common consensus that allows a 
classification. Moreover, the KR domains exceed the common KR domain length of approximately 180 
amino acids by additional 30 amino acids.   
 
Table S11: Analysis of the ketoreductase domains (KR) within the msc biosynthetic gene cluster 
 
region 88-103 region 134-149 KR type 
MscA-KR2 So ce38 H L A G A L D D G V L L Q Q S W F S S I A S V L G S A A Q G N Y B-type 
MscA-KR2 MSr9139 H L A G S L D D G V L V Q Q S W F S S I A S I L G S A G Q G N Y B-type 
MscC-KRSo ce38 H A A G V A G A R D L S A L D A T S S I A S L W G S R G Q A H Y A-type 
MscC-KRMSr9139 H A A G V G G Y C E L S R L D A Y S S I A S L W G S R G Q A H Y A-type 
MscG-KRSo ce38 Y A A G V D D P A L I G - G I G S S S L S A I L G G R G L G A Y B-type 
MscG-KRMSr9139 Y A A A I D D A G L L G - A V G G S S L S A I L G G R G L A A Y B-type 
MscI-KRSo ce38 H A A G A R G D G T F M V P L A L S S T S A I L G G L G L G P Y unknown 
MscI-KRMSr9139 H A A G A R G D G T F M T S L A L S S T S A I L G G L G L G P Y unknown 
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 A domains 3.6.3.5
Three genes of microsclerodermin biosynthesis (mscF, mscH and mscI) harbor at least one NRPS 
module.  In order to determine the A domain specificity of each module the respective amino acid 
sequences were analyzed using the NRPSpredictor2 tool.7 The results are listed in Table S12. The 
predicted specificity of each A-domain is consistent with the observed amino acid incorporated into the 
microsclerodermin scaffold.   
Table S12: Prediction of A-domain specificity for each A-domain present in the msc biosynthetic gene cluster using 
the NRPSpredictor2 software-tool.
7
 
 
domain 
amino-acid specificity 
So ce38 MSr9139 
MscF-A asn asn 
MscH-A1 gly gly 
MscH-A2 trp trp 
MscH-A3 gly gly 
MscI-A gly gly 
 C domains  3.6.3.6
All C domains of the msc biosynthetic gene cluster were analyzed using the NaPDoS web tool.4 
Especially the hybrid module MscF is of interest as the incorporated S-asparagine is (a) cyclized to form 
and pyrrolidone moiety and (b) converted to the R-asparagine. The mechanism behind these reactions is 
not understood yet. Analysis of the respective C domain, MscF-C1, characterizes the domain as a 
common PKS/NRPS hybrid domain (Figure S12). Hence, the observed cyclization as well as inversion of 
asparagine is not done by the C domain. It is more likely related to the amidohydrolase MscE which is 
found in both clusters. Its detailed function remains elusive at the current stage of research. 
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Figure S12: Phylogenetic tree highlighting different C domain types and the C-domains found in the msc 
biosynthetic gene cluster in So ce38 and MSr9139.  
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  MT-domains 3.6.3.7
The N-methyltransferase present in module 1 of MscH is found in both clusters and is responsible 
for the N-methylation of the glycine right next to the pyrrolidone ring. Both of them harbor the common 
consensus-motif GxGxG at the N-terminal end which is responsible for SAM Co-factor binding (Table 
S13).8 These N-methyltransferases belong to the UbiE/COQ5 family. In addition, the msc-cluster of 
Jahnella sp. encodes a second methyltransferase domain which is located in MscA. This methyl 
transferase has homology to the PRMT5 family. However, the MT domain is likely inactive as the SAM 
binding motif GxGxG is changed to GxGxE. The exchange of the small glycine to a charged glutamic acid 
may prevent cofactor binding. 
Table S13: Active site analysis of the methyltransferase domains (MT) within the msc biosynthetic gene cluster. 
active consensus G x G X G  
MscA-MTJahnella sp. G T G K E  
MscH-MTSo ce38 G C G T G  
MscH-MTJahnella sp. G C G T G  
3.6.4 Determination of configuration 
The conformation of all stereogenic centers of the isolated microsclerodermins is identical to that 
of the microsclerodermins C – I and confirms the assumed stereochemistry of the pedeins.9–11 In detail, 
the scaffold is based on an R-tryptophan, a (3R)-4-NH2-3-OH-butyric acid moiety, a side chain with 
(2S,3R,4S,5S)-configuration and an (R,R)-pyrrolidone.  
 Absolute configuration of 3-aminobutyric acid and tryptophan 3.6.4.1
Microsclerodermin has several stereogenic centers. We identified the configuration of the γ-
aminobutyric acid (GABA) moiety and tryptophan by acid hydrolysis followed by advanced Marfey 
analysis using FDLA reagent. (3S)-GABA was ordered from Sigma and used as a reference together with 
S-tryptophan and S-6-chloro-tryptophan. Derivatization of the γ-amino functionality with L-FDLA and D-
FDLA results in two products with reproducible retention time differences (3 seconds using 10 technical 
replicates, see Figure S13) which allows annotation of the stereochemistry. In conclusion, the new 
microsclerodermins L and M have an (3R)-configured carbon atom in the GABA subunit which is in 
agreement with the other microsclerodermins reported. 
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Figure S13: Overlay of LC-MS chromatograms highlighting the retention time difference of the GABA subunit when 
derivatized with Marfey’s reagent (FDLA). The graph features the (3S)-GABA reference compound as well as 
microsclerodermin M and L. 
The tryptophan in microsclerodermin M, D and L is R-configured. This applies to all microsclerodermins 
known so far and is in agreement with the epimerization domain found within the respective module of 
the biosynthetic assembly lines in So ce38 and MSr9139. Microsclerodermin M was compared to S-
tryptophan whereas microsclerodermin D and L were compared to a S-6-Cl-tryptophan reference (Figure 
S14). 
 
Figure S14: Overlay of the LC-MS chromatograms for tryptophan characterization using advanced Marfey’s reagent 
(FDLA). The stereogenic center of tryptophan is (R)-configured in microsclerodermin M and L. 
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 Configuration of the pyrrolidone moiety 3.6.4.2
The pyrrolidone moiety of the microsclerodermins is derived from an asparagine as indicated by 
feeding labeled S-asparagine. Incorporation of labeled S-asparagine suggested that the pyrrolidone ring 
keeps this configuration. However, this turned out to be wrong. Microsclerodermins M, D and L 
underwent the same chemical degradation steps as reported for the microsclerodermins A-I.9,10,12 After 
dehydration at the pyrrolidone moiety the respective dehydromicrosclerodermins were subjected to 
ozonolysis. The reaction products were hydrolyzed and derivatized with Marfey’s reagent. Marfey 
derivatization and HPLC-MS measurements revealed an R-configured pyrrolidone moiety in the 
microsclerodermin derivatives M, L, and D. Although this chemical degradation protocol is used for the 
microsclerodermins A – I in literature, the method is not that elegant in terms of the result as 
ozonolysis, oxidative workup and hydrolysis of R-tryptophan will result in R-asparate as well. At the 
same time this procedure will generate aspartate out of the pyrrolidone moiety. By doing a short 
hydrolysis step of not more than 60 minutes we observe a notable amount of R-asparagine in the 
sample which can only originate from the pyrrolidone moiety. Based on these results we were able to 
identify R-tryptophan and R-pyrrolidone in microsclerodermin M and D. We verified the results by 
applying the above mentioned protocol to pure R-tryptophan as well as to the synthesized, 
enantiomeric pure S-dehydropyrrolidone fragment (98 % ee). R-tryptophan is converted to R-aspartate 
while the S-dehydropyrrolidone fragment is converted to asparagine and aspartate with a S:R-ratio of 
approximately 4:1. This partial inversion clarifies the origin of the R- and S-asparagine mixture which is 
observed in all samples of microsclerodermin, there with the opposite S:R-ratio of 1:4 (Figures S15) 
 
Figure S15: Marfey analysis result of ozonolysis product of microsclerodermin M. The chromatograms show the 
peaks for asparagine and aspartate, both as an overlay display with the respective S-configured reference 
compound. 
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Microsclerodermin D and L are both isolated from strain MSr9139. In case of microsclerodermin L, 
the pyrrolidone moiety has an additional methoxy group resulting in a 3-methoxy-aspartate after the 
above mentioned reactions whereas microsclerodermin D has the same pyrrolidone moiety as the M 
derivative (So ce38). Unfortunately we were not able to get suitable enantiomeric pure reference 
compounds for 3-methoxy-aspartate. However, based on the rule of thumb that an L-Marfey derivative 
of an L-configured amino acid elutes earlier than that of an D-Marfey derivative13 we can conclude that 
it is the other way round in our sample and we do have an D-configured amino acid, (2R)-3-methoxy-
aspartate, present in microsclerodermin L (Figure S16). This is supported by the detection of R-
asparagine in the microsclerodermin D derived sample which is isolated from the same strain and 
thereby underlying the same biosynthesis. The stereogenic center at the methoxy group was not 
assigned by this method. 
 
Figure S16: Marfey analysis result of ozonolysis product of microsclerodermin L. The chromatograms show the 
peaks for 3-MeO-aspartate. As the D-marfey derivative (upper part) elutes before the L-marfey derivative (lower 
part) the 3-MeO-aspartate has a 2R-configured stereogenic center. There is no reference compound available. 
 Configuration of the side chain 3.6.4.3
The side chain’s vicinal hydroxyl groups OH-4 and OH-5 were converted to an acetonide in order to 
identify the relative stereochemistry of this part of the molecule. The acetonide formation was done for 
microsclerodermin M from S. cellulosum So ce38 and microsclerodermin L from Jahnella sp. MSr9139. 
Acetonides were purified using the same HPLC method as for the natural product isolation. Purity was 
checked by HPLC-MS analysis prior to NMR analysis. Respective NOE couplings are detected using 
selective irradiation experiments for the protons attached to the acetonide moiety. The NOE couplings 
are identical to those determined for the microsclerodermins known to literature. Based on this result 
we conclude to have the same relative stereochemistry as reported for microsclerodermins A – I which 
have a 2S,3R,4S,5S-configured side chain. We assigned the absolute stereochemistry of the side chain by 
diol cleavage at OH-4 and OH-5. The product is oxidized to the respective carboxylic acid and hydrolyzed 
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using 6 N HCl. After Marfey derivatization we observed a peak for L-threo-ß-OH-aspartate (2S,3S 
configuration) which would be in agreement with the 2S,3R,4S,5S-configured side chain.  
 
Figure S17: Marfey analysis of diol cleavage product (Microsclerodermin M).Peak identified by reference compound 
L-threo-ß-OH-aspartate. 
 
Figure S18: Acetonide purification and selective irradiation experiments of dehydromicrosclerodermin M. 
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Figure S19: Acetonide purification and selective irradiation experiments of dehydromicrosclerodermin D. 
3.6.5 Experimental section 
 Dehydration of microsclerodermin 3.6.5.1
A solution of microsclerodermin (2 mg) in 100 µl DMSO was diluted with 1 % aqueous TFA (400 µl). 
The mixture was kept at 40 °C for 15 minutes and dried afterwards using a GeneVac Evaporator 
(GeneVac Ltd, Suffolk, UK). Quantitative conversion to the respective dehydromicrosclerodermin was 
verified by dissolving the products in methanol and measuring them by LC-MS analysis.  
 Ozonolysis of dehydromicrosclerodermin 3.6.5.2
Dehydromicrosclerodermin (100 µg) was dissolved in 400 µL dry methanol. A stream of ozone was 
bubbled through the cooled solution (-78 °C) for 20 minutes. The excess reagent was removed by a 
stream of nitrogen before warming the solution to 20 °C. Remaining solvent was then removed under 
reduced pressure and the dry ozonide dissolved in 1 mL formic acid/hydrogen peroxide (2:1, v/v). The 
reaction mixture was heated to 80 °C for 30 min before drying the mixture under reduced pressure. The 
sample was then used for hydrolysis and Marfey derivatization. 
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 Diol cleavage of microsclerodermin 3.6.5.3
Microsclerodermin (500 µg) was dissolved in 50 µL DMSO and added to 300 µL of sodium periodate 
solution in water (0.5 mg/mL), adjusted to pH 4.0 with acetic acid. The sample was stirred at room 
temperature for 16 hours and dried afterwards. The residue was dissolved in hydrogen peroxide (1 mL) 
and formic acid (0.5 mL) and heated to 70 °C for 20 min. After removing the solvent under reduced 
pressure the sample was ready for hydrolysis and Marfey derivatization. 
 Acetonide of dehydromicrosclerodermin 3.6.5.4
Under an atmosphere of dry nitrogen 200 µL of 2,2-dimethoxy propane is added to a stirred 
solution of dehydromicrosclerodermin (2 mg) in 150 µL dry DMF. The reaction is initiated by adding 
catalytic amounts of pyridinium p-toluene sulfonic acid and stirred for 16 hours at room temperature. 
The reaction is quenched by adding 20 µl pyridine and dried using a stream of nitrogen. The residues are 
diluted in 100 µL H2O/DMSO (1:1, v/v) and the respective acetonide purified using the same HPLC 
method as for the initial purification of the microsclerodermins in this work. 
 Marfey derivatization protocol 3.6.5.5
Marfey derivatization was performed with NMR, ozonolysis and diol-cleavage samples of the 
compounds. The protocol is as follows: 
 Put at least 50 µg of sample into a 1.4 mL glass vial 
 Add 100 µL of 6 N HCl. Fill the vial with nitrogen and close it. Keep it at 110 °C for 45 minutes. 
Open the vial to let dry at 110 °C for another 15 minutes. Do not exceed 60 min as tryptophan 
easily decomposes. 
 Dissolve the residues in 110 µL H2O. Prepare two 1.5 mL PP tubes and add 50 µL of the aqueous 
solution in each. 
 Add 20 µL of 1 N NaHCO3 in each tube (pH adjusted to approx. 9) 
 Add 20 µL of 1 % (w/v) Marfey’s reagent in acetone: D-FDLA or L-FDLA, respectively.  
 Keep for 1 hour at 40 °C, 700 rpm. 
 Add 10 µL of 2 N HCl to stop reaction and 300 µL of ACN to end up with 400 µL total volume. 
 Centrifuge the sample and measure the supernatant by HPLC-MS 
 
 HPLC-MS analysis of Marfey samples 3.6.5.6
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH 
C18, 100 x 2.1 mm, 1.7 µm dp column by injection of 1 µl sample. Separation was achieved by a gradient 
using (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 550 µl/min and 45 °C. The gradient was 
as follows: starting at 5 % B to increase to 10 % B in 1 min, from 1 to 15 min increase to 35 % B, from 15 
to 22 min increase to 50 % B, from 22 to 25 min increase to 80 % B. After a 1 min hold at 80 % B the 
system was reequilibrated with initial conditions for 5 minutes.  UV data was acquired at 340 ± 8 nm and 
MS detection was performed simultaneously. Coupling the HPLC to the MS was supported by an Advion 
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Triversa Nanomate nano-ESI system attached to a Thermo Fisher Orbitrap. LC flow is split to 500 nL/min 
before entering the ion source. Mass spectra were acquired in centroid mode ranging from 150 – 
1000 m/z at a resolution of R = 30000. 
3.6.6 HPLC-MS based screening 
We searched our in-house database for producers of microsclerodermins. This screening included 
LC-MS data from 791 myxobacterial extracts covering a broad diversity of myxobacterial genera (Figure 
S20). Eleven different Sorangium sp. were identified as producers of microsclerodermin M. 
Microsclerodermin M is a rather instable compound that readily forms isobaric isomers. This effect is 
most likely related to the unsaturated side chain and causes several peaks that nearly coelute under 
standard LC-MS screening conditions. Thus, extracted ion chromatograms (EICs) for the [M-H2O+H]
+ 
signal at 869.38283 m/z (blue trace, Figure S21) show up with a broadened peak including multiple 
isomers. In addition, the [M+H]+ signal at 887.39340 m/z is detected albeit with lower abundance. We 
observe an additional, later eluting peak in the EICs with a [M+H]+ signal at 869.38283 m/z, most likely 
caused by a loss of water at the pyrrolidone ring upon extract preparation and storage. 
 
 
Figure S20: Myxobacterial genera as covered in our LC-MS based screening data set. 
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Figure S21: List of microsclerodermin M producers as identified by searching our in-house database. All strains are 
of the genus Sorangium. Microsclerodermin M and its isobaric isomers are highlighted by the EIC of 869.38283 m/z 
([M-H2O+H]
+
 
 
ion, blue trace). Abundance of derivatives is related to the different producer strain. Irregular peak 
shape is due to isobaric, almost coeluting derivatives occurring during storage of the extracts. Identification of 
microsclerodermin M is based on accurate m/z, isotope pattern fit, retention time and MS² pattern compared to 
the reference compound. 
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Another group of myxobacteria is producing the known microsclerodermin D as well as pedein A 
and B. In addition, one new derivative (Microsclerodermin L) is identified in this work (Figure S22). The 
strain Chondromyces pediculatus Cm p3 is also part of this group.11 
 
Figure S22: The known derivatives of microsclerodermin in four producer strains are highlighted by colored 
extracted ion chromatograms (EICs) overlaying the base peak chromatogram (BPC, grey). The producers are of the 
genus Jahnella and Chondromyces. Abundance of derivatives is related to the different producer strain. 
Identification of microsclerodermin derivatives is based on accurate m/z, isotope pattern fit, retention time and 
MS² pattern compared to the reference compounds. 
 LC-MS method for screening 3.6.6.1
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a BEH C18, 
100 x 2.1 mm, 1.7 µm dp column (Waters, Germany). Separation of 1 µl sample was achieved by a linear 
gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 °C. The 
gradient was initiated by a 0.5 min isocratic step at 5 % B, followed by an increase to 95 % B in 18 min to 
end up with a 2 min step at 95 % B before reequilibration with initial conditions. UV spectra were 
recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 75 µl/min before entering 
the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, Germany) using the Apollo ESI source.  Mass 
spectra were acquired in centroid mode ranging from 150 – 2500 m/z at 2 Hz scan rate. 
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3.6.7 Double Bond rearrangement 
A retro-biosynthetic approach of the microsclerodermin side chain will initially result in a putative 
incorporation of a very uncommon C3 extender unit. This finding is owing to the double bond order 
which usually indicates the C2 extender units in between the double bonds. However, in 
microsclerodermin this does not hold true as the double bonds can rearrange in order to form a 
π-system conjugated to the phenyl ring. Taking this into account, the retro-biosynthetic proposal is 
based on a phenylacetate derived starter unit followed by C2 units, which is in agreement with 
conventional biosynthetic logic and the results from feeding experiments with labeled precursors. It 
remains elusive if this rearrangement is the result of sample extraction and workup or already takes 
place during/after biosynthesis in vivo. 
 
Figure S23: Retro-biosynthetic proposal for the microsclerodermin side chain. a) C3 extender unit is likely not 
incorporated during biosynthesis. b) A double bond rearrangement leads to C2 extender units. c) A reasonable 
biosynthetic proposal is starting with a phenylacetate starter followed by several C2 extender units. 
3.6.8 Targeted inactivation of the msc locus in So ce38 
Genetic modification of the So ce38 strain was accomplished according to a previously described 
protocol.14 Putative single cross-over transformants were grown in H-Medium (0.2 % soybean meal, 0.2 
% glucose, 0.8% starch, 0.2% yeast-extract, 0.1 % CaCl2 ·2 H2O, 0.1 % MgSO4·7H2O, 8 mg/L FeEDTA, 
50 mM HEPES, adjusted to pH 7.4 using 10N KOH) supplemented with hygromycin (100 µg/mL) and 1 % 
adsorber resin (XAD-16, Rohm & Haas) for at least 5 days at 180 rpm and 30 °C. Methanolic extracts of 
cells and the XAD resin were analyzed by LC-MS and compared with WT extracts. For isolation of 
chromosomal DNA the mutant strain was grown in M-medium containing 100 µg/mL hygromycin. The 
integration of the plasmid at the right position in the genome was verified by PCR as shown in 
supporting Figure S24, using mutant and wild-type DNA as templates. 
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Figure S24: (A) Site of homologous recombination in So ce38. (B) Verification of KO-mutant So ce38::pSUPmscH_KO 
using PCR resulting in two amplicons “check_up” and “check_down”. (C) Abolishment of microsclerodermin 
production as detected by comparative LC-MS analysis of wildtype and mutant strains. An extracted ion 
chromatogram for the most abundant [M-H2O+H]
+ 
signal is shown. (D) Regular secondary metabolite production of 
the mutant strain was verified by identification of a known secondary metabolite in both wild-type and mutant 
strain. 
Table S14: Primers used for amplification and verification of the microsclerodermin knock-out mutant in So ce38. 
oligonucleotide sequence  
mscH_KO_for GAT CCA GCG CTG GTT CCT CG 
mscH_KO_for ACT CGC CCT CGC GGA GGT TCT 
pSUPHyg_fwd ATG TAG CAC CTG AAG TCA GCC 
pSUPHyg_rev ACG CAT ATA GCG CTA GCA GC 
mscH_KO_check_up ACA ACT TCT TCG CGC TCG G 
mscH_KO_check_down TCG TCG TAC GAG AGC CGG 
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3.6.9 Feeding experiments using labeled precursors 
 Feeding in S. cellulosum So ce38 3.6.9.1
 
Figure S25: Isotopic peak pattern of the highly abundant [M-H2O+H]+ signal at 869.38283 m/z proves 
incorporation of labeled precursors into microsclerodermin M (So ce38). The observed mass shifts do perfectly fit to 
the heavy isotopes that were incorporated. 
 
 
Figure S26: Incorporation of labeled L-asparagine subunit characterized by MS² and MS³ spectra acquisition. Data 
shows the feeding experiment in S.cellulosum So ce38. The most abundant fragment with 731.3 m/z is identical for 
the wild type peak and the enriched derivative (see MS³ data). 
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Figure S27: Incorporation of labeled phenylalanine subunit characterized by MS² and MS³ spectra acquisition. Data 
shows the feeding experiment in S.cellulosum So ce38. The mass difference of 8 Da is present in all the highlighted 
fragments indicating that phenylalanine is incorporated into the side chain. 
Feeding in So ce38. Cultivation of So ce38 was performed in 25 mL H medium using 1 % (w/v) XAD-16. 
Labeled amino acids (5 mg) were dissolved in 250 mM HCl (320 µL) and sterile filtered. The labeled 
precursor stock (0.16 mg/mL) was added in three portions to the culture. 80 µL were added on first and 
third day followed by the remaining 160 µL on the fifth day of cultivation. Labeled benzoic acid and 
cinammic acid were dissolved in 80 µL DMSO and added in 2 x 20 µL and 40 µl portions to the respective 
culture. The cultures were harvested after 9 days and extracted with 2 x 25 mL methanol. The organic 
solvent was removed and the residuals dissolved in 500 µL methanol.  
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 Feeding in Jahnella sp. MSr9139 3.6.9.2
 
Figure S28: Isotopic peak pattern of the highly abundant [M-H2O+H]
+
 signals for microsclerodermin D (88 m/z) and 
L (881.32312 m/z) prove incorporation of labeled precursor in Jahnella sp. MSr9139. The observed mass shifts do 
perfectly fit to the heavy isotopes that were incorporated. 
LC-MS analysis of feeding experiments. Measurements were performed on a Dionex Ultimate 3000 
RSLC system using a Waters BEH C18, 50 x 2.1 mm, 1.7 µm dp column by injection of two µl methanolic 
sample. Separation was achieved by a linear gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a 
flow rate of 600 µL/min and 45 °C. The gradient was initiated by a 0.3 min isocratic step at 5 % B, 
followed by an increase to 95 % B in 9 min to end up with a 1 min flush step at 95 % 
B before reequilibration with initial conditions. UV and MS detection were performed simultaneously. 
Coupling the HPLC to the MS was supported by an Advion Triversa Nanomate nano-ESI system attached 
to a Thermo Fisher Orbitrap. Mass spectra were acquired in centroid mode ranging from 200 – 2000 m/z 
at a resolution of R = 30000. The measurements were repeated to obtain high resolution CID data in 
order to support the experiment with annotation of the obtained fragments. 
3.6.10 Bioactivity Testing 
 Bacterial Cultures 3.6.10.1
All microorganisms were handled under standard conditions recommended by the depositor. 
Overnight cultures of microorganisms were prepared in EBS medium (0.5 % peptone casein, 0.5 % 
proteose peptone, 0.1 % peptone meat, 0.1 % yeast extract; pH 7.0) or TSB medium (1.7 % peptone 
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casein, 0.3 % peptone soymeal, 0.25 % glucose, 0.5 % NaCl, 0.25 % K2HPO4; pH 7.3). The latter medium 
was used for E. faecalis and S. pneumonia cultures. Yeast and fungi were grown in Myc medium (1% 
phytone peptone, 1 % glucose, 50 mM HEPES, pH 7.0). 
 Microbial Susceptibility Assay (MIC) 3.6.10.2
Overnight cultures of microorganisms were diluted to OD600 0.01 (bacteria) or 0.05 (yeast/fungi) in 
the respective growth medium. Serial dilutions of compounds were prepared as duplicates in sterile 96-
well plates. The cell suspension was added and microorganisms were grown overnight on a microplate 
shaker (750 rpm, 30 °C or 37 °C).  Growth inhibition was assessed by measuring the OD600 on a plate 
reader. MIC50 values were determined as average relative to respective control samples by sigmoidal 
curve fitting.  
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Chapter 4 – Secondary Metabolomics 
 
Myxobacterial Secondary Metabolomics: 
Contributions to a 
Comprehensive Screening Workflow 
 
 
4 Secondary Metabolomics 
4.1 Introduction  
Natural products from microorganisms are a valuable source for pharmaceutical lead structures.1 
Novel bioactive scaffolds are urgently needed for the development of new drugs to overcome the 
increasing antibiotic resistance amongst pathogenic bacteria.2 A promising approach for the discovery of 
new chemical entities is to search for natural products in formerly underexploited sources, following the 
notion that chemical diversity comes along with phylogenetic diversity. In the long run, the main 
challenge is finding new natural products and isolating substantial amounts of these for full 
characterization and bioactivity testing. However, detection of potentially new compounds and their 
classification as novel scaffolds comes first. In addition, natural product discovery workflows are 
increasingly linked to genome mining approaches to support the identification of new secondary 
metabolites (Figure 1); a trend which certainly requires reliable analytical data to draw meaningful 
conclusions. 
Traditional activity-guided isolation efforts are efficient in finding new bioactive molecules albeit 
this methodology suffers from being limited to a small set of assays and indicator strains.3 Especially 
complex assays or those based on high-risk pathogenic bacteria of the ESKAPE group (see Chapter 1) are 
rarely used for routine screening. As a consequence, compounds with potent activities are frequently 
found after isolation rather than being the driving force behind the isolation. In summary, all efforts 
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point toward finding compounds that are new and active whereas it does not matter what was revealed 
first, activity or structural novelty.  
The crucial part of compound identification in natural product research is usually based on 
analytical techniques like LC-MS as these are able to cope with the complexity of biological samples. 
Utilizing LC-MS or LC-MS/MS analysis provides a powerful and well established approach to identify 
known compounds based on reference substance databases. This process of dereplication facilitates the 
search for new secondary metabolites as the risk of re-isolating a known compound is thereby reduced.4 
However, targeted LC-MS workflows are limited to known compounds whereas methods addressing the 
problem of specifically revealing new compounds are still on their advent. Several computational 
techniques have recently emerged that use MS/MS data for classification of compounds5, such as 
fragmentation trees6,7, cyclic peptide de novo sequencing8,9, and spectral network construction10,11. In 
addition, statistical data mining approaches were used to characterize knock-out mutants by principal 
component analysis (PCA)12 or they served as a method to prioritize strains based on crude extract 
measurements in order to identify those strains that are the least similar to others within a given sample 
set.13,14 
It is quite obvious that results obtained from these approaches critically depend on the coverage 
and quality of LC-MS(/MS) data available for a given sample set. This basic presumption applies 
particularly to secondary metabolites that are easily missed in a complex matrix owing to their low 
abundance or because of the overwhelming number of accompanying signals at the same retention 
time. Indeed, LC-MS profiles from microbial producers are frequently overloaded with large numbers of 
intense signals derived from highly abundant matrix components present in a sample. This can become 
a problem when fragmentation data is needed, e.g. in an untargeted approach where auto-MS² settings 
usually follow an intensity-based precursor selection. Unsupervised acquisition of MS/MS data will end 
up with high numbers of matrix components being fragmented while supposedly important peaks may 
be missed due to their lower abundance compared to matrix peaks. Hence, in this study we aim to 
improve LC-MS/MS analysis towards a reasonable MS/MS precursor selection in order to focus on 
compounds that are actually produced de novo by a bacterial strain, as within this selection of 
compounds chances are best to discover new and bioactive secondary metabolites.  
This work demonstrates how statistical data mining in combination with subsequent scheduled 
MS/MS acquisition can help to highlight and identify mass spectral features that are related to bacterial 
metabolism. In particular, these features are defined by retention time, m/z value and a detection 
response measure (i.e. peak intensity or peak area). The whole method is based on the presumption 
that these features originate from distinct compounds which are detected by the mass spectrometer in 
the course of chromatographic separation. Hence, such an analysis results in a list of putative microbial 
metabolites (represented by molecular features) that helps to address two important issues, namely the 
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identification of potentially interesting peaks in loaded regions of the chromatogram plus the acquisition 
of the corresponding MS/MS spectra irrespective of matrix compounds that cover the compounds of 
interest.  
We exemplify the devised workflow for myxobacteria which usually produce complex crude 
extracts, a consequence of the complex media needed to support growth of many myxobacterial species 
and the minimalistic workup procedures used for extract preparation. The methodology described here 
in combination with in-house database queries and directed bioactivity screening of fractionated crude 
extracts enabled us to generate a well-defined set of candidate signals with their MS/MS spectra that is 
focused on relevant myxobacterial compounds.  
 
Figure 1: Schematic overview of three important approaches supporting and driving natural product research: LC-
MS analysis, bioactivity screening, and genome mining. The combination of these techniques helps to uncover new 
natural products from crude bacterial extracts.  
4.2 LC-MS Performance Evaluation and System Suitability 
The suitability of an analytical platform for a given task critically depends on the system’s 
performance. In terms of dereplication, which is regarded as a method of targeted metabolomics, 
retention time stability, an accurate m/z value with less than 5 ppm error, and a flawless detection of 
isotope intensities is essential to facilitate successful identification of known compounds. Reliability is 
even more crucial for approaches of untargeted secondary metabolomics as no references are available 
that indicate systemic errors. Thus, any analytical platform has to fulfill pre-defined performance criteria 
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tailored to the specific requirements. This performance needs to be approved on a regular basis to 
confirm that the system can deliver the expected quality and that measurements must not be 
conducted if the system fails to meet specified criteria. In this regard, an analytical platform was 
established for the analyses of myxobacterial extracts aiming to serve as the basis for a comprehensive 
screening program for both, targeted methods of dereplication and for untargeted secondary 
metabolomics approaches. 
The system is based on chromatographic separation employing reversed phase chromatography 
with C18-modified particles of the sub-2 µm class combined with mass spectrometric data acquisition 
using an QqTOF machine in positive ESI mode. An unspecific linear gradient is used to separate 
secondary metabolites as they are found at any elution strength (Figure 2). The compounds of interest 
are mostly polyketides, peptidic compounds, or hybrids thereof that are usually further modified by 
various tailoring enzymatic steps such as oxidation, methylation, chlorination and others (see Chapter 
1). Although some of the identified compounds feature ionic moieties such as carboxylic acids, amines, 
phosphate groups, or sulfate moieties, retention is always high enough to separate these compounds 
with reversed phase chromatography.  
 
Figure 2: Myxobacterial secondary metabolites are found at various retention times when they are separated with 
an unspecific gradient using reversed phase chromatography. A large scale screening project must not be specific 
as too many compounds would be missed. 
A certain bias is always introduced by the methods of extraction and measurement, but this is to 
some degree volitional as the workflow thereby focusses on the detection of secondary metabolites. In 
particular, secondary metabolites are enriched on polymeric adsorber resin during bacterial growth and 
eluted afterwards by methanol or acetone. Compounds of primary metabolism are poorly adsorbed 
when using this approach. At the same time, the LC-MS method is based on RP-HPLC using a C18-
modified stationary phase thereby addressing secondary metabolites rather than small ionic 
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metabolites of primary metabolism. In summary, the analytical platform is suitable for almost all known 
myxobacterial secondary metabolites. In addition free fatty acids, lipids and steroids are frequently 
detected by this method although it is conceivable that other types of analysis may be better for certain 
classes of metabolites and some metabolites may even circumvent detection when this method is used. 
 All known myxobacterial compounds were measured on this analytical platform resulting in a large 
reference set of retention time, observed adducts, and MS² spectra deposited in an in-house database. 
The “Myxobase” is a proprietary database that aims to be comprehensive with respect to myxobacterial 
research by aggregating all relevant information about strains and compounds together with previously 
acquired analytical information and bioactivity testing results. At the time of this work the Myxobase 
comprised analytical information of more than 900 compounds and approximately 2500 LC-MS data sets 
derived from myxobacterial extracts. Pure compounds and extracts were measured using standardized 
conditions and subsequently served as input for two different processing and analysis workflows:   
1) Targeted screening 
Known compounds are identified and annotated in LC-MS data of extracts by matching 
against compound information that is deposited in the Myxobase. 
2) Molecular feature “warehousing” 
Each LC-MS run is subjected to comprehensive molecular feature extraction and the 
resulting set of molecular features is deposited in Myxobase.  
These feature sets, generated in a largely unbiased way, can represent the informational content as 
found in the respective raw data files. A putatively new compound can be searched within this huge 
data set, thereby offering the chance to find other strains that produce the same compound in higher 
yield. It goes without saying that a large-scale analytical framework like this requires a well-monitored 
and validated analytical system to rely on. Hence, several important cornerstones of such a screening 
platform in natural product research will be addressed in the following.  
4.2.1 LC-MS Robustness 
Retention time is an important analytical readout as it is orthogonal to mass spectral information 
and thus mandatory to use when conducting LC-MS based screening of microbial extracts. With respect 
to this, reproducible retention times are essential to support identification of known compounds when 
utilizing database queries (Chapter 4.3). Similarly, the data mining approaches described later in Chapter 
4.5 of this work  
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Figure 3: Long term retention time stability. Plot of test mix retention times spanning five months and 2800 
samples measured during this time. Shown are only the test mix samples that were part of this project’s sequence 
lists.  
critically depends on reproducible retention times. For this reason, daily test mix runs were employed to 
ensure retention time stability. Excellent retention time stability was maintained throughout this project 
as depicted in Figure 3. In line with the long-term stability, Table 1 shows the very good retention time 
stability for a series of measurements (120 LC-MS runs) spanning 48 hours of data acquisition which is 
the basis for the data mining workflow of Chapter 4.5,  
Table 1: Test mix performance data (N = 9, main data set from 2013-09-10). 
Peak m/z RT [min] RT RSD Area RSD Intensity RSD m/z error [ppm] 
1 279.091023 2.82 0.3% 6.0% 4.6% -1.84 ± 0.49 
2 285.020751 3.23 0.2% 10.4% 6.9% -3.26 ± 0.46 
3 311.080852 4.05 0.2% 8.1% 6.7% -1.61 ± 0.53 
4 278.190326 4.89 0.1% 2.8% 3.0% -0.75 ± 0.51 
5 314.138685 6.19 0.1% 4.6% 6.9% -2.48 ± 0.49 
 
In addition, a myxobacterial crude extract was measured after each test mix. Being a more complex 
quality control sample, this extract covers a broad range of known secondary metabolites and thereby 
provides an overview on the system’s m/z accuracy, mSigma values and area value deviations. The 
“mSigma” value is a measure for the quality of the isotope intensity distribution. It compares the 
experimental isotope intensity with the calculated isotope intensity of a known compound (based on 
the known sum formula). Acceptable values cover values below 30 mSigma. The results presented in 
Table 2 highlight the robustness of the analytical platform with most part of the m/z errors below 3 ppm 
and very good mSigma values. Chromatographic peak area deviations of around 10 % RSD are in line 
with typical values when using an ESI ion source. 
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Table 2: System repeatability study using known compounds in a crude extract of So ceGT47. Samples were 
measured in the course of a 48 h sequence just after the test mix samples of Figure 3 (N=9). 
Compound name 
Myxobase 
ID 
RT [min] m/z  error [ppm] mSigma Area Int.  
mean STDEV mean STDEV mean STDEV RSD RSD  
Cyclic Tyr-Pro  2425 2.41 0.01 0.90 1.72 6.5 3.3 9.3% 7.6%  
SH-Myxo-373_1   2824 4.29 0.00 0.70 1.16 13.3 2.1 11.5% 11.7%  
SH-Cm7-407   2889 4.73 0.01 0.59 1.37 12.9 4.8 11.3% 11.7%  
Lipothiazole A   2572 9.17 0.01 0.61 1.91 15.8 1.2 6.8% 5.1%  
Lipothiazole B   2702 9.73 0.01 0.38 0.72 20.9 2.8 9.1% 8.4%  
Lipothiazole D   2704 9.91 0.01 -1.10 1.89 13.8 1.4 11.7% 10.9%  
Lipothiazole C   2703 9.94 0.01 -1.24 2.12 11.6 1.6 10.7% 10.7%  
Ambruticin VS-5   224 10.69 0.02 -0.13 1.69 9.6 9.6 9.8% 12.3%  
Ambruticin VS-3   83 10.96 0.02 0.08 0.92 18.1 3.3 11.2% 9.5%  
Ambruticin VS-1   221 11.17 0.02 -0.04 0.68 20.8 2.6 11.6% 9.0%  
Thuggacin B   305 12.40 0.01 0.88 0.88 23.6 3.0 12.4% 9.9%  
Ambruticin S   216 12.84 0.01 -0.94 4.01 7.6 3.4 8.2% 6.6%  
Ambruticin F   311 13.20 0.01 0.51 1.48 12.0 3.7 3.5% 2.7%  
Thuggacin A   75 13.46 0.01 0.10 0.73 22.2 3.2 5.0% 5.6%  
Thuggacin C   528 14.06 0.01 -0.21 1.49 17.7 1.4 21.1% 19.5%  
 
 
These results well justify the conclusion that the system is highly stable and able to deliver 
reproducible chromatographic separations alongside with accurate and reliable mass spectrometric data 
acquisition. 
4.2.2 Biological Reproducibility 
Sample to sample reproducibility with respect to cultivation and extract preparation is an 
important aspect when trying to identify differences between sample groups. Differential analysis 
requires as a prerequisite that significant variations are largely absent within a group but are detectable 
in between groups. Using seven different cultivation conditions – all produced in biological triplicates – 
we can evaluate whether cultivation and preparation of crude extracts is sufficiently reproducible. An 
overlay chromatogram of three independently prepared extracts reveals the biological reproducibility 
(Figure 4). The overlay display is split into four retention time ranges to allow better comparison of the 
single chromatogram traces. 
For most part of a LC-MS run, the peaks of a base peak chromatogram (BPC) are congruent for biological 
replicates of an extract. However, at very late retention times with high organic content the BPC is 
frequently different (Figure 4 D, blue trace). The compounds causing the BPC in this region remain 
unknown although there is certain likelihood that lipids play a role. The important conclusion of these 
triplicate measurements is that the number of outliers was remarkably low within the extracts used in 
this study. Only one extract showed additional peaks in the chromatogram while for two extracts some 
peak areas varied gradually. Altogether, this low biological variance is quite remarkable as strains were 
grown and extracted independently. A single crude extract may be different for unknown reasons, e.g. 
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one of the six So ceGT47 in P medium shows a few additional huge peaks. The reason for this may be a 
contamination or irregular growth conditions but fortunately, deviations comprising only a few peaks in 
single samples do not affect the statistics-based workflow.  
 
Figure 4: Overlay display of the base peak chromatograms of three So ceGT47 crude extracts derived from P-
medium cultures (red, blue, green). The different panels feature several retention time windows, which were 
zoomed for a better comparison.  
4.2.3 Matrix effects in crude extracts 
The effect of a complex sample matrix on the detection of known compounds was evaluated. This 
analysis is of interest as estimations of production rates are often based on measuring the peak area of 
a compound in crude extracts. This bears a risk as the influence of ion suppression is not predictable. In 
particular, ion suppression for a compound is caused by other compounds eluting at the same retention 
time. Different complex cultivation media will certainly cause different peaks within a chromatographic 
separation. As these peaks can elute at different retention times, it becomes clear that suppression 
effects are related to retention time and the medium used. Hence, we set out to quantify the effect of 
ion suppression for three known myxobacterial compounds eluting at the beginning, the middle and the 
end of the standard chromatographic separation (Figure 5 B). These compounds are not naturally 
present in extracts of So ceGT47 but were spiked at different concentrations into the crude extracts 
derived from cultivation of this strain using A, P, H, or M medium, respectively. In addition to spiking 
crude extracts, a dilution series in pure methanol was used as reference. Area values derived from 
spiked crude extracts were set in relation to the reference samples to receive a measure for the matrix-
induced suppression. A value of 100 % suppression means total loss of peak detection (Figure 5). While 
concentrations of 0.1 µg/µL are readily identified in reference samples, the same concentration is not 
detectable in crude extracts. This suppression effect is very strong for the highly lipophilic chlorotonil, 
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whereas sorangicin is only slightly affected.  Chlorotonil elutes at the very end of the chromatogram and 
is heavily suppressed although almost no other peaks are visible. There may be apolar components not 
detected by ESI-MS which strongly suppress ionization in this chromatographic region. An influence of 
the cultivation medium is obvious when M-medium and A-medium are compared with respect to the 
detection of chlorotonil (Figure 5 D).  
Overall, numerous influences add up to a suppression that cannot be foreseen. As a consequence, 
yield estimations in crude extracts relying on LC-MS measurements should be regarded as rough 
estimates as long as they are based on a simple calibration curve that was created with pure samples, 
e.g. methanolic dilutions of a compound. Concentration values obtained using such simple calibrations 
are most likely an underestimate of the real value. Thus, exact ways to quantify the production in crude 
extracts by LC-MS are limited to standard addition methods or methods considering compound-specific 
suppression factors. 
 
Figure 5: A, C, D Suppression of signal intensities for selected spiked myxobacterial compounds. Values refer to the 
change in intensity compared to a methanolic sample of equal concentration, i.e. 100 % is total loss of detection. 
Concentration values are corrected for compound purity as determined independently. B So ceGT47 M medium 
crude extract spiked with 3-compound mix to a final concentration of 50 µg/mL. 
138 Secondary Metabolomics 
 
This finding is also of importance when different media are compared as an increase or decrease of 
a peak area is not necessarily owing to a change in production rate. The suppression effect should be 
considered when statistical mining approaches aim toward the analysis of a sample set that was derived 
from extracts grown with different media. However, all comparative analyses presented in this work are 
restricted to samples grown in the same medium; hence, no problems should arise by the suppression 
effect in this study. 
4.3 Identification of Known Compounds 
Research at the Helmholtz Center for Infection Research, Braunschweig, Germany and at the Helmholtz 
Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany yielded more than 900 
myxobacterial compounds of around 140 compound classes, with a notable unpublished number (as of 
01/2014). With few exceptions these compounds are listed in our proprietary database “Myxobase” 
with analytical information such as retention time, typical adducts and neutral loss fragments that are 
usually observed (Chapter 4.2). By having this information available, we can query the database and 
identify already known compounds in a myxobacterial extract. The database query is performed with 
the Bruker TargetAnalysis™ software based on a reference list from the Myxobase containing the 
necessary analytical information. A LC-MS run is checked for presence of the compounds as listed in this 
reference. Scoring of hits is based on retention time accuracy, m/z accuracy and the isotope intensity 
distribution of each isotope pattern (mSigma value). The isotope pattern is a function of the sum 
formula which is provided with the reference list and comparing the theoretical isotope pattern with the 
measured one gives an orthogonal analytical readout, thereby adding another level of confidence. This 
readout is especially important for compounds exceeding molecular weights of 500 g/mol like it is the 
case for many natural products.15 In addition, commonly observed adducts or neutral loss peaks of 
compounds are also deposited in the database. Their identification further increases the true positive hit 
rate. Applying this workflow to a myxobacterial extract  enables detection of known compounds which 
results in a fully annotated chromatogram for a convenient manual evaluation if necessary (Figure 6).  
Knowledge of which compounds are present in a bacterial extract allows prediction of the extract’s 
bioactivity profile. Especially activities that do not match the known compounds are of interest as they 
point toward new chemical entities. While this annotation of compounds helps a lot, caution is advised 
regarding the linkage between compounds and bioactivity. An obvious link between a known compound 
class and an activity does not exclude that other unknown compound classes can contribute to the same 
type of bioactivity as well. This problem can be addressed by fractionation of crude extracts following 
bioactivity assays for single fractions as discussed in Chapter 4.4. With respect to this, another pitfall 
may be the presence of formerly unknown derivatives of a known compound class. Some strain may 
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produce new derivatives which have not been characterized in previous studies. Hence, a detailed 
evaluation whether a putatively new compound is just a derivative of a known scaffold is indispensable.  
 
Figure 6: Automatically annotated LC-MS chromatogram (Bruker maXis platform) using the TargetAnalysis™ 
software. Known compounds are highlighted by color and name tag (left part). Annotation of peaks is based on 
retention time, m/z, and isotope pattern fit (right part). All data are saved within the Mxbase, our proprietary data 
base. 
In this study the myxobacterial strains S. cellulosum So ceGT47 and S. cellulosum So ce38 were 
tested for the presence of new bioactive compounds. At the time when this work was initiated the 
known secondary metabolites of both strains were limited to merely a handful compound classes as 
shown in Table 3. As a result of genome mining approaches conducted for both strains it became 
evident that there is sufficient biosynthetic potential to produce additional compounds. First of all, a 
brief overview on what is known is given to provide insight into which bioactivities can be expected. 
Found in So ceGT47, the ambruticins are potent antifungal compounds initially isolated from strain 
S. cellulosum So ce10.16 Their remarkable structural feature is a cyclopropane moiety in the center of the 
molecule’s chain. The thuggacins are cyclic PKS compounds found in two different myxobacterial 
genera, Sorangium and Chondromyces, whereas the derivatives of both genera do only vary in an alkyl 
side chain.17,18 The microsclerodermin class was the only known metabolite in So ce38.  
In the course of this thesis, the complete structure with all stereogenic centers as well as the full 
biosynthesis of microsclerodermin was elucidated (Chapter 3). Furthermore, pellasoren was identified in 
So ce38 as well, alongside with the elucidation of its biosynthesis (Chapter 2). Aside of this, there were 
new compound classes identified as secondary metabolites such as SH-373, SH-407 and the lipothiazoles 
in So ceGT47 (see Chapter 4.5.7 for lipothiazole). The metabolites SH-373 and SH-407 are uncommon δ-
amidated glutamates that were recently identified by Stephan Hüttel in a Chondromyces sp. turned out 
to be present in numerous myxobacterial strains. In So ce38 two additional compound classes were 
identified as secondary metabolites albeit not isolated and fully characterized. Soce38-cpd01 was 
identified by gene knockout of an unassigned PKS cluster and subsequent search for changes in the 
resulting extracts using statistical analysis. This compound turned out to be highly unstable hampering 
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its isolation which is partly attributed to its phosphorylation. Soce38-cpd02 is a large, most likely NRPS-
derived compound class as judged by its fragmentation pattern. It is noteworthy, that producers of 
microsclerodermin M (Chapter 3) do produce this compound class as well. However, based on MS/MS 
data, a relation of this structure to microsclerodermin can be ruled out.  
Table 3: Overview of secondary metabolites found in the myxobacterial strains So ceGT47 and So ce38. 
Strain Compound class 
known 
before 
this work activity 
So
 c
eG
T4
7
 
Ambruticin X X 
antifungal (C. albicans, P. anomala) 
antibiotic (S. aureus) 
Thuggacin X 
 
antibacterial, cytotoxic 
Lipothiazole 
 
X - 
SH-373
a 
 
X - 
SH-407
a 
 
X - 
So
 c
e3
8
 Microsclerodermin X X antifungal (P. anomala, C. albicans) 
Pellasoren 
 
X cytotoxic (HTC-116 ) 
Soce38-cpd01
b 
 
X antibacterial (S. aureus) 
Soce38-cpd02
b 
 
X - 
a 
identified and characterized by Stephan Hüttel, 
 b 
not purified, structure not elucidated 
4.4 Bioactivity Testing 
The driving force behind natural product isolation is the identification and characterization of new 
pharmaceutically or agrochemically relevant compounds. In light of this it is of utmost interest to 
include a suitable bioactivity screening in the overall workflow. Crude extracts or compounds showing 
antibiotic effects are ideally identified by bioactivity assays in an early stage of research, e.g. by 
monitoring growth inhibition. Although these assays do only cover a small set of representative 
indicator strains the results point toward promising compounds and thereby initiate further work on a 
bacterial extract (commonly referred to as an activity-guided approach. For this purpose crude extracts 
of strains are subjected to a panel of indicator organisms covering Gram negative bacteria, Gram 
positive bacteria, and fungi. Extracts are applied by means of a dilution series with consecutive 1:2 
dilutions starting from undiluted (A) to the highest dilution of 1:128 (H). Comparing bacterial extracts of 
the same strain grown under different cultivation conditions allows detection of changes in activity 
strength or even the emergence of new activities. 
 In this work extracts of S. cellulosum So ce38 and So ceGT47, both cultivated with different media, 
were tested in a standardized assay with the results shown in Table 4. Bioactivity of So ceGT47 extracts 
is largely constant whereas differences are more pronounced for extracts of So ce38. The antifungal 
effects of So ceGT47 and So ce38 are at least to a certain extend attributed to the known compounds 
ambruticin and microsclerodermin. The remaining activities were not linked to these strains before, and 
are thus of particular interest. 
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Table 4: Results of bioactivity testing of crude extracts. Letters indicate the strength of inhibition ranging from 
weak (A) to strong (H). Each consecutive letter resembles a 1:2 dilution of the precedent letter. (Assays and analysis 
performed by Viktoria Schmitt and Jennifer Herrmann). 
Strain Medium 
S.
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0
0
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1
6
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SM
6
7
6
6
 
M
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D
SM
2
6
5
6
 
So ceGT47 A B 0 0 0 0 0 0 F H C 
So ceGT47 H B 0 0 0 0 0 B F H C 
So ceGT47 M B 0 0 0 0 0 A F H C 
So ceGT47 P B 0 0 0 0 0 A F H B 
So ce38 A F 0 0 C A A 0 D D 0 
So ce38 H H A A E B A 0 E E 0 
So ce38 M C 0 0 B 0 C 0 F G 0 
blank H 0 0 0 0 0 0 0 0 0 0 
blank P H 0 0 0 0 A F 0 0 0 
 
For So ceGT47, the question what causes the effect against Staphylococcus aureus and Micrococcus 
luteus initiated approaches to track down the active compounds. This was done by HPLC-based 
fractionation following a convenient approach which directly links the fractionation to MS detection. 
Two HPLC methods for fractionation are used with one being identical to the standard screening 
method using acidic eluents and the other method being based on a buffered eluent system to 
overcome decomposition of acid-labile compounds during workup. In addition, the use of two eluent 
systems causes different retention times and alters the sensitivity toward distinct compounds thereby 
increasing the informational content. For both methods a 20.5 min HPLC run is fractionated into 
microtiter plates with 96 wells resulting in 93 wells with 110 µl per well and spanning 0.22 minutes each. 
The fractions are dried afterwards and tested for activity against a specific microorganism. By applying 
this method we define chromatographic regions with a direct link between observed activity and the 
compounds eluting in this region as identified by MS.  
A simple example to illustrate bioactivity testing of HPLC fractions is shown for a So ceGT47 extract. 
Initial tests using crude extract resulted in an activity against Staphylococcus aureus irrespective of the 
culture conditions. The strain So ceGT47 is known to produce ambruticins and thuggacins albeit both are 
not reported to be active against S. aureus. This suggested the presence of a new secondary metabolite 
being responsible for this activity or a novel derivative exhibiting changed activity. Testing of HPLC 
fractions eventually revealed ambruticin S and F to be active against S. aureus which was not known 
before (Figure 7 B). Moreover, two additional active fractions were identified which is an important 
result only obtained upon HPLC-based fractionation. It should be noted that results from the two 
different eluent systems are not identical which in turn confirms using both methods. In the end, three 
compound classes add up to the observed activity against S. aureus in crude extract. 
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Figure 7: LC-MS chromatograms of So ceGT47 H-medium extract acquired online whilst fraction collection. The 
same sample was fractionated twice with (A) a 0.1 % formic acid eluent and (B) a 5 mM ammonium formate buffer 
eluent. Both times, two consecutive runs (Vinj = 5 µL) were collected to the same microtiter plate. The plates were 
dried and tested for activity against S. aureus. Fractionation as well as generation of ions by nano-ESI is done by an 
Advion Triversa Nanomate. The BPC of such samples is usually a little overloaded which frequently results in bad 
peak shapes and strong ion suppression (B).  
In a similar fashion, fractionation avoids drawing wrong conclusions in terms of an observed 
bioactivity, like it is the case for ambruticins in So ceGT47. The ambruticins are known to be very potent 
antifungal natural products. The antifungal activity of the crude extract is easily attributed to this 
compound class without considering that there may be other antifungal compounds as well (Table 4). 
Upon fractionation we realized that there is another compound class present with activity against C. 
albicans and P. anomala (Figure 8).  
  
Figure 8: LC-MS chromatogram of So ceGT47 M-medium extract, acquired online whilst fraction collection. The high 
antifungal activity of the crude extract is not solely attributed to the ambruticin class. An unknown compound class 
(2 derivatives) contributes to the antifungal activity as well. 
These two examples show how a combination of targeted secondary metabolomics and 
bioactivity screening helps to track down known compounds as well as active unknown compounds. 
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4.5 Targeted MS/MS in an Untargeted Secondary Metabolomics 
Workflow 
With respect to a screening workflow, the preceding steps yielded very important results by the 
identification of known compounds alongside with the assignment of chromatographic regions 
exhibiting bioactivity. The next step of a screening workflow addresses the search for all unknown 
compounds of which a subset is responsible for the newly observed bioactivity found in some fractions. 
Using statistical methods is regarded a suitable way to carry out such a task. While various statistical 
methods have found widespread use in typical metabolomics studies, both data mining in untargeted 
secondary metabolomics and computational methods for automated analysis of MS/MS spectra are 
currently still at an early stage. This is partly owing to the fact that comprehensive metabolomics studies 
lag behind targeted approaches focusing on identification and quantification of a small number of 
compounds. Methods of untargeted metabolomics or even methods that use MS/MS spectra for 
creating de novo structural information are fairly new to the rapidly developing field of metabolomics.  
Several recently emerged methods use fragmentation spectra from metabolites in order to classify 
compounds  by clustering according to spectral similarity or even to partially elucidate structures, e.g. in 
case of peptide moieties on the basis of characteristic backbone fragmentation or neutral losses.5,9,10,19 
The focus of this work is to improve the MS/MS  data generation step preceding all computational 
analysis approaches, aiming at “reasonable” data dependent MS/MS acquisition in a sense that high 
MS/MS coverage of putatively interesting features should be achieved (as opposed to automatically 
fragmenting the most abundant signals). 
The basic assumption of the approach taken here is that bacterial metabolism has a measurable 
and significant effect on the set of observed LC-MS features (defined by retention time, m/z, and 
intensity). In particular, the differences between feature sets observed from measurement of a “blank” 
cultivation medium and the same medium inoculated with a bacterium are considered to correlate with 
growth of the bacterium. Several effects contribute to these differences:  
1) Media components are metabolized by growing bacteria 
2) Nutrients composed of complex macromolecules are partly digested by excreted enzymes which 
eventually results in metabolite-like small molecules  
3) Cell apoptosis adds additional compounds 
4) Complex media can degrade when kept at elevated temperature for prolonged time 
Secondary metabolites produced by the bacterium in the course of cultivation are also part of this 
complex mixture. Thus, analyzing the LC-MS features which newly appear during bacterial growth 
enables us to direct MS/MS measurements toward the subset of features containing the signals which 
potentially represent secondary metabolites. A straightforward way to perform comparative analysis in 
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order to reveal growth-related features is based on measuring two sample types, “strain” and “blank” 
samples. A “strain” sample is derived from a myxobacterial strain cultivated in liquid medium 
supplemented with adsorber resin. A “blank” sample is the same liquid medium incubated with 
adsorber resin but without bacterial inoculate. Both “cultures” are subjected to identical treatment 
throughout the experiment starting from cultivation, extraction, measurement, up to data processing. 
The key processing step to prepare LC-MS data for statistical mining is a software-aided bucketing across 
all samples based on the extracted molecular features (retention time, m/z, intensity). More precisely, 
the presence or absence of a distinct feature is evaluated across all samples, as judged on the basis of 
retention time and m/z pairs. Upon detection of a feature, its intensity value is included into the bucket  
 
Figure 9: Overview scheme of a targeted MS/MS approach. After creating a suitable sample set the LC-MS data are 
processed with a feature finding algorithm and transformed to a bucket table covering all features. Filtering this 
bucket table according to user-specific constraints yields a precursor list that is used for re-measuring the strain-
derived extract. MS² events are distributed according to the occurrence of growth-derived compounds in the strain 
extract.  
table. This procedure yields a table covering intensity values of all extracted molecular features for all 
samples (Figure 9 B). The resulting feature table is filtered according to the constraint that only features 
found in “strain” samples remain. This workflow results in a list that comprises retention time and m/z 
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for each feature that is related to bacterial metabolism. In a last step, this list is used to specifically 
target these features as precursors for MS/MS analysis (Figure 9).  
Generally spoken, the described processing workflow effectively transforms an intrinsically 
untargeted secondary metabolomics approach into a semi-targeted method. In the following, details of 
the established workflow will be explained alongside with a critical evaluation of data generated using 
this method.  
4.5.1 Molecular Feature Annotation 
Feature annotation is a crucial prerequisite for any LC-MS-based data mining workflow. A mass spectral 
feature is a “clean” spectrum representing a single charge state of a single molecular entity, free of 
noise or other signals. It essentially consists of m/z values and the intensities of all related isotope 
signals. In this study we used the molecular feature annotation algorithm as implemented in the Bruker  
DataAnalysis software. The “find molecular features” algorithm (FMF) searches for signals that belong 
together based on their elution profile.  
 
Figure 10: Survey view on LC-MS data highlighting the detection of single isotope (blue dots). Isotope signals 
belonging to one molecular feature are grouped according to their time correlation as depicted by the blue lines in 
between the blue dots. The yellow area marks the molecular feature based on the m/z of the first isotope and its 
time range. A molecular feature is a combination of m/z and intensity values for all isotope signals as well as the 
retention time range covered by the most intense isotope signal. 
More precisely, the algorithm creates extracted ion chromatograms (EICs) of each m/z value that is 
part of a presumed isotope cluster. EIC traces originating from one specific molecular feature reveal 
themselves through their matching retention time profiles, a finding which is expressed as a correlation 
factor. Traces that fall into a specific correlation factor range are combined to create a mass spectral 
feature which comprises the corresponding isotope signals (Figure 10). Different charge states for the 
same compound are detected similarly and are merged into one molecular feature, thereby reducing 
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the overall number of mass spectral features. A high feature count appears useful to cover as much 
information from the LC-MS data set as possible; however, we aimed to restrict the features to “true” 
chromatographic peaks. For that reason, only features detectable in at least 10 consecutive spectra with 
an S/N-value ≥ 10 were considered. The number of molecular features identified depends on the 
bacterial strain, its growth and on the cultivation medium used, as reflected by values in Table 5. 
Bacterial extracts show an increase in feature numbers compared to the respective blank medium 
extracts; basically a consequence of both primary metabolism of the growing bacterium and the 
formation of secondary metabolites. In this experiment we observed between 3000 and 9000 molecular 
features spanning a retention time window of 19.5 min (Table 5). 
Table 5: Molecular feature count for S. cellulosum extracts of strains So ceGT47 and So ce38 alongside with blank 
extracts for different media used (N = 3 for each value). 
10 spectra/feature  
S/N ≥ 10 
So ceGT47 So ce38 blank  
P-medium 6729 ± 101 - 4218 ± 286  
M-medium 5479 ± 552 3681 ± 60 3322 ± 131  
H-medium 4613 ± 266 4634 ± 100 2302 ± 81  
A-medium 5752 ± 398 5484 ± 308 2478 ± 309  
 
 
The high number of molecular features is owing to the rather tolerant settings used for feature 
finding. Settings are chosen to preserve as much information as possible as a succeeding statistical data 
evaluation is not limited by a large number of features. The fact that nothing is initially known about the 
origin of these features is the reason why only moderate filtering should be applied in this very early 
stage of data processing.  
4.5.2 Binning of Features – The Bucket Table 
The feature sets of all samples are then used to prepare an overview matrix covering intensity values of 
all features (Figure 9 B). This type of processing is basically a two-dimensional binning of molecular 
features across all samples according to retention time and m/z value. Note that intensity values are not 
binned but transferred as distinct entry to the bucket table. First, buckets are generated using the 
advanced bucketing method of the ProfileAnalysis software (Bruker Daltonics). For this purpose a bucket 
is created by setting a region defined by retention time and mass accuracy ranges of 0.25 min and 10 
ppm around every feature. If there are several features in one bucket due to overlapping signals, the 
bucket is split until only one feature remains per bucket. In the second step, features of other samples 
are checked if they fit to one of the existing buckets. Matching features are added to the existing 
bucket. In case a feature does not fit to any of the existing buckets a new bucket will be created. This 
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procedure is repeated for all the samples of the experiment until every feature of every sample is part of 
a bucket. Finally, bucket intensity values are log-transformed to overcome heteroscedasticity.20 The 
term heteroscedasticity describes the effect that measurement uncertainty is not equally distributed for 
the acquired data, i.e. the statistical variance is usually bigger for low abundant peaks. This difference in 
variance can have several reasons, e.g. metabolite changes due to irreproducible cultivation issues or 
systematic deviations in mass spectrometric detection. This effect should always be considered when 
dealing with wide concentration ranges as present in complex biological samples.  
 
Figure 11: A bucket of predefined RT and m/z range is created around each feature. All samples are checked for 
features matching the bucket constraints upon which the respective intensity values are saved within the bucket 
table. The example shows two strain samples having the feature of interest and two blank samples were no 
features fit to the bucket table.    
A bucket table processed by these methods may be used as input for multivariate data analyses. 
Principal component analysis (PCA) is good technique to visualize the differences between samples and 
thereby allows a grouping of samples in order to reveal trends and outliers. PCA reduces the 
dimensionality of a multivariate dataset while the information of the underlying data set is retained. 
Such a method is of interest when the variations between strain samples and blank samples are of 
interest (Figure 12). For this type of unsupervised analysis, a Pareto scaling is applied which is commonly 
used in the metabolomics field as it lowers the impact of highly abundant peaks on statistical model 
calculation.20,21  
A PCA scores plot gives a first hint whether the underlying data contains samples which are critical 
outliers having negative influence on the statistical model. If a single sample is not well explained by the 
model it has to be removed from further data mining, as it may abnormally affect the final result and 
lead to invalid conclusion. The expected output of PCA analysis provides the information that is needed 
for further processing by clearly distinguishing feature sets from “strain” and “blank” samples. The 
underlying reason for this differentiation is depicted in the loadings plot in which all buckets are shown 
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(Figure 12). The more off-center a bucket is located, the more this bucket contributes to the observed 
grouping in the PCA model. A grouping of buckets is frequently observed as a consequence of similar 
 
Figure 12: Example of a PCA analysis for a S. cellulosum So ceGT47 sample set highlighting the ability to distinguish 
between different samples (left part) by grouping the buckets belonging to the data set (right part). 
characteristics with respect to the whole data set as depicted with the marked area in Figure 12. This 
group represents all buckets that are solely found in six out of six “strain” samples but never in “blank” 
samples (strain count = 6) and thereby represent only compounds that are related to bacterial growth 
(Figure 9 B or Figure 12). A suitable way to get a full list of such buckets is filtering the respective bucket 
table according to the given constraints whereas determining reasonable constraints for the underlying 
data set was one objective of this work. When comparing a set of “strain” samples with the 
corresponding set of “blank” (medium) samples the question arises how many biological and technical 
replicates are needed to reduce the number of false positive hits, e.g. originating from inconsistent 
cultivation conditions or technical issues. For this reason it is not advisable to take solely two data files 
into account as it will certainly yield vague results, i.e. results based on too many false positive hits witch 
causes questionable conclusions. An adequate compromise of workload and expected outcome is 
necessary when preparing samples. To test the effect of technical and biological replicates we used a 
sample set of S. cellulosum So ceGT47 in P medium, consisting of twelve extracts comprising six “strain” 
extracts and six “blank” extracts where each sample was measured twice. Bucket tables were generated 
using different numbers of files starting from 2 vs. 2 up to 6 vs. 6 biological samples. Having replicate 
measurements of all biological samples allowed us to create bucket tables of type 2R vs. 2R up to 6R vs. 
6R where “R” indicates the use of technical replicates. All bucket tables were filtered for the strictest 
condition which is  
 
“bucket count strain”/”bucket count blank” = max value / 0, 
 
e.g. for a 3R-3R data set only buckets of type 6/0 are counted. The amount of buckets for each table is 
plotted against the number of biological samples to evaluate the effect of the sample set size (Figure 
13).  
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Figure 13: Bucket count in relation the number of samples involved in analysis. The bucket count seems to approach 
a basal level as a consequence of reducing false-positive hits when using larger sample sets. The benefit of replicate 
measurements is remarkable when using two or three samples, respectively. A 3R-3R data set is regarded as 
suitable for data mining. 
The decrease in buckets is not linear but rather approaches a basal level. This is expected as noise 
features are more effectively eliminated when using larger sample sets. An important result is the 
delineation of impact of replicate measurements upon which we decided to continue this study with 
data sets that consist of three samples per set with each sample measured twice. Hence, those buckets 
which are present in every measured sample fulfill the condition “strain”/”blank” = 6/0. We also 
consider buckets that match a 5/0 and 4/0 condition, based on practical considerations since the 5/0 
condition can mitigate the influence of one failed measurement e.g. if it faced technical problems. A 4/0 
condition even allows for additional drop-out of a biological sample, e.g. owing to inappropriate growth 
of the culture.  
4.5.3 Creating a MS/MS Precursor List 
The filtered bucket table is the basis for a precursor list that is used in subsequent LC-MS/MS 
measurements. It is important to note that bucket tables exported from Bruker ProfileAnalysis 2.1 (build 
250) are not suitable to use them directly as a precursor list albeit they basically comprise RT and m/z 
values. However, each bucket is labelled with the m/z value of the respective [M+H]+ ion even if only 
higher charge states were detected, i.e. a compound only showing up as +2 ion will get a bucket label 
that refers to the +1 ion m/z value.  
As a technical workaround, charge state information can be preserved by exporting distinct lists 
(RT, m/z) for each charge state. After creating charge state lists for +1, +2, +3, +4, and +5, each row of 
the charge state list (RT, m/z) is searched amongst the complete bucket table using a SQL query (Figure 
14). Upon a matching pair, the respective row in the bucket table is extended by the charge state 
information. This downstream processing is realized by KNIME software (Konstanz Information Miner 
software) in combination with a MySQL database using a workflow that annotates observed charge 
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states to each bucket. The SQL query was repeated for all rows of all charge state lists to end up with a 
bucket table covering charge state information for every bucket. It is moreover necessary to allow for 
some RT and m/z deviation when running the SQL query as the automatically exported charge state files 
do not exactly fit to the bucket labels, i.e. entries in the charge state list comprise time windows while 
the bucket table has fixed values. As there is no way to circumvent this, all time windows were replaced 
by the mean values and these mean values compared to the bucket table by allowing a narrow retention 
time tolerance. This processing yields a precursor list with full charge state information which is further 
used to calculate the m/z value based on each charge state.  
 
 
Figure 14: SQL query for identification of charge states of each bucket table row. The query is performed for each 
charge state list (X = 2, 3, 4, 5) and the query result is added to the bucket table for each list. 
After applying an intensity threshold, all buckets with intensity values less than 10,000 are 
excluded from the list. This bucket table is again filtered according the “strain count”/”blank count” 
constraints and exported from KNIME as three independent lists (RT, ΔRT, m/z ) named “only-6”, “6+5”, 
and “6+5+4” referring to the “strain” count that is used in each list (Figure 13). This type of list covers all 
the information necessary to perform a precursor selection for MS/MS analysis. All molecular features 
that are most likely related to bacterial metabolism – as based on statistical data evaluation – are part of 
this list. The size of such a scheduled precursor lists (SPL) spans from 463 to 922 entries for a 19.5 min 
chromatographic run of So ceGT47 extract cultivated in P medium. A histogram view of the “SPL_only-6” 
presented in Figure 15 illustrates in which time slot acquisition of MS/MS spectra will be triggered.  
With this precursor lists in hand we set out to measure samples in SPL-MS² mode and in auto-MS² 
mode. Noteworthy, the sample material used for MS/MS analysis is always a mixture of the strain 
extracts that were used to create the bucket table. This enables analysis of “4/0” bucket scenarios as 
those may be related to a feature physically missing in one of the three samples. Only a mixture of the 
three samples can cover all “4/0”-related features. 
 
SELECT 
 buckettable.RT_bucket, buckettable.mz_bucket,  
 chargelistX.time, chargelistX.MZ_SPL 
FROM 
 buckettable, chargelistX 
WHERE 
 (chargelistX.time BETWEEN (buckettable.RT_bucket-0.2) 
 AND (buckettable.RT_bucket+0.2)) 
AND  
(chargelistX.MZ_SPL BETWEEN (buckettable.mz_bucket-0.1) 
 AND (buckettable.mz_bucket+0.1)) 
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Figure 15: Overlay display of base peak chromatograms of a P-medium blank extract (grey) and a So ceGT47 P-
medium extract (orange). The blue graph is a time-based histogram of the MS² events that are listed in one of the 
SPL used for LC-MS/MS. The number of MS² events resembles the orange chromatogram. 
4.5.4 MS/MS Data Acquisition and Processing 
The next step of this data mining workflow is the acquisition of MS/MS spectra using the trigger 
events as defined in the SPL which was generated in the preceding steps.  In particular, the mass 
spectrometer is supposed to use the information on retention time and m/z value as saved in the SPL to 
exclusively select matching ions as precursors for subsequent MS/MS analysis.  Ideally, the instrument 
should be able to select all desired precursors and perform the requested high-resolution MS/MS 
measurements. However, full coverage of the SPL may not be achievable for several reasons: 
1) Compounds responsible for low abundant peaks may circumvent detection in subsequent 
MS/MS measurements upon degradation 
2) Some SPL entries are false positives owing to errors during feature bucketing 
3) Time slots may cover more MS/MS triggers than the instrument  
duty cycle can cope with 
Especially the latter can be addressed by optimization of the MS/MS parameters and considering 
some practical constraints. As a result of small chromatographic peak widths of only 6 to 10 seconds and 
the complexity of the sample, SPL entries are dense with respect to the retention time scale. This is 
exemplified by a histogram for a typical SPL with around 500 entries revealing time slots with frequently 
more than 4 precursors (Figure 15). Especially time slots with a high number of potential precursor ions 
could be a problem for the overall coverage of SPL entries. This is owing to a prolonged duty cycle which 
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eventually causes a subsequent time slot not to be taken into account. In order to avoid interference 
with subsequent time slots, the duty cycle time should be limited, e.g. by restricting the number of 
MS/MS scans per full scan. If a MS² method is used which is limited to a maximum of 4 precursors 
(dashed line in Figure 15) some of the listed precursors for this particular time slot will be missed for the 
sake of a better coverage of all time slots. However, one of the methods tested has a strict precursor 
selection which causes all precursors listed for a given time slot being addressed, no matter how many 
are affected.  
The origin of such time slots loaded with SPL entries is partly attributed to compounds susceptible 
to strong in-source fragmentation as respective fragment ions are individually added to the potential 
precursor list during the initial statistical approach. In principle, applying MS/MS fragmentation to those 
in-source derived fragments can increase confidence for compound identification, but on the other 
hand these data add redundancy to the dataset. Hence, restricting the number of precursors of a duty 
cycle can help to increase coverage for diverse compounds alongside with avoiding redundant 
information. With respect to this problem, an automatic adduct finder algorithm could help to combine 
frequently observed adducts and neutral-loss-derived features into a single feature.  
In summary, a compromise between cycle time, spectra quality, and number of selected precursor 
ions had to be evaluated as part of this project. Several MS/MS settings were tested to check for a high 
SPL coverage. In particular, the effect on SPL coverage was tested with settings varying in the type of 
precursor selection (auto-MS² or SPL-MS²), the number of precursor ions, and scan speed. The duration 
of each duty cycle is a function of the respective precursor intensity and the time necessary for one full 
scan and all preceding MS/MS scans. It is noteworthy, that for SPL-MS² methods the number of 
precursors is variable but limited to a maximum. Hence, duty cycle time in SPL-MS² acquisition can vary 
depending on both, the number of precursors for a given time slot and the precursor intensity. On the 
contrary, duty cycles for auto-MS² methods do only vary based on precursor intensity for the methods 
used in this work. 
The most important value to rate the quality of these analyses is the “SPL coverage” which reflects 
how many SPL entries were fragmented during one run. To achieve coverage of 100 %, each SPL entry 
needs to be fragmented at least once. Since the SPL coverage is not affected when a single precursor is 
measured several times, an additional value named “MS/MS efficiency” is introduced. This value reflects 
the percentage of MS/MS events that act on precursors which are listed in the SPL. MS/MS efficiency is 
generally not 100 % even though a SPL-guided precursor selection is used. This is owing to the fact that 
precursor selection constraints were not that strict, i.e. a precursor m/z was selected if the determined 
value matched within a window of +/- 0.2 m/z to the value as listed in the SPL. When using complex 
biological samples there is a chance that some impurities match the constraints as well. In light of this it 
becomes clear that a 100 % value is usually not achievable albeit it would reflect the ideal situation.  
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Table 6: Different MS/MS methods as used in this study. Changes are related to acquisition speed, number of 
precursors and the way precursors are selected, i.e. automatically based on most abundant ions (auto-MS²) or 
based on pre-filtered precursor lists (SPL, scheduled precursor list). Measurements were done in duplicate for each 
setting. 
# mode precursor 
acq.speed 
#1 [Hz] 
acq.speed 
#2 [Hz] 
Prec. Int. 
#1 
Prec Int. #2 
duty cycle 
[s] 
1 auto MS² 2 1.5 2.9 1E+04 5E+04 1.2 - 1.8 
2 auto MS2² 3 1.5 2.9 1E+04 5E+04 1.5 - 2.4 
3 auto MS²_fast 3 1.5 6.7 1E+04 1E+05 0.9 - 2.4 
4 SPL 2prec 2 1.5 2.9 1E+04 5E+04 1.2 - 1.8 
5 SPL 3prec 3 1.5 2.9 1E+04 5E+04 1.5 - 2.4 
6 SPL 3prec_fast 3 2.0 6.7 1E+04 1E+05 0.9 - 2.0 
7 SPL 4prec_fast 4 2.0 6.7 1E+04 1E+05 1.1 - 2.5 
8 SPL strict all 2.0 10.0 1E+04 1E+05 - 
 
 
In conclusion, “MS/MS efficiency” and “SPL coverage” are both used to rate the methods whereas 
“SPL coverage” is of higher explanatory value. Aside of this, it is of interest to analyze how many known 
compounds ─ as identified by database query ─ are captured by the MS² events of one measurement. To 
address this question, reports of known compounds were created using the Bruker TargetAnalysis 
software and manually curated. These reports were compiled for each strain/medium combination in 
this study and used to search for matching MS/MS events in an analysis. The processing is accomplished 
by a combination of Bruker DataAnalysis, KNIME, and a MySQL database. First, MS/MS events of a given 
measurement are exported from DataAnalysis and imported to the MySQL database covering the 
necessary information, i.e. retention time, m/z, and intensity of each precursor ion. In the next step the 
SQL language is used to compare the SPL with the list of MS/MS events using the query shown in Figure 
16. Matches must fulfill the constraints of a 0.4 min retention time window and a 0.04 m/z window 
around the distinct SPL values. 
 
 
Figure 16: SQL query used to identify SPL entries being measured in a real sample. 
MS/MS event lists were compared to the corresponding SPL, e.g. a SPL-MS² sample measured using a 
list of type “SPL-only6” is compared to the same list by means of a SQL query. In line with this, auto-MS² 
samples are compared to lists of different type such as “SPL-only6”, “SPL-6+5”, and “SPL-6+5+4”. In 
SELECT  
 SPLlist.RT_SPL, SPLlist.MZ_SPL, SPLlist.Intensity, SPLlist.charge,  
 MS2event.RT_exp, MS2event.MZ_exp, MS2event.Intensity, MS2event.I_fragments 
 
FROM SPLlist, MS2event 
 
WHERE 
(MS2event.RT_exp BETWEEN (SPLlist.RT_SPL-0.2) AND (SPLlist.RT_SPL+0.2)) 
AND  
(MS2event.MZ_exp BETWEEN (SPLlist.MZ_SPL-0.02) AND (SPLlist.MZ_SPL+0.02)) 
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addition, all MS/MS events were compared to the corresponding list of known compounds derived from 
the TargetAnalysis report using a similar query (Figure 17). 
 
 
Figure 17: SQL query used to identify the number of MS/MS scans related to known compounds within list of 
MS/MS events. 
Although detailed information on matching entries is available, the classification of the methods used 
here considers solely the sum of all hits. For example, 80 % SPL coverage is achieved if 400 out 500 SPL 
entries were fragmented irrespective of the detailed characteristics underlying each entry, e.g. whether 
the spectrum shows a lot of fragment signals or whether the precursor was fragmented once or twice.  
The effect of different MS/MS acquisition methods is depicted in Figure 18. First of all, an obvious 
difference between auto-MS² and SPL-MS² methods is observed with respect to both SPL coverage and 
MS/MS efficiency. Effects within each type of method are less pronounced as for example auto-MS² 
methods show a slightly higher SPL coverage when using 3 instead of 2 precursors (#1 to #3, Figure 18). 
At the same time MS/MS efficiency is lowered indicating that more fragment spectra were executed 
although those are not related to the potentially interesting SPL. In terms of SPL-MS² methods, speeding  
 
Figure 18: Effect of different MS/MS settings on SPL coverage and overall MS/MS efficiency (N = 2 for all values). An 
SPL coverage of 100 % is equal to acquisition of at least one MS/MS scan for all precursors listed in the SPL (463 
entries for this list). The MS/MS efficiency is the relative number of single MS/MS scans that were related to an SPL 
entry. The bars highlighted in orange represent the setting that is used for all upcoming measurements. 
SELECT  
known.RT_TA, known.MZ_TA, known.`Name`, MS2event.RT_exp, MS2event.MZ_exp, 
MS2event.Intensity, MS2event.I_fragments 
 
FROM   known, MS2event 
 
WHERE 
(MS2event.RT_exp BETWEEN (known.RT_TA-0.2) AND (known.RT_TA+0.2)) 
AND  
(MS2event.MZ_exp BETWEEN (known.MZ_TA-0.02) AND (known.MZ_TA+0.02)) 
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up the duty cycle time has a weak effect on SPL coverage, e.g. if comparing setting #5 and #6. However, 
SPL coverage increases when 4 precursors are taken into account while there is no change between 2 or 
3 precursors (settings #4 to #8). This is reasoned by the higher coverage in time slots with many SPL 
triggers. Expectedly, the best coverage is achieved for the strict precursor selection when all precursors 
that are listed are actually subjected to fragmentation. However, this setting can lead to the above 
mentioned problem of prolonged duty cycles. Using 4 precursors seems to be a good compromise 
between coverage and scan speed. 
Taken together, the devised MS/MS method in this study was set to allow a maximum of 4 
precursors using a full scan acquisition time of 2 Hz followed by MS/MS spectra acquisition at variable 
scan speed (method #7, Table 6). In detail, scan speed in MS/MS scans is governed by precursor 
intensity and follows a linear increase from 2 to 6.7 Hz between the two intensity set points yielding 
duty cycles ranging from 1.1 to 2.5 seconds. The mass spectrometer’s software reads the SPL for the 
upcoming 2 seconds and fragments the four most intense precursors in this time slot. After this duty 
cycle the upcoming 2-second-window is evaluated. Each precursor is moved to an exclusion list when 2 
fragment spectra were acquired and remains there for 0.2 minutes. Note that auto-MS² mode selects 
the 3 most abundant m/z of a full scan and fragments those using the same scan speed settings as for 
the SPL mode. Hence, the only difference in these experiments is in fact the approach taken for 
precursor selection. 
Apart from optimizing acquisition settings, full SPL coverage is hard to achieve since some 
components of the crude extract are susceptible to degradation. Indeed, in-depth manual analysis 
reveals that missing SPL precursors most often show up with low intensities in the bucket table, e.g. an 
intensity median value of 19,000 is given for the 100 missing SPL entries in case of the above shown 
strict method (method #8, Table 6). Thus, these precursors were already low abundant at the time the 
extracts were initially measured and may escape MS/MS fragmentation in a subsequent run. Stability 
drawbacks can be overcome when all samples are measured in a shorter time, which is indeed feasible 
once a suitable method has been established. 
4.5.5 Evaluation of SPL-derived Data 
A first impression of the usefulness of a SPL-MS² method has been given in the preceding chapter 
when the precursor selection of auto-MS² is compared to SPL-MS². However, a more detailed evaluation 
is necessary to estimate the efficacy of the whole approach. The initial feature annotation and the 
following statistics-based bucketing (Chapter 4.5.1 and 4.5.2) may already introduce false positive 
entries to the SPL. As bucketing is – like every technique of such type – error-prone, there are likely 
features that were assigned to the strain group although they were present in blank samples as well. 
Such entries should be detectable by applying the respective SPL-MS² method to a medium blank 
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sample with the results shown in Table 7. Here,  up to 5 % of the SPL list entries were fragmented in a 
blank sample run and most part of this can be attributed to wrong SPL entries.  
Table 7: Comparison of blank and strain samples when measured with a SPL-only6 method. The table shows the 
number of MS/MS events measured in each run together with all MS/MS events that are related to a SPL entry, no 
matter if scans belong to identical precursors. The SPL coverage is calculated based on filtered MS/MS scans to 
account for scans that belong to identical precursors (not shown in this table). Values are average values of 
duplicate measurements. 
Sample 
all MS/MS 
events 
measured 
MS/MS events 
related to SPL 
entries 
SPL size 
SPL 
coverage 
 
blank, P medium 56 23 459 4%  
blank, A medium 66 37 483 2%  
blank, M medium 116 39 485 5%  
blank, H medium 52 13 436 2%  
      
So ceGT47, P medium 683 583 459 76%  
So ceGT47, A medium 651 514 483 68%  
So ceGT47, M medium 586 503 485 70%  
So ceGT47, H medium 647 566 436 78%  
 
 
The table reveals a problem which is related to precursor selection and the constraints used 
therefor. There are MS/MS scans which are not directly linked to the SPL entries causing the discrepancy 
between the first two data columns of Table 7, e.g. 56 scans were measured but only 23 are of 
relevance in case of P-medium blank. These additional MS/MS scans are related to – mostly low 
abundant – peaks or chemical noise matching the constraints for precursor selection without actually 
being the correct precursor. This effect is pronounced with increasing complexity, e.g. when comparing 
the highly complex strain samples to the moderately complex blank samples. Higher complexity does 
usually come along with more chemical noise and thereby increases the chance to accidently select a 
wrong precursor. By adjusting the constraints for precursor selection in terms of m/z range these wrong 
selections may be further reduced if necessary. The end, the comparison of blank and strain samples 
measured with identical SPL-MS² mode clearly shows that some of the SPL entries are wrong as they are 
also found in blank samples. However, a false positive rate of usually less than 5 % is an acceptable level 
of confidence. 
Another approach to prove the usefulness of SPL-MS² is based on a serial dilution experiment. Two 
crude extracts were diluted with respective blank extracts in order to maintain or even increase the 
complexity of the sample while at the same time the concentration of strain-related compounds is 
decreased. As a consequence, strain-related peaks will be suppressed by matrix peaks from the blank 
sample or simply too diluted to be detected or selected as a precursor by auto-MS². Each sample was 
  5.1 Predicting Secondary Metabolite Structures 157 
 
measured with auto-MS² and with SPL-MS² using a SPL of type “SPL_6+5”. For both methods, auto-MS² 
and SPL-MS², the SPL coverage (dark grey bar, Figure 19) decreases to a comparable extend with the 
coverage being better for all SPL-MS²-derived runs. The overall decrease of coverage in the course of a 
dilution series is reasoned by the fact that signals fall below the limit of detection. The notable result of 
this experiment is that SPL-MS² methods are capable to use MS/MS scans more efficiently. In detail, the 
number of overall MS/MS events (red line, Figure 19) is always lower for SPL-MS² methods than for 
auto-MS² methods while at the same time more precursors of potential interest are subjected to 
MS/MS scans (light grey bars remain high).  
 
Figure 19: Dilution series of a crude extract of (A) So ce38 – H medium and (B) So ceGT47 – P medium. Left part of 
each graph shows the SPL coverage when using a SPL-MS² method. Right part of each graph features the same 
samples measured with an auto-MS² method. The red points represent the number of overall MS/MS scans 
performed for each setting. 
Some of these results are depicted with the help of Euler diagrams which allow a comprehensive 
view on the efficiency of the method. For this purpose, Euler diagrams were created to represent the 
overlap between all MS/MS events of a run in comparison to the SPL entries and the list of known 
compounds as determined for the respective measurement. On the basis of the dilution experiment 
described before, Figure 20 shows three data acquisition conditions for So ceGT47 P-medium extract 
diluted with P-medium blank. Note that the figure is based on the same data as used for Figure 19 B. 
The MS/MS efficiency of SPL-MS² methods becomes clear when the size of the orange circles (MS/MS 
events) is considered. A dilution causes less MS/MS scans but still a higher coverage of SPL entries for 
SPL-MS² methods (numbers highlighted in bold font). The right part of Figure 20 reveals that auto-MS² 
uses a comparable amount of MS/MS scans for each dilution but misses significantly more SPL entries as 
those are not anymore the dominant peaks of a spectrum owing to dilution. 
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Figure 20: Evaluation of the effect of SPL-based LC-MS/MS acquisition for a dilution series. The data is based on So 
ceGT47 P-medium extracts which were diluted with P-medium blank in the ratios 1/10 and 1/20 and measured 
under the control of a SPL-MS² method or an auto-MS², respectively. 
Another set of Euler diagrams was created for measurements based on an identical sample 
measured with different SPL (Figure 21). The idea behind this experiment is to rate the effect of SPL size 
on SPL coverage, i.e. does SPL coverage remain high even though the SPL size is significantly increased? 
This would be the case if the system is able to handle the additional MS/MS triggers predetermined by 
the SPL. This was checked by using three different SPL for So ceGT47 P-medium: 
 
(1) SPL-only6: Buckets found in 6 out of 6 samples (459 SPL entries) 
(2) SPL-6+5: Buckets found in 6/6 or 5/6 samples (701 SPL entries, 1.5-fold “only6”) 
(3) SPL-6+5+4: Buckets found in 6/6, 5/6, or 4/6 samples (780 SPL entries, 1.7-fold “only6”) 
A SPL-MS² run with “SPL-only6” addresses 321 out of 459 SPL entries (70 %). By using “SPL-6+5” 
and “SPL-6+5+4” the SPL size is increased by factor 1.5 and 1.7 whereas the number of MS/MS scans is 
increased by a factor of 1.4 and 1.5. At the same time the SPL coverage remains high with around 65 %. 
This result is depicted by Figure 21 where a high central overlap region indicates the high SPL coverage 
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throughout the SPL-MS² runs. With respect to this result it is concluded that the significantly increased 
SPL size is still adequately processed by the instrument. Again, there is a remarkable difference to the 
auto-MS² methods which addresses only 35 to 40 % of the SPL entries although having more than 
double the number of MS² events. In terms of the known compounds, no significant difference is 
observed for both acquisition methods; this result is however anticipated owing to the fairly high 
abundance of known compounds found in this crude extract.  
 
Figure 21: The effect of using different SPL for the same sample represented by Euler diagrams. The overall areas as 
well as the overlap areas are size-proportional to the values that contribute to the respective field. Data derived 
from S. cellulosum So ceGT47 P-medium data set.  
In a next step, the reason for the discrepancy between methods auto-MS² and SPL-MS² is 
investigated. In particular, why is the auto-MS² method missing so many of the potentially interesting 
precursors? Can the initial assumption be confirmed that only the intensity-based precursor selection is 
causing this effect? A suitable approach to answer this is to check the characteristics of the overlapping 
regions in the Euler diagram of Figure 21 A and B where one method results in 321 SPL entries measured 
and the other in only 188. The intensity data for each precursor of these SPL entries was used to create 
a histogram based on intensity value binning following the creation of an overlay display to directly 
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compare the SPL-MS²-derived hits with the auto-MS²-derived ones (Figure 22). This was done for a “SPL-
only6” and a “SPL-6+5+4” measurement which significantly differ in the overall SPL size as well as in this 
overlap region.  
 
Figure 22: Overlay display of MS/MS event histograms for auto-MS² and SPL-MS² data. The additional MS/MS 
events of a SPL-MS² run compared to an auto-MS² run are usually found for precursor intensities of less than 1x10
5
 
counts (highlighted area within the histograms). 
The bars reflect the number of MS/MS events with respect to the precursor intensity used in each 
case. With this graph it becomes evident that using a SPL-MS² method enforces the selection of low 
abundant precursor ions (blue bars). More precisely, the most part of the additional 133 MS/MS events 
of the first example of Figure 22 is related to precursor ions with intensities less than 1x105 as can be 
seen by the difference of blue and grey bars in the highlighted area. A similar trend is observed for large 
precursor lists, i.e. when using the “SPL-6+5+4” as shown in Figure 22 B.  
This proves that using a SPL-MS² method enforces the acquisition of precursor ions irrespective of 
their relative intensity. Furthermore, it was shown that the benefit of a SPL-based MS/MS acquisition in 
terms of SPL coverage and MS/MS efficiency persists for all sample sets measured in the course of this 
work, i.e. two different myxobacterial strains using four different media. For all sample sets that were 
tested, the superior selection of precursor ions was observed when using SPL-methods. In this study, an 
auto-MS² run covered a maximum of 50 % of the SPL entries which is reasoned by the selection of the 
abundant peaks of interest. However, the auto-MS² method misses the low abundant peaks of interest 
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although these should be considered important in terms of being related to bacterial growth (as 
revealed by the initial statistics-based filtering step) 
It should be noted that the capability to select such precursors of lower abundance is only of 
interest if the resulting fragment spectra bear enough informational content for further use, i.e. by 
manual evaluation or computational techniques. This requests an evaluation of MS/MS spectra quality 
when spectra are derived from low intensity precursors. A suitable approach to do so is based on 
fragmentation of known compounds using the SPL method as established in the course of this work. The 
concentration of known precursor was reduced on purpose by diluting crude extract with blank extract 
until a dilution was reached where auto-MS² was not able to select this particular precursor anymore. 
This diluted extract was then measured using a SPL-MS² method and indeed, relevant precursor ions 
were still selected for fragmentation. The fragment spectra derived from these measurements were 
then compared to reference spectra in order to evaluate the spectra quality. This experiment was 
carried out for three known compounds; two tripeptides named “SH-myxo373” and “SH-myxo407” 
which are both found in So ceGT47 crude extract as well as for microsclerodermin M which is found in 
So ce38 extracts. The tripeptides are a new class of δ-amidated glutamates which were recently 
structurally elucidated by Stephan Hüttel at the Helmholtz Institute for Pharmaceutical Research, 
Saarland, Germany. 
Figure 23 shows the result for compound “SH-myxo373” from the So ceGT47 extract where the 
[M+H]+ ion is missed in an auto-MS² acquisition but successfully fragmented by SPL-MS². The figure 
features the full scan spectrum of the auto-MS² and the SPL-MS² method with selected precursor ions 
marked red  (Figure 23 A, B). Moreover, the resulting MS/MS spectrum (Figure 23 C) features 6 out of 7 
relevant fragment ions when compared to a reference MS/MS spectrum of this compound (Figure 23 D). 
The good quality of this fragment spectrum could be reasoned by the moderate intensity of the 
precursor ion in the range of 5*104 counts. With respect to the LC-MS system used for this work, signals 
with intensity lower than 1*104 counts frequently result in fragment spectra with less informational 
content.  
Figure 24 is related to the second tripeptide named “SH-myxo407” which is also found in 
So ceGT47 extracts. For this particular compound the fragment spectrum shows only few signals albeit 
these are all in agreement with the reference spectrum. Together with the accurate mass determination 
and isotope pattern fit of the parent ion, this result is sufficient to tentatively classify this compound. 
The spectra quality is also sufficient to recognize that both peptides “SH-myxo373” and “SH-myxo408” 
belong to the same class, thus the fragment data fits the needs for manual evaluation and likely also 
computational techniques.  
 
162 Secondary Metabolomics 
 
 
Figure 23: Analysis of the tripeptide “SH-myxo373”. (A) Auto-MS² does not select the low abundant precursor of 
interest whereas (B) using a SPL-MS² enables MS/MS acquisition. All signals that were selected as precursor for 
MS/MS analysis are marked red. (C) The MS/MS spectra quality as derived from the low abundant precursor 
(5.4*10
4
 Int.) is evaluated by comparison to a reference spectrum (D). The crude extract of So ceGT47-P was diluted 
10-fold with a P-medium blank extract. All m/z values belonging to known fragments are written in red bold letters. 
The spectra quality remains when complex molecules like microsclerodermin M are fragmented 
(Figure 25). Microsclerodermin M is a PKS/NRPS hybrid compound, which was isolated from So ce38 
(Chapter 3). The identity of several fragment ions has been proven by feeding studies and these are 
marked red in Figure 25. Including several fragments that are derived from water loss, the reference 
spectrum covers 8 characteristic fragment ions. The fragment spectrum obtained from the SPL-guided 
acquisition covers 7 out this 8 fragment ions. This is remarkable as the precursor intensity is at the lower 
limit of what is considered to be reasonable for precursor selection (8900 counts).  
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Figure 24: Analysis of the tripeptide “SH-myxo407”. (A) Auto-MS² does not select the low abundant precursor of 
interest whereas (B) using a SPL-MS² enables MS/MS acquisition. All signals that were selected as precursor for 
MS/MS analysis are marked red. (C) The MS/MS spectra quality as derived from the low abundant precursor 
(1.9*10
4
 Int.) is evaluated by comparison to a reference spectrum (D). The crude extract of So ceGT47-P was diluted 
25-fold with a P-medium blank extract. All m/z values belonging to known fragments are written in red bold letters. 
In light of these results we can conclude that selection of low abundant precursor ions and 
acquisition of corresponding MS/MS spectra is feasible as reliable fragment spectra can be indeed 
obtained. In particular, fragment spectra were acquired for three low abundant compounds out of 
complex crude extracts and each case has proven that the obtained spectra cover a sufficient number of 
characteristic fragment ions. This result is mandatory when thinking of using this technique of targeted 
MS/MS-acquisition prior to computational analyses. Computational approaches critically rely on 
accurate MS and MS/MS data, a request that is feasible using the method developed in this work. 
Moreover, only MS/MS spectra of “interesting” signals will be used by those downstream processing 
tools; hence, drawing wrong conclusions should be significantly reduced, e.g. media compounds 
clustering similar to an interesting compound are out of scope because there will be no MS/MS data 
available for media compounds. The same is true for algorithms that specifically track peptidic natural 
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Figure 25: Analysis of microsclerodermin M. (A) Auto-MS² does not select the low abundant precursor of interest 
whereas (B) using a SPL-MS² enables MS/MS acquisition. All signals that were selected as precursor for MS/MS 
analysis are marked red. (C) The MS/MS spectra quality as derived from the low abundant precursor (8900 Int.) is 
evaluated by comparison to a reference spectrum (D). The crude extract of So ce38-H was diluted 53-fold with a 
H-medium blank extract. All m/z values belonging to known fragments are written in red bold letters. 
products. The plethora of nutritional peptides found in complex media is not selected for the acquisition 
of MS/MS. A detailed evaluation of the method’s benefit when using data processing based on the 
fragmentation tree algorithm6 is a matter of upcoming research. However, two straight-forward 
examples of how to benefit from this approach are demonstrated in the two upcoming chapters. First, 
the SPL is used to identify putatively bioactive compounds in a bioactive fraction of So ceGT47 by 
highlighting only those compounds that are linked to bacterial metabolism (Chapter 4.5.6). Then, the 
results of multivariate data analysis supported the fast identification of a new compound class found in 
So ceGT47 (Chapter 4.5.7). 
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4.5.6 Revealing Unknown Compounds using the SPL Approach 
When crude extracts of Sorangium cellulosum So ceGT47 were tested for bioactivity, all of them 
showed an antimicrobial effect against Staphylococcus aureus. Since this activity is of particular interest 
the crude extract was forwarded to an LC-based fractionation as described in Chapter 4.4 using both, 
the buffered (pH 6.5) and the acidic eluent system (pH 2.7). The acidic run revealed that ambruticins F 
and S – both found at similar amounts in all extracts – are active against S. aureus which was not known 
before. In addition another compound with the tentative sum formula C24H33O3 was identified to be 
active against S. aureus as well. This activity was easily linked to a single peak eluting within the 
designated retention time window. Upon testing fractions of the buffered HPLC run, a single fraction 
with bioactivity against S. aureus, M. luteus, and M. hiemalis was identified which was not found in the 
acidic run before. This could be attributed to an unknown compound which is acid-labile and 
decomposes upon drying the fractions. How can this particular compound be tracked down with the 
help of statistics based data evaluation? Is the activity related to an abundant peak or is some low 
abundant secondary metabolite responsible? 
The fact that the activity is found in H and M medium culture helps to identify the compound. The 
retention time range from the HPLC fractionation is known and the information from statistical data 
mining can be used to reduce the number of putative compounds that are found within this particular 
retention time window. For this purpose, the respective SPL from H and M medium experiments are 
checked for an overlap, i.e. which buckets are found in both SPL. The compound of interest must be part 
of this “overlap list” as the activity is found in both extracts. The active fraction we are interested in 
covers the chromatographic region from 7.33 – 7.55 min when using the buffer run (Figure 26 A). Since 
the statistics data is based on acidic runs, the retention for compounds may be different between both 
eluent systems. Hence, it is important to allow a larger retention time window in such a case, e.g. a 
window ranging from 6 to 9 minutes. By comparing both SPL a small subset of only 9 buckets is found in 
both SPL whereas two of those buckets are relatively high abundant (Figure 26 B). The potentially 
interesting signals are then located within the buffer run which initially yielded the bioactive fraction in 
order to check whether those peaks match the bioactive fraction.  
Using this methodology, only two signals match the retention time window for which activity was 
observed: a compound with 241.19156 m/z and one with 398.15856 m/z. Moreover, MS/MS data for 
these signals is available as the respective signals are part of the SPL list and hence, selected for the 
acquisition of fragment spectra. The most abundant signal with 241 m/z is a cyclic dipeptide based on 
accurate mass measurement and fragmentation pattern. These cyclic dipeptides are known to have an 
antibiotic effect against some Gram positive bacteria including S. aureus. The high abundance of this 
compound is a good indication for its involvement in the observed bioactivity. However, the second  
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Figure 26: A Bioactivity-guided fractionation of H and M-medium cultures of So ceGT47 revealed a fraction being 
active against S.aureus, M. luteus, and M. hiemalis between 7.33 and 7.55 min in a HPLC run using buffer eluents. 
B SPL features present in both data sets (H and M medium) were searched within a wide retention time window 
with the abundant ones highlighted. C The identified m/z values were then searched within the initial fractionation 
run of A and checked whether they match the active region.   
compound with 398 m/z turned out to be a new compound as well. This result would be a good starting 
point for further approaches toward compound purification and classification. In the end, following this 
method allows tracking down signals which are most likely responsible for bioactivity. It is moreover no 
problem to compare buffer and acidic runs even though retention times may vary. The small number of 
putatively interesting signals makes a search within both data sets achievable and even superior to the 
manual search without any preliminary information. 
4.5.7 Lipothiazoles – A New Compound Class in S. cellulosum So ceGT47 
A new compound class was identified during this work. The focus on lipothiazoles was initiated by 
the high impact of lipothiazole-related features in the very first attempts of principal component 
analysis using extracts of So ceGT47 (Figure 27).  This compound family was a good proof of principle for 
the data mining workflow as explained before. Indeed, the lipothiazole class showed a strong influence 
in our data mining workflow as depicted in the PCA loadings plot of Figure 27.  
In addition, a bioactivity assay of fractionated crude extract indicated a weak activity against 
Micrococcus luteus in this chromatographic region. The two abundant derivatives, lipothiazole A and B 
were isolated in the course of this work from S. cellulosum So ceGT47 extract. The lipothiazoles are 
NRPS/PKS hybrid structures with a very weak, rather unspecific activity against Micrococcus luteus 
(approx. 100 µg/mL for lipothiazole A). The scaffold of the lipothiazole class features a saturated alkyl 
chain attached to a thiazole moiety, followed by a short polyketide and two amino acids attached of  
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Figure 27: A PCA loadings plot from a So ceGT47 data set. Part of the orange area (strain count = 6 / blank count = 
0) are zoomed in order to see the high impact of lipothiazole-related features on the model (green dots). The more 
left a dot is found, the more impact it has on the overall model. B Base peak chromatogram of So ceGT47 – M 
medium extract highlighting the 4 lipothiazoles 
which serine and alanine are S-configured. Lipothiazole A and B were structurally elucidated by NMR, 
Marfey analysis, and mass spectrometry. HMBC couplings between H2-C3 and H4-C5 confirmed the 
peptide backbone which is supported by MS/MS fragmentation data (Figure 28). The thiazole moiety 
was set by HMBC couplings between H9 and C7, C8, and C10 and the chiral carbon of the C-terminal 
serine is of S-configuration as determined by advanced Marfey analysis. Lipothiazole B is almost 
identical to derivative A and differs solely in the hydroxyl group at the serine. In lipothiazole B, the 
serine is replaced by an alanine as unambiguously determined by the change in NMR signal shifts of 
position 18. The identification of lipothiazole B suggests that the serine found in derivative A does 
originate from an alanine which is hydroxylated in a tailoring step of biosynthesis. 
There are additional derivatives identified based on accurate m/z measurements and MS/MS 
analyses. Lipothiazole C seems to be a shunt product of the assembly line. Lipothiazole D has a 
molecular weight increased by 14 Da compared to lipothiazole A suggesting an additional CH2 unit 
somewhere in the molecule. Based on analyses of the different fragmentation patterns we propose the 
location of this additional CH2 must be within the alkyl chain. This is reasoned by the fact that fragments  
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Figure 28: The members of the lipothiazole compound class as found in S. cellulosum So ceGT47. The structure of 
derivatives C and D is based on the results from MS/MS experiments. 
derived from MS³ analysis are identical for lipothiazole A, B, C, and D (Figure 34). However, the exact 
position of the additional CH2 group was not established. 
An early evaluation of lipothiazole A fragment spectra suggested the presence of a C-terminal 
serine followed by a glycine or alternatively the combination alanine followed by glycine (referring to 
lipothizaole B). With this knowledge we set out to check whether matching NRPS modules are found 
somewhere in the genome of So ceGT47. For that reason, all biosynthetic gene clusters of So ceGT47 
were annotated using antiSMASH2.0. As a consequence of the currently bad sequence quality we were 
not able to find the cluster at a glance. The information on two NRPS modules was not sufficient. Upon 
full structure elucidation of lipothiazole It became evident that a thiazole moiety is present in the 
molecule. These structural elements are usually biosynthesized by special cyclization domains found in 
NRPS modules that specifically form a 5-membered heterocycle from cysteine whereas the resulting 
intermediate is frequently oxidized to yield an aromatic heterocycle. With this information in hand, the 
 
Figure 29:Part of a NRPS-based gene cluster within the S. cellulosum So ceGT47 genome fits to the eastern part of 
the lipothiazole scaffold. The cluster fragment was found based on a retrobiosynthetic analysis of lipothiazole 
following the search for matching NRPS modules. Owing to bad sequence quality, the complete cluster could not be 
identified. 
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genome was searched for an adenylation domain specific for cysteine in combination with a cyclization 
and an oxidation domain. For this particular query two hits were obtained. The strain So ceGT47 is a 
known producer of thuggacins which feature a thiazole moiety as well. By comparing the surrounding 
genes for both query hits one hit could be assigned to thuggacin biosynthesis. Hence, the remaining 
cluster should be linked to lipothiazole biosynthesis. This notion was supported by the fact that the 
NRPS module harboring the Cy and HC domain starts with a domain showing homology to fatty acyl 
adenylate ligases (FAAL). Such a domain could be involved in recruiting the N-terminal alkyl chain found 
in lipothiazoles (Figure 29). With the currently available genome data the cluster cannot be closed but a 
full characterization of the biosynthetic machinery behind lipothiazole was not within the scope of this 
project. 
The example of lipothizaole shows how a retrobiosynthetic approach helps to link a compound to 
the respective gene cluster. However, the ideal situation of using solely the MS/MS data to identify the 
respective gene cluster like it is proposed by peptidogenomics was not achieved.22  This puts emphasis 
on the fact that this approach critically relies on the quality of the available genome data. 
4.5.8 Conclusion 
Taken together, the established method of statistics-based filtering of LC-MS data is suitable to 
extract a subset of molecular features that is related to the metabolism of a bacterium. This was done 
by comparing bacterial strain samples with blank medium samples following the basic assumption that 
molecular features related to the strain’s metabolism are solely found in strain samples. This process of 
comparing two sample groups was realized by a software-based two-dimensional binning (bucketing) of 
molecular features with respect to m/z and retention time. Features that matched the constraint of only 
being found in strain samples were extracted from the data set to create a new list. This list covers 
signals of potential interest as signals originating from secondary metabolites must be related to 
bacterial metabolism as well. The benefit of such a list becomes obvious when used as the basis for a 
precursor list for subsequent LC-MS/MS acquisitions. It was clearly shown, that precursor selection is 
not anymore depending on precursor intensity, a fact of notable importance when thinking of the wide 
concentration range of metabolites in complex biological samples. The method’s efficiency is 
underpinned by several observations:  
1) Measurement of a blank sample under the control of an SPL list results in a low number of 
MS/MS events related to a basal error level within the SPL and during precursor selection. 
2) SPL-MS² of strain extracts diluted with blank extracts maintains a high MS/MS efficiency largely 
independent of the dilution. This is owing to the fact that high abundant matrix compounds of 
the blank extract do not affect precursor selection when using a SPL. 
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3) The quality of SPL-MS² derived fragment spectra is sufficient even though low abundant 
precursor ions were used. 
In conclusion, the approach presented in this study has the potential to overcome critical 
limitations that arise by non-targeted precursor selection in LC-MS/MS acquisition. Modern 
instrumental platforms such as the hr-QqTOF device used here allow highly accurate and highly resolved 
MS/MS spectra but acquisition of such data is time consuming. Thus acquisition time should not be 
wasted for the fragmentation of unneeded precursor ions. This was realized by the approach taken 
herein. Moreover, the possibility to filter raw data for potentially interesting signals is of interest when 
searching for new compounds in a bioactivity-based approach.  Complex LC-MS data may be a problem 
when trying to link an observed bioactivity to a certain signal within the LC-MS chromatogram. With 
respect to fractions covering 10 to 20 seconds of the chromatogram it is laborious to identify m/z signals 
related to bacterial metabolism within such a region. The statistics-based approach supports tracking 
down peaks of interest as it delivers a selection of m/z values of potential interest for every time slot. 
  
  5.1 Predicting Secondary Metabolite Structures 171 
 
4.6 Supporting Information 
4.6.1 Results of the SPL-based measurements 
The upcoming graphs show the results of all measurements that were performed under control of 
SPL lists. The data covers data sets from So ceGT47 and So ce38. For all data sets a similar result is 
observed which underpins the reproducibility of the observed effects as well as the overall efficacy of 
the method. 
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4.6.2 Spiking Results 
Table 8 shows the results of the spiking samples measured as triplicate. Values are area values 
derived from peak integration in the respective extracted ion chromatograms.  EICs were created with a 
0.1 Da window around the exact m/z value. Integration was done automatically but checked manually, 
though. The purity of the spiked compounds was checked by means of LC-MS and peak integration of all 
peaks of the base peak chromatogram.  
Table 8: Area values (mean value and standard deviation) of the spiked compounds at different concentrations and 
different crude extracts used. (N=3). 
Chlorotonil A MeOH So ceGT47-P So ceGT47-M So ceGT47-H So ceGT47-A  
c [µg/mL] mean dev mean dev mean dev mean dev mean dev  
0.04 582 1008 0 0 0 0 0 0 0 0  
0.08 4169 509 0 0 0 0 0 0 0 0  
0.38 16524 549 0 0 0 0 0 0 0 0  
0.76 29585 1242 0 0 0 0 0 0 1893 0  
3.80 111306 3314 23657 4439 32462 4736 12291 3661 19909 3545  
7.60 205205 35109 69443 4575 86337 9882 45170 10460 78354 9472  
38.00 124548 20145 58420 10943 407318 8773 36197 6631 29617 7584  
           
 
Myxochelin A MeOH So ceGT47-P So ceGT47-M So ceGT47-H So ceGT47-A  
c [µg/mL] mean dev mean dev mean dev mean dev mean dev  
0.05 0 0 0 0 0 0 0 0 0 0  
0.10 2345 2118 0 0 2029 3514 0 0 0 0  
0.50 13868 750 13484 11686 0 3922 0 0 13122 3362  
0.99 31493 3762 28388 3717 29286 3922 0 0 27866 0  
4.95 131888 4846 126680 15209 129772 14504 77455 4785 103760 20505  
9.90 312056 87528 257967 5662 287741 18723 169451 6805 271681 16493  
49.50 1363237 36647 1028127 28801 1112899 95758 735288 19818 999281 50773  
           
 
Sorangicin A MeOH So ceGT47-P So ceGT47-M So ceGT47-H So ceGT47-A  
c [µg/mL] mean dev mean dev mean dev mean dev mean dev  
0.05 0 0 0 0 0 0 0 0 0 0  
0.10 2834 120 0 0 0 0 2242 2070 0 0  
0.48 11877 1677 10138 2848 0 379 8784 6587 13707 1397  
0.96 23577 2424 20974 5290 19692 379 19323 1361 20670 0  
4.80 97854 7404 98754 2050 93780 3130 86538 4617 76502 4544  
9.60 212205 64886 191862 3177 220933 15469 205599 7585 201807 7410  
48.00 837681 57944 789297 12809 971202 67613 833516 14151 835399 31137  
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4.6.3 Lipothiazoles 
 Lipothiazole A 4.6.3.1
 
Figure 30: Structure and atom numbering of lipothiazole A (left part) together with HMBC and COSY data mapped 
onto the structure (right part). The compound was isolated from the myxobacterium S. cellulosum So ceGT47. 
 Assignment δC 
a
 δH (mult., J in Hz) 
b
 HMBC 
Serine 1 173.8 - - 
 2 55.9 4.06 (t, 4.1) 1, 18 
 18 62.5 3.85 (dd, 11.3, 3.7) 
3.92 (dd, 11,3, 
4.6) 
1, 2 
Glycine 3 171.2 - - 
 4 43.4 4.06 (ov) 3, 5 
α,β-unsaturated 5 168.8 - - 
 6 134.1 7.50 (d, 15.3) 5, 7, 8 
 7 122.9 6.86 (d, 15.4) 5, 6, 8 
Thiazole 8 152.4 - - 
 9 121.8 7.59 (s) 7, 8, 10 
 10 173.2 - - 
 11 33.8 3.02 (t, 7.6) 10, 12, 13 
 12 30.8 1.81 (m) 11, 13 
 13 29.8 ov ov 
 14 29.8 1.39 (m) ov 
 15 32.6 1.31 (m) ov 
 16 23.4 1.32 (m) ov 
 17 14.1 0.91 (t, 6.8) 15, 16 
a
 Recorded at 175 MHz, referenced to residual solvent MeOH-d4 at 49.15 ppm. 
b
 
Recorded at 700 MHz, referenced to residual solvent MeOH-d4 at 3.31 ppm. 
c
 Not 
observed. 
ov 
overlapping signals. 
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 Lipothiazole B 4.6.3.2
 
Figure 31: Structure and atom numbering of lipothiazole B. The compound was isolated from the myxobacterium S. 
cellulosum So ceGT47. 
 Assignment δC 
a
 δH (mult., J in Hz) 
b
 HMBC 
Alanine 1 172.0 - - 
 2 49.5 4.41 (d, 7.3) 1, 18 
 18 17.9 1.40 (d, 7.3) 1, 2 
Glycine 3 173.0 - - 
 4 43.3 4.01 (ov) 3, 5 
α,β-unsaturated 5 165.5 - - 
 6 134.1 7.48 (d, 15.4) 5, 7, 8 
 7 123.2 6.85 (d, 15.4) 5, 6, 8 
Thiazole 8 151.1 - - 
 9 121.5 7.59 (s) 7, 8, 10 
 10 171.6 - - 
 11 33.9 3.02 (t, 7.6) 10, 12, 13 
 12 30.7 1.81 (m) 11, 13 
 13 28.4 ov ov 
 14 28.4 1.39 (m) ov 
 15 32.5 1.31 (m) ov 
 16 23.4 1.40 (m) ov 
 17 14.2 0.91 (t, 6.6) 15, 16 
a
 Recorded at 175 MHz, referenced to residual solvent MeOH-d4 at 49.15 ppm. 
b
 
Recorded at 700 MHz, referenced to residual solvent MeOH-d4 at 3.31 ppm. 
c
 Not 
observed. 
ov 
overlapping signals. 
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 Analytical Data  4.6.3.3
 
Figure 32:CID spectra of Lipothiazole A using the maXis 4G QqTOF  at different fragmentation energies. All spectra 
are recorded for 1 minute using a direct infusion experiment.  
 
Figure 33:Results of the advanced Marfey analysis of a hydrolyzed sample of lipothiazole A. The serine derivative of 
Marfey’s reagent elutes at the same retention time as the S-configured amino acid reference and thereby proves 
the presence of a S-serine in lipothiazole A. 
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Figure 34: The structure of lipothiazole C and D is concluded from high accurate fragment ions together with the 
accurate m/z of the precursor ion. All derivatives show a prominent fragment of the western part in MS² (A). 
Further fragmentation of this western part using MS³ results in identical fragments for all four lipothiazoles (B). This 
indicates that the additional CH2 group of lipothiazole D must be located within the alkyl chain.  
 Isolation of Lipothiazoles 4.6.3.4
The production medium for So ceGT47 was M medium (10 g/L peptone, 10 g/L maltose, 1 g/L 
CaCl2·2H2O, 1 g/L MgSO4·7H2O, 8 mg/L Fe-EDTA, 50 mM HEPES, adjusted to pH 7.4 with 10 N KOH). A 5 L 
shaking flask was used to cultivate 2 L of So ceGT47 using 2 % (w/v) XAD-16 adsorber resin 
(Rohm & Haas). The culture was harvested after 7 days of fermentation at 30 °C. Cells and XAD was 
extracted with 4 x 200 mL of methanol. The combined fractions yielded 1.92 g dry weight of crude 
extract after lyophilization. The crude extract was fractionated using silica flash chromatography with a 
chloroform/methanol (C/M) eluent system where lipothiazoles elute at 50:50 C/M. The combined 
fractions were concentrated and subjected to preparative HPLC using a Waters Autopurifier System 
equipped with a Waters XBridge C18, 150 x 19 mm, 5 µm dp column operated at room temperature. The 
eluent was (A) H2O + 0.1 % FA and (B) ACN + 0.1 % FA delivered at 25.5 mL/min. The gradient started at 
43 % B, increased to 54 % B in 6 min and to 95 % B in another 0.5 min where it remained for 1.5 min for 
column flushing. Since there was an unknown plasticizer in our fractions, another purification step was 
necessary. The combined fractions of interest were dried, dissolved in methanol, and forwarded to a 
semipreparative Dionex HPLC system (P680 pump, TCC100 thermostat, and PDA100 detector) equipped 
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with a Phenomenex Luna C18, 250 x 4.6 mm, 4 µm dp column. Separation was achieved by a linear 
gradient using (A) H2O + 0.1 % FA and (B) ACN+ 0.1 % FA at a flow rate of 5 mL/min and 30 °C. The 
gradient started at 45 % B and increased to 80 % B in 15 min where it remained for 1 min before 
reequilibration under initial conditions. UV data were acquired at 280 nm. A maximum of 100 µL of the 
sample was manually injected before fraction collection, yielding 1.2 mg of lipothiazole A and 0.7 mg of 
lipothiazole B as white amorphous solid. 
4.6.1 LC-MS Test Mix 
The test mix is injected at least after every 15 samples (Vinj = 1 µl). In well plate sequences the test 
mix is measured after each row. The data is compared to a reference which was acquired with a new 
column. Deviations in retention time must be less than 0.1 minutes with a perfect peak shape.  
Table 9:Components of the LC-MS test mix at HIPS-MINS, Saarland University. The test mix is dissolved in 
H2O/MeOH mixture of 9:1 (v/v). 
Compound Structure Sum formula MW [g/mol] CAS Conc. [mg/L] 
Sulfamethazine 
 
C12H14N4O2S 278.33 57-68-1 10 
Sulfamethizole 
 
C9H10N4O2S2 270.33 144-82-1 10 
Sulfachloropyridazine 
 
C10H9ClN4O2S 284.72 80-32-0 10 
Sulfadimethoxine 
 
C12H14N4O4S 310.33 122-11-2 10 
Amitriptyline 
 
C20H23N*HCl 313.9 549-18-8 10 
Coumarin-314 
 
C18H19NO4 313.4 55804-66-5 20 
 
Amitriptyline is important to track the behavior of basic compounds in our standard screening. This 
is important to monitor as it may change although other peaks remain constant. Coumarin-314 is strong 
fluorescent dye which allows tracking of the fractionated peak. Even very low amounts of coumarin-314 
can be detected by UV irradiation. All components are detected at 220 nm and (+)-ESI-MS. A stock 
solution of the sulfa drugs (c = 2000 µg/mL) is prepared in water/methanol 1:1 (v/v). Coumarin-314 is 
diluted in methanol to a concentration of 1000 µg/mL. Amitriptyline is dissolved in water to a 
concentration of 1000 µg/mL. A working solution is prepared in a 10 ml volumetric flask, which is filled 
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with 8 mL of water and 1 mL of methanol. To this is added: 50 µL of sulfa drugs stock, 100 µL of 
amitriptyline stock, and 200 µL of coumarin-314 stock. The flask is filled with water to end up with the 
final concentrations as given in Table 9. The final solution is in a water/methanol mixture in ratio 9:1 
(v/v). Higher amounts of methanol must be avoided as this will alter retention of the early eluting sulfa 
drugs. The mix is stable for months when stored in glass vials in a dark place (autosampler rack).  
4.7 Experimental Section 
4.7.1 Culture Conditions and Extraction 
Experiments are based on two Sorangium cellulosum strains, So ceGT47 and So ce38. Fresh 
cultures were received from cryogenic stocks and used to inoculate M medium cultures. These pre-
cultures inoculated new cultures but using four different media (M, P, H, A). Cultures were transferred 
once again to fresh media of the same type to guarantee a full adaption of each strain to the nutrition 
conditions. Such adapted cultures are then used to prepare XAD cultures for screening. XAD is a PS-DVB-
based adsorber resin (XAD-16, Rohm & Haas) that is supplemented to the liquid broth in order to adsorb 
secondary metabolites. Cultivation was done in 300 mL shaking flasks filled with 45 mL of medium, 1 mL 
of XAD-16 slurry (1 % w/v, Rohm & Haas) and 4 mL of inoculation culture. In case of “blank” media 
cultivations, 49 mL of medium and 1 mL of XAD-16 slurry were used. The flasks were incubated at 30 °C 
and 140 rpm for 6 days (So ceGT47) or 8 days (So ce38), respectively. After the incubation time cultures 
were harvested, centrifuged and the adsorber resin together with cells extracted using 2 x 25 mL of 
methanol. The combined organic extracts were filtered and dried using a rotational evaporator. 
Residues were suspended in 1 mL methanol, which corresponds to a 50-fold concentration compared to 
cultivation. Samples need to be centrifuged to obtain a clear supernatant, which is used for LC-MS. Each 
strain/medium combination was prepared as three independent biological replicates. 
4.7.2 Cultivation Media 
A medium. Glycerin 4 g/L, soluble starch 8 g/L, soy flour 4 g/L, yeast extract 2 g/L, CaCl2·2H2O 1 g/L, 
MgSO4·7H2O 1 g/L, 50 mM HEPES 11.9 g/L, Fe-EDTA 8 mg/L. The pH value is adjusted to 7.4 using 10 M 
KOH. 
H medium. Glucose 2 g/L, soluble starch 8 g/L, soy flour 2 g/L, yeast extract 2 g/L, CaCl2·2H2O 1 g/L, 
MgSO4·7H2O 1 g/L, 50 mM HEPES 11.9 g/L, Fe-EDTA 8 mg/L. The pH value is adjusted to 7.4 using 10 M 
KOH. 
M medium. Maltose 10 g/L, soy peptone 10 g/L, CaCl2·2H2O 1 g/L, MgSO4·7H2O 1 g/L, 50 mM HEPES 
11.9 g/L, Fe-EDTA 8 mg/L. The pH value is adjusted to 7.4 using 10 M KOH. 
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P medium. Peptone 2 g/L, soluble starch 8 g/L, probion 4 g/L, yeast extract 2 g/L, CaCl2·2H2O 1 g/L, 
MgSO4·7H2O 1 g/L, 50 mM HEPES 11.9 g/L, Fe-EDTA 8 mg/L. The pH value is adjusted to 7.5 using 10 M 
KOH. 
4.7.3 Pre-cleaning of Adsorber Resin XAD-16 
The adsorber resin product Amberlite XAD16 (Rohm & Haas) is shipped under slightly wet 
conditions of pH 10 with high amounts of NaCl and Na2CO3. In addition, there are polymeric impurities, 
which affect the LC-MS screening. In order to clean the adsorber resin it is necessary to adjust the pH 
value to neutral conditions and wash off the salts. Furthermore, polymeric impurities are removed by 
two consecutive Soxhlet extractions with acetone and methanol. Any solvent residues are removed by 
thoroughly washing with water prior to autoclaving aqueous slurries of XAD-16 to yield a very clean 
product suitable for screening purposes. 
4.7.4 Standardized LC-MS Screening Method 
All measurements were performed on a Dionex Ultimate 3000 RSLC comprising a high pressure 
gradient pump (HPG-3400RS) with a 150 µl mixing chamber. All LC connections are realized by 0.13 µm 
stainless steel capillaries before the column. The method is based on separation with BEH C18, 
100 x 2.1 mm, 1.7 µm dp column (Waters, Eschborn, Germany). One µl sample is separated by a linear 
gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and 45 °C. The 
gradient is initiated by a 0.5 min isocratic step at 5 % B, followed by an increase to 95 % B in 18 min to 
end up with a 2 min step at 95 % B before reequilibration under the initial conditions. UV spectra are 
recorded by a DAD in the range from 200 to 600 nm with 2 nm width. The LC flow is split to 75 µL/min 
before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, Germany) using the Apollo 
ESI source. A fused silica (f.s.) capillary (20 cm, 100 µm ID, 360 µm OD) coming from the mass 
spectrometer’s switching valve is connected to an Upchurch PEEK microtight T-junction. Another f.s. 
capillary of 20 cm and 75 µm ID is connected to the inlet of the mass spectrometer whereas an f.s. 
capillary of 10 cm and 100 µm ID is directed to waste. The split is approximately 1:8 based solely on the 
f.s. capillary ratio. The real split is even more than 1:8 as the effect of the ESI needle is not taken into 
account here. The ion source parameters are: capillary, 4000 V; endplate offset, -500 V; nebulizer, 1 bar; 
dry gas, 5 L/min; dry gas temperature, 200 °C. Ion transfer parameters were: funnelRF, 350 Vpp; 
multipoleRF, 400 Vpp; quadrupole ion energy, 5 eV @ low m/z 200. Collision cell is set to 8 eV with a 
collisionRF of 2500 Vpp in full scan mode. Ion cooler settings are: transfer time, 90 µs; ion cooler RF, 120 
Vpp; pre puls storage, 5 µs. Mass spectra are acquired in centroid mode ranging from 150 – 2500 m/z at 
a 2 Hz scan rate in full scan positive ESI mode. Each measurement is started with the injection of a 20 µL 
plug of basic sodium formate solution, which is introduced by a loop that is connected to the system’s 6-
port switching valve. The resulting peak is used for automatic internal m/z calibration. In addition, a lock 
180 Secondary Metabolomics 
 
mass (Agilent Chip Cube High Mass HP-1221, Art.# G1982-85001) is present in the ion source all the time 
and allows recalibration of each spectrum.  
4.7.5 Different settings for MS/MS acquisition 
The MS/MS methods used in this study are identical to the standard LC-MS screening method in 
terms of chromatography, ion source and ion transfer parameters. They differ only in some MS/MS 
parameters (see Table 10) and in the ion cooler settings.  
Table 10: Different MS/MS methods as used in this study. Changes are related to acquisition speed, number of 
precursors and the way precursors are selected, i.e. automatically based on most abundant ones (auto-MS²) or 
based on a precursor list (SPL, scheduled precursor list).  
# mode precursor acq.speed #1 [Hz] acq.speed #2 [Hz] acq.int 1 acq.int 2 duty cycle [s] 
1 auto MS² 2 1.5 2.9 1E+04 5E+04 1.2 - 1.8 
2 auto MS² 3 1.5 2.9 1E+04 5E+04 1.5 - 2.4 
3 auto MS²_fast 3 1.5 6.7 1E+04 1E+05 0.9 - 2.4 
4 SPL 2prec 2 1.5 2.9 1E+04 5E+04 1.2 - 1.8 
5 SPL 3prec 3 1.5 2.9 1E+04 5E+04 1.5 - 2.4 
6 SPL 3prec_fast 3 2.0 6.7 1E+04 1E+05 0.9 - 2.0 
7 SPL 4prec_fast 4 2.0 6.7 1E+04 1E+05 1.1 - 2.5 
8 SPL strict all 2.0 10.0 1E+04 1E+05 - 
 
Ion cooler settings for MS/MS mode do timely vary within a single MS/MS acquisition (ion cooler 
sweeping). Ion cooler RF sweeps from 120 to 80 Vpp while CID energy sweeps from 90 to 120 % of the 
set value. Both sweeps are done in 50/50 timing (Table 11). 
Table 11: Ion cooler sweeping during a MS/MS scan. Ion cooler RF reduction allows better detection of low m/z 
fragments.  
Time [%] IC RF [Vpp] Coll. Energy [%] 
0 120 90 
25 120 120 
50 80 120 
75 80 90 
 
Fixed MS/MS parameters were an m/z-adjusted precursor isolation width and fragmentation 
energy. Values are interpolated in between the set points [300 m/z / 4 m/z / 30 eV], [600 m/z / 6 m/z / 
35 eV], [1000 m/z / 8 m/z / 45 eV], and [2000 m/z / 10 m/z / 55 eV].  The precursor intensity threshold is 
always set to 5000. All methods are set up with an active precursor exclusion, which puts precursors 
after two spectra on an exclusion list. Each precursor m/z remains there for 0.2 minutes. 
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4.7.6 Method for Fractionation of Crude Extracts 
 Fractionation using Acidic Eluent 4.7.6.1
Fractionation was performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH C18, 
100 x 2.1 mm, 1.7 µm dp column by injection of 5 µl methanolic sample. Separation was achieved by a 
linear gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 550 µL/min and 45 °C. The 
gradient was initiated by a 0.27 min isocratic step at 5 % B, followed by an increase to 95 % B in 18 min 
to end up with a 1.5 min flush step at 95 % B before reequilibration under the initial conditions. 
Coupling the HPLC to the MS was supported by an Advion Triversa Nanomate nano-ESI system attached 
to an Orbitrap (Thermo Scientific, Dreieich, Germany). Mass spectra were acquired in centroid mode 
ranging from 200 – 2000 m/z at a resolution of R = 30000. The flow was split to 500 nL/min before 
entering the ion source. The Nanomate transfers the remaining LC flow into a 96 well plate within the 
time range from 0.6 to 20.6 min. Each well is filled for approx. 0.22 min (120 µl) yielding 92 wells in 
summary. The well plate is dried using a Genevac centrifugal evaporator (Genevac Ltd., Suffolk, UK) for 
at least 3 h at 30 °C and reduced pressure. The dry plate is used for bioactivity assay afterwards. 
 Fractionation using Buffered Eluent 4.7.6.2
For buffered fractionation the same setup as described in 4.7.6.1 is used. The eluents are changed 
to (A) 5 mM NH4HCOO in H2O and (B) 5 mM NH4HCOO in ACN/H2O 9:1 (v:v). The pH is not adjusted. 
Gradient separation is initiated with a 0.27 min isocratic step at 5 % B, followed by an increase to 100 % 
B in 18 min to end up with a 1.5 min step at 100 % B before reequilibration under the initial conditions. 
4.7.7 Marfey Analysis 
 Marfey derivatization protocol 4.7.7.1
Marfey derivatization was performed with NMR, ozonolysis and diol-cleavage samples of the 
compounds. The protocol is as follows: 
 Put 50 µg of sample into a 1.4 mL glass vial 
 Add 100 µL of 6 N HCl. Fill the vial with nitrogen and close it. Keep it at 110 °C for 45 minutes. 
Open the vial to let the contents dry at 110 °C for another 15 minutes. Do not exceed 60 min as 
tryptophan easily decomposes (if present). 
 Dissolve the residues in 110 µL H2O. Prepare two 1.5 mL PP tubes and add 50 µL of the aqueous 
solution in each. 
 Add 20 µL of 1 N NaHCO3 in each tube (which will adjust the pH to approx. 9) 
 Add 20 µL of 1 % (w/v) Marfey’s reagent in acetone: D-FDLA or L-FDLA, respectively.  
 Keep for 1 hour at 40 °C, 700 rpm. 
 Add 10 µL of 2 N HCl to stop reaction and 300 µL of ACN to end up with 400 µL total volume. 
 Centrifuge the sample and measure the supernatant by HPLC-MS 
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 HPLC-MS analysis of Marfey samples 4.7.7.2
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH 
C18, 100 x 2.1 mm, 1.7 µm dp column by injection of 1 µl sample. Separation was achieved by a gradient 
using (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 550 µl/min and 45 °C. The gradient was 
as follows: starting at 5 % B to increase to 10 % B in 1 min, from 1 to 15 min increase to 35 % B, from 15 
to 22 min increase to 50 % B, from 22 to 25 min increase to 80 % B. After a 1 min hold at 80 % B the 
system was reequilibrated with initial conditions for 5 minutes.  UV data was acquired at 340 ± 8 nm and 
MS detection was performed simultaneously. Coupling the HPLC to the MS was supported by an Advion 
Triversa Nanomate nano-ESI system attached to a Thermo Fisher Orbitrap. LC flow is split to 500 nL/min 
before entering the ion source. Mass spectra were acquired in centroid mode ranging from 150 – 
1000 m/z at a resolution of R = 30000. 
4.7.8 Bioactivity assay 
 Bacterial Cultures 4.7.8.1
All microorganisms were handled under standard conditions recommended by the depositor. 
Overnight cultures of microorganisms were prepared in EBS medium (0.5% peptone casein, 0.5% 
protease peptone, 0.1% peptone meat, 0.1% yeast extract; pH 7.0) or TSB medium (1.7% peptone 
casein, 0.3% peptone soymeal, 0.25% glucose, 0.5% NaCl, 0.25% K2HPO4; pH 7.3). The latter medium 
was used for E. faecalis and S. pneumonia cultures. Yeast and fungi were grown in Myc medium (1% 
phytone peptone, 1% glucose, 50 mM HEPES, pH 7.0).  
 Microbial Susceptibility Assay (MIC) 4.7.8.2
Overnight cultures of microorganisms were diluted to OD600 0.01 (bacteria) or 0.05 (yeast/fungi) in 
the respective growth medium. Serial dilutions of compounds were prepared as duplicates in sterile 96-
well plates. The cell suspension was added and microorganisms were grown overnight on a microplate 
shaker (750 rpm, 30°C or 37°C).  Growth inhibition was assessed by measuring the OD600 on a plate 
reader and supported by manual evaluation. MIC50 values were determined as average relative to 
respective control samples by sigmoidal curve fitting. 
4.7.9 Spiking of Myxobacterial Crude Extracts 
Methanolic crude extracts of S. cellulosum So ceGT47 were spiked with a 3-compound mixture 
containing myxochelin A, sorangicin A, and chlorotonil A. Stock solutions (2500 µg/mL) of myxochelin A 
and sorangicin A were prepared in methanol while chlorotonil A was dissolved in chloroform. A 100 µL 
of each stock were mixed with 200 µL of methanol to give a mixture that contains 500 µg/mL of each 
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compound. This main stock solution (#1, Table 12) is subsequently diluted with methanol to give 
another 6 solutions.  
Table 12: Dilution scheme as used for the preparation of spiking samples. 
c_stock [µg/mL] 3-cpd-mix MeOH [µl] final volume [µl] 
500 - - - 
100 #1, 100 µl 400 500 
50 #2, 100 µl 100 200 
10 #2, 100 µl 900 1000 
5 #3, 200 µl 200 400 
1 #4, 100 µl 400 500 
0.5 #5, 200 µl 200 400 
 
Five µL of each stock (#1-7, Table 12) is mixed with 45 µL crude extract. All pipetting was 
performed in a temperature-controlled room maintained at 4 °C in order to avoid evaporation of the 
highly volatile solvents. LC-MS analysis of 1 mg/mL samples were used to determine the compound 
purities of myxochelin A (99 %), sorangicin A (96 %), and chlorotonil A (76 %). All samples were 
measured as triplicate using the standard LC-MS screening method with an injection volume of 1 µL. 
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5 Discussion 
This thesis covers several aspects of natural product research. On the one hand it deals with isolation 
and structure elucidation of three secondary metabolite classes from Sorangium cellulosum So ce38 and 
So ceGT47 alongside with the characterization of the underlying biosynthetic machinery. On the other 
hand, an analytical approach is presented which addresses the high complexity of LC-MS data that is 
frequently observed for myxobacterial crude extracts. In detail, a new approach for precursor selection 
in LC-MS/MS analyses is achieved which increases the informational content of the acquired data. Both 
aspects can be advantageously combined as they contribute to complementary approaches of natural 
product research that emerged with the increasing availability of whole genome data over the last 
decade. These data lead to a tremendous increase in characterized biosynthetic gene clusters, which in 
turn initiated the development of computational methods to characterize compounds on gene level. In 
principle, two different methods of how a compound can be linked to its gene cluster exist:  
 
 The compound-to-gene approach is based on a known or partially known compound and uses 
retrobiosynthetic considerations and compound-specific structural elements (e.g. amino acid 
building blocks, halogenations, et cetera) to link a given compound to a matching biosynthetic 
cluster. 
 
 The gene-to-compound approach starts with in silico analysis of genomes aiming toward 
detection of biosynthetic gene clusters which can facilitate the prediction of a molecular 
structure and/or the attempt to create a knock-out mutant of a given cluster in order to link the 
gene cluster to a compound. 
 
The overall idea aims toward connecting both approaches in order to link a gene cluster to its compound 
and vice versa, thereby supporting the fast characterization of new compounds and their underlying 
biosynthesis. Such a project is rationalized by the feasibility of the compound-to-gene approach at the 
stage of LC-MS analysis. In particular, the combination of accurate m/z measurements and 
fragmentation data of secondary metabolites holds information about structural features, e.g. amino 
acid building blocks. With state-of-the-art mass spectrometric devices, these data are reliably accessible 
from crude extracts when analyzed by LC-MS/MS. This information can facilitate either the identification 
of a compound or help to classify it as member of a certain compound class. Similarly, the 
gene-to-compound approach can provide structural information based on the biosynthetic modules 
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identified in a given genome. At this point the approaches connect as both determine structural features 
derived from different types of analysis.  
Such an approach depends on two crucial aspects, in particular the reliability of computational 
models for the in silico characterization of biosynthetic gene cluster and the informational content of LC-
MS data. This thesis supports this project by contributing to both aspects: the identification and in depth 
characterization of two gene clusters helps to improve existing computational models, whereas the 
introduction of an improved LC-MS/MS workflow increases the informational content of acquired 
analytical data.  
5.1 Predicting Secondary Metabolite Structures – Discrepancies 
between Genome-based in silico Analysis and Real Structure 
With the feasibility of whole genome sequencing, an ever-growing importance is given to in silico 
based analysis of genomes. The past years have seen tremendous advances in using genome data to 
characterize biosynthetic pathways but some methods related to the characterization of biosynthetic 
gene cluster still suffer from weaknesses as discussed in the following. While the initial identification of 
genomic loci harboring NRPS, PKS, or other biosynthetic genes is based on powerful tools of high 
reliability, subsequent steps of specifically addressing catalytic domains is less reliable. A number of 
catalytic domains usually found in NRPS or PKS modules have been well-studied to allow a prediction of 
substrate specificities or the stereochemical outcome of the catalyzed reaction. However, it should be 
noted that only in rare cases complete core structures can be predicted whereas getting first hints on 
how a partial structure looks like or what a special domain does is frequently achieved. Aside of being 
subject to wrong predictions attributed to inaccurate models, the prediction of a biosynthetic product is 
additionally complicated by unexpected effects of tailoring enzymes and deviations from so-called 
textbook biosynthetic logic. As the latter is a common finding, ambitions to accurately predict the final 
product of a biosynthetic gene cluster is far from reliable or even unreasonable. 
This thesis utilizes genome mining techniques to characterize and subsequently analyze 
biosynthetic domains in a detailed manner. In particular, the biosynthetic machinery of pellasoren and 
microsclerodermin production was identified on the basis of the Sorangium cellulosum So ce38 genome 
followed by an in-depth analysis of the involved catalytic domains. In the following, the capabilities and 
limitations of in silico predictions are exemplified for pellasoren biosynthesis.  
  5.1 Predicting Secondary Metabolite Structures 187 
 
 
Figure 35: Pellasoren biosynthetic gene cluster as predicted by the antiSMASH2.0 annotation pipeline.
1
 All domains 
were correctly annotated. Based on this result a draft molecule can be predicted and manually curated as discussed 
in the text.  
Pellasoren is a linear NRPS/PKS hybrid natural product isolated from S. cellulosum So ce38. 
Analyzing the pellasoren gene cluster using the AntiSMASH2 annotation pipeline results in a set of 
biosynthetic genes that could largely fit the pellasoren structure as elucidated by NMR (Figure 35).1 
Pellasoren biosynthesis follows the colinearity rule, i.e. each module holds responsible for a single NRPS 
or PKS-related extension cycle. This type of textbook biosynthetic logic clearly facilitates prediction of 
the final structure which should in turn result in an acceptable structure proposal.  
Although having good similarity, the predicted core structure looks different to the real molecule 
(Figure 36, A and D). This initial prediction is based on the number of modules found in the cluster and 
their presumed substrate specificity as identified by protein sequence alignments for the domains 
responsible for substrate discrimination. Similar analyses for the remaining catalytic domains reveal 
whether these are active and whether they can act in the course of biosynthesis. In 
 
Figure 36: Comparison of predicted and real structure of pellasoren A. The colored areas mark four different 
aspects of in silico prediction: 1) the incorporation of uncommon extender units (blue, PKS part of PelA), 2) the 
choice between R and S-configured amino acids (orange, NRPS module of PelA), 3) the stereochemistry of enoyl 
reduction (red, PelD and PelF), and 4) the stereochemistry of ketoreductase domains (green, PelE). 
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the last step, the prediction of stereogenic centers is achieved by alignment of protein sequences of 
relevant domains in order to identify class-specific fingerprint motifs. The resulting structure shown in 
Figure 36 B is in very good agreement with the respective real structure as shown in Figure 36 C. 
However, the incorporation of the methoxy group (highlighted in blue) as well as the configuration of 
one methyl group (highlighted in red) could not be correctly predicted which in turn causes the 
structure to be slightly different to the real one shown in Figure 36 C. Alongside with this, the 
configuration of an alanine-derived stereogenic center has to be carefully reviewed (highlighted in 
orange). For that reason, the capabilities and limitations of the in silico-based methods related to the 
prediction of these specific structural moieties are discussed in the upcoming sections. They correspond 
to the highlighted groups shown in Figure 36 B and comprise an insight on the A-domain specificity 
toward D-amino acids, the incorporation of uncommon methoxymalonyl extender units by PKS modules, 
and the stereochemical outcome of KR and ER domains. 
5.1.1 Incorporation of Amino Acid Building Blocks 
One methyl moiety of the pellasoren scaffold is derived from an alanine that is incorporated by the 
NRPS module of the biosynthesis cluster (Figure 36, highlighted in orange). In this special case, it was not 
possible to determine the stereochemistry of the carbon atom by means of spectroscopic analysis or 
chemical degradation experiments. Hence, in silico analysis of the corresponding NRPS module provides 
an alternative approach to get further insights into the stereochemistry that is presumably set during 
biosynthesis of this particular structural unit. A typical minimal NRPS module of A-C-PCP architecture 
usually incorporates L-configured amino acids rather than D-configured ones. Such an assumption is 
reasoned by the fact that L-amino acids are easily available due to primary metabolism and by the 
observation that D-amino acids are derived from L-amino acids by an epimerization domain within a 
NRPS module (A-C-E-PCP). However, in case of alanine there is a certain chance that D-alanine is present 
in the primary metabolome owing to its requirement for murein biosynthesis. Indeed, direct activation 
of D-alanine was recently reported for NRPS-related biosynthesis of fusaricidin and leinamycin.2,3 
Leinamycin is the first example where a D-amino acid is directly loaded onto a PCP domain to prime the 
NRPS biosynthesis. In fusaricidin biosynthesis the scaffold comprises four D-amino acids whereas three 
of them can be explained by the action of an epimerase within the module. The fourth module features 
only the A-C-PCP architecture although it holds responsible for D-alanine incorporation, and in vitro 
assays with the respective adenylation domain indeed confirmed that direct loading of D-alanine is 
taking place. In light of these results, the substrate specificity toward alanine enantiomers seems to be 
ambiguous and a conclusion drawn just based on the domain architecture is not suitable for alanine. 
Recent studies of the crystal structure of the D-alanine-D-alanyl carrier protein ligase (DltA) involved in 
lipoteichoic acid biosynthesis in gram positive bacteria revealed that D-ala adenylation domains are 
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distinguishable from those being specific for L-ala.4 Although myxobacteria do not have this type of 
biosynthesis the activation of D-ala in murein-related or NRPS-related biosynthesis is comparable as the 
adenylation domains belong to the same family of enzymes.4 In line with this result, D-ala-specific A 
domains were aligned with PelA-A from pellasoren biosynthesis and the A domains found in 
microsclerodermin biosynthesis (Figure 37). Yonus et al. reported that L-aa incorporating A domains do 
have an alanine or glycine at position 268 whereas a cysteine, an isoleucine, or an aspartate point 
toward activation of D-configured amino acids.4 Based on this alignment and the reported classifiers it 
was possible to determine which amino acid enantiomer is presumably activated. 
In case of microsclerodermin and pellasoren biosynthesis, all A domains use L-amino acids which is 
in agreement with the alignment as shown in Figure 37. The stereogenic center of lipothiazole’s cysteine 
is lost during thiazole formation but the above shown alignment suggests activation of L-cysteine. The 
microsclerodermin structure features two amino acid residues with R-configuration, a tryptophan and a 
pyrrolidone moiety which is derived from an asparagine. The R-tryptophan is based on an epimerization 
domain in the respective module and thereby represents the common way of how this particular 
stereochemistry is set on an assembly line. The configuration of the asparagine residue is S-configured 
based on the 268G found in MscF-A1 which is in agreement with the incorporation of fully labeled S-asn 
as verified by feeding experiments. However, it turned out that this stereogenic center is of 
R-configuration in the final microsclerodermin structure. 
 
Figure 37: Alignment of the D-alanine-D-alanyl carrier protein ligase (DltA) to known D-ala activating A domains 
from fusaricidin and leinamycin biosynthesis and the A domains as found in pellasoren, microsclerodermin, and 
lipothiazole biosynthesis. Position 268 is a bulky cysteine, aspartate, or Isoleucine for D-ala specific A domains. L-
specific domains feature a glycine or alanine at this position. Numbering according to DltA.
4
 Accession numbers for 
the sequences are 3E7W (PDB database, DltA), EF451155 (GenBank, fusaricidin, FusA), AF484556 (GenBank, 
leinamycin, LnmQ), HE616533 (EMBL, pellasoren, PelA), and KF657738 (GenBank, microsclerodermin, MscF, MscH, 
MscI)  
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Thus, there must be a configuration swap during biosynthesis, most likely as a result of the cyclization of 
the asparagine side chain. This finding illustrates well the limits of in silico prediction which are related 
to the presence of uncommon tailoring enzymes and deviations from textbook biosynthetic logic. After 
all, a hypothesis based on in silico analysis still needs to be verified by suitable methods such as full 
structural elucidation, total synthesis, or chemical degradation experiments. The myxobacterial 
compound classes characterized in this work agree well with the prediction of the amino acid-related 
stereogenic centers. Notably, all stereogenic centers were confirmed by degradation experiments in 
case of microsclerodermin or by total synthesis in case of pellasoren. Such information on biosynthetic 
domains in combination with a proven structural outcome of the respective domains is essential to 
further strengthen the predictive power of the underlying model. 
 After all, the direct loading of D-amino acids ─ at least for D-ala ─ seems predictable although the 
number of such adenylation domains is still rather low. The fact that this model is built on 
crystallographic data together with the highly conserved structure of adenylation domains makes it a 
valuable contribution to future computational tools. 
5.1.2 The Glycolate Extender Unit 
Pellasoren biosynthesis features an enol ether moiety, which is still rather uncommon amongst the 
products of natural product biosynthetic pathways. With regard to common biosynthetic logic of PKS 
systems, one would assume that a methoxymalonyl-CoA extender unit is loaded to the ACP by an AT 
domain in the same way like it is done for malonyl and methylmalonyl-CoA. However, this is not the 
case and it has been shown that the N-acetylcysteamine thioester of methoxymalonate or 
hydroxymalonate is not incorporated although it would be the biosynthetic mimicry for the involvement 
of methoxymalonyl-CoA in biosynthesis.5 Instead, it has been hypothesized that the methoxymalonyl-
moiety is derived from a glycolate attached to an ACP via a thioester bond with subsequent oxidation 
and methylation to yield methoxymalonyl.6 This hypothesis is based on the first “glycolate extender" 
gene cassette which has been described for FK520 biosynthesis. This cassette covers five genes, one acyl 
carrier protein (FkbJ), one of unknown function (FkbH), one methyl transferase (FkbG), and two 
homologues of a fatty acid acyl-CoA dehydrogenase (FkbK and FkbI).6 Later, the crystal structure of the 
dehydrogenase FkbI revealed that it acts on ACP-bound substrates rather than on CoA-bound ones.7 In 
particular, FkbI catalyzes the second oxidation of a glycerate-derived template that is bound to FkbJ to 
yield the aldehyde as shown in Figure 38. In addition it has been proven by feeding studies with labelled 
glycerol and glycerate that the substrate is indeed glycerate albeit it is not known if the glycerate is 
phosphorylated.8  
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Figure 38: Proposed mechanisms underlying the biogenesis of the glycolate extender unit as found for three 
different biosynthetic pathways. A The first gene cassette for glycolate extender biogenesis identified in a 
Streptomyces sp. involved in FK520 biosynthesis. The protein of unknown function FkbH is supposed to load 
bisphosphoglycerate onto the ACP domain. B Soraphen biosynthesis has no FkbH-like enzymes but rather uses an 
acyl transferase domain. C For pellasoren biosynthesis enzymes of both types are found which seems to be 
redundant.   
It has been shown that two different enzymes can load the glycerate in the very beginning of 
biogenesis.6,8 For FK520 biosynthesis there is an enzyme of unknown function named FkbH likely loading 
the glycerate starter while in soraphen biosynthesis no homologue of FkbH is found. Instead an 
additional acyl transferase (SorC-AT) is most likely catalyzing the loading step (Figure 38). Intriguingly, 
pellasoren biosynthesis has both an AT domain (PelG-AT) and an FkbH-like protein (PelK). This fuels 
speculation whether there are two congruent ways of loading the same substrate, or whether these 
enzymes have preferences toward slightly different substrates, e.g. 3-P-glycerate or 1,3-P2-glycerate.  
In silico analysis of the So ce38 genome led to correct annotation of the single domains belonging 
to the glycolate gene cassette. While this indicates the strain’s capability to produce glycerate-related 
extender units it is currently impossible to infer which module of the biosynthetic assembly line 
incorporates this special extender unit. In theory, the pellasoren scaffold could have a methoxymalonyl 
unit incorporated at all PKS-related positions or even multiple times. One possible approach to propose 
a module incorporating an uncommon extender unit is based on the phylogenetic analysis of KS 
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domains as they have to accept the extender unit to catalyze the elongation step. Such a phylogenetic 
analysis is based on alignments conducted on protein level. For pellasoren biosynthesis, PelD-KS2 and 
PelA-KS1 are different compared to the other KS domains found in this cluster. PelD-KS2 is supposed to 
catalyze bond formation between a malonyl precursor and a methylmalonyl-ACP which likely causes the 
“difference”. PelA-KS1 might be different because of its priming function or because of conducting a 
methoxymalonyl substrate. Although this is not a clear-cut result, it points toward incorporation of this 
special extender unit by module 1, which would be correct in case of pellasoren. 
Interestingly, microsclerodermin biosynthesis incorporates hydroxymalonyl extender units in the 
early stages of biosynthesis although there is no glycolate extender gene cassette in proximity to the 
cluster. This finding could be rationalized by “pellasoren’s” glycolate extender gene cassette being 
responsible for both the pellasoren and microsclerodermin pathway in So ce38. It has indeed been 
reported that the glycolate extender cassette is not necessarily located in proximity to the secondary 
metabolite gene cluster.9 However, the dual use of the cassette remains puzzling as pellasoren 
biosynthesis solely incorporates a methylated glycolate extender while microsclerodermin biosynthesis 
uses a non-methylated one.  The fact that the methyl transferase is translationally linked to the ACP 
harboring the extender unit supports the assumption that a methylation happens during maturation of 
the methoxymalonyl extender unit. This is obviously not necessarily the case as this would prevent the 
biogenesis of hydroxymalonate for microsclerodermin biosynthesis. Searching the genome of S. 
cellulosum So ce38 for an alternative glycolate cassette was not successful; hence, the extender cassette 
has to deliver both methoxymalonyl and hydroxymalonyl extender units. This brings up the discussion at 
which point of biogenesis the O-methylation takes place. The trifunctional protein as found in soraphen 
biosynthesis and in So ce38 would imply to have the methylation at an early stage.8 However, the fact 
that two different precursors are generated in So ce38 ─ and indeed used in metabolite biosynthesis ─ 
supports a late methylation step (Figure 38). The discrimination between both extenders is then most 
likely achieved by the KS domains of the respective PKS modules PelA-KS1 and MscC-KS1. 
Inactivation of the glycolate extender cassette could lead to new insights regarding the use of this 
special extender unit in S. cellulosum So ce38. The expected result of this single knock out would be the 
abolishment of pellasoren and microsclerodermin production at the same time. Since the cassette is 
part of the pellasoren operon, a knock out will likely affect the expression of the remaining pellasoren 
cluster owing to downstream polar effects. However, the microsclerodermin operon would remain 
intact and thus disruption of the glycolate cassette will either result in abolishment of 
microsclerodermin production or in new microsclerodermin derivatives based on a common extender 
unit such as malonyl-CoA. 
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5.1.3 The Stereochemistry of Enoyl Reduction in PKS 
The criteria that govern the configuration of the stereogenic center being set during enoyl reduction of 
α-substituted extender units has to date only been poorly investigated. Kwan et al. set up a model to 
predict the stereochemical outcome based on an alignment with numerous ER domains.10 The study is 
based on 39 domains from Streptomyces sp., 3 from Sorangium sp., and 12 from Mycobacterium sp. 
alongside with several others. There is a certain chance that the resulting model is biased toward 
Streptomyces-related ER domains; however, the result should be an adequate basis for myxobacterial 
domains as well. As a result of their study, Kwan et al. highlighted a tyrosine (Tyr52) that is highly 
conserved amongst ER domains yielding a 2S-configured stereogenic center when the extender unit is 
bound to the ACP. This Tyr52 residue most likely discriminates which stereochemistry is created during 
reduction by NADPH. By mapping two ER domains onto the crystal structure of the E. coli quinone 
oxidoreductase QOR (PDB ID 1QOR) they eventually proposed that Tyr52 is within the active site pocket 
and thereby reduces the space that is available in the pocket (Figure 39 C).10 The involvement of Tyr52 
was verified by site directed mutagenesis with subsequent analysis of the respective mutant’s 
biosynthetic products. However, results of these experiments already indicated that Tyr52 is not 
exclusively directing the stereochemical outcome. 
For pellasoren biosynthesis, an ER domain classification based on Tyr52 does not hold true for one 
of the two ER domains, PelD-ER1. Both domains are supposed to create 2R-configured carbons based on 
alignment of the respective ER domains. However, total synthesis of the pellasoren molecule has 
unambiguously proven that one ER yields a 2R-configuration while the other ER domain creates a 2S-
configuration (Figure 39 B). Similarly, the proposed Tyr52 classifier does not apply for one of the ER 
domains found in soraphen biosynthesis as characterized in Sorangium cellulosum (SorA-ER3).11 Hence, 
out of 5 domains from Sorangium sp. analyzed with respect to the method Kwan et al. proposed, two do 
not match. In both cases a Leu52 is present while the structure has S-configuration at the respective 
position. For soraphen biosynthesis this may be reasoned by the methoxymalonyl extender unit. 
However, in pellasoren biosynthesis a typical methylmalonyl-CoA extender is used. Since the genome of 
S. cellulosum So ce38 was sequenced four times independently, the chance to have a sequencing error is 
negligible as well. Remarkably, both ER domains of the pellasoren cluster set a different stereochemistry 
while being identical in 291 out of 316 amino acids (92.4 %). Based on the protein structure of 1QOR, 
the differences between both Pel-ER domains were located within the 3D structure and it turned out, 
that the only obvious difference within the active site groove is Arg43 (Figure 39 C, numbers according 
to 1QOR).  
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Figure 39: A An alignment of both Pel-ER domains shows remarkable identity although different stereogenic 
centers are set during biosynthesis. Marked positions correspond to the numbering of the 1QOR sequence. B 
Pellasoren structure: Mismatch between observed and predicted stereochemistry. C Crystal structure of 1QOR with 
residues 43 and 52 highlighted. Both residues directly affect the size of the groove and likely undergo interactions 
with the substrate thereby influencing the stereochemical outcome of enoyl reduction. The cofactor NADPH is 
shown in blue. D Alignment of the active site region of several ER domains that create 2S or 2R stereochemistry, 
respectively. 2S-ER domains show a higher degree in conserved residues compared to 2R domains. The two 
domains of pellasoren and soraphen biosynthesis that produce 2S stereogenic centers although lacking the 
presumed conserved residue Tyr52 are highlighted in red.  
Both Arg43 and Tyr52 belong to the same α-helix and both are in contact to the substrate and the 
cofactor which could be sufficient to influence the stereochemical course of the reduction. Its position 
within the 1QOR structure underpins this hypothesis. By comparing the conserved residues within the 
active site groove it becomes evident that ER domains generating a 2S stereochemistry do have the 
combination Phe42, Arg43, Leu46, Tyr52 (Figure 39 D). In particular, Phe42 points towards the cofactor 
while the basic Arg43 points into the substrate cavity. For those domains that hold responsible for 2R 
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configuration, positions 43 and 46 are frequently different in addition to the lack of Tyr52. The 
combination of these residues likely governs the stereochemistry as the corresponding helix directly 
affects the cavity size and thus protein-substrate interactions. Aside of this, the origin of the divergent 
stereochemistry in pellasoren may be related to some effect induced by the tethered substrate and not 
solely governed by the amino acid sequence of the ER domain. A dramatic influence of the substrate on 
the stereochemical outcome was recently reported for KR domains.12,13 This can be attributed to 
different ways of how a substrate approaches the active site groove.14 ER domains are likely prone to 
similar effects.   
After all, the underlying model by Kwan et al. needs to be improved by including ER domains of, for 
example, myxobacterial origin which will most likely result in a better model. At least the key amino acid 
residues that are supposed to classify a 2S stereochemistry should be extended to the combination 
Phe42, Arg43, Leu46, Tyr52 and not rely solely on Tyr52. Moreover, the absence of Tyr52 is no 
guarantee for 2R stereochemistry but rather a hint. For a full understanding of stereochemical 
discrimination in enoyl reduction a crystal structure of PKS-related ER domain seems mandatory. With 
respect to their high identity on protein level and yet diverse stereochemical outcome, the ER domains 
of pellasoren biosynthesis are certainly a good choice to study enoyl reduction in more detail. 
5.1.4 The stereochemistry of Ketoreduction 
The principles that govern stereochemistry in keto reduction are heavily studied compared to enoyl 
reduction. Based on two crystal structures, Keatinge-Clay defined six different types of KR domains, four 
are based on the diverse configurations set at the extenders C2 and C3 atoms whereas two are related 
to KR domains that lack the reduction capability at C3, but isomerize C2 (Figure 40).14 The fact that R and 
S-configured C2 atoms exist suggests an epimerization activity since the AT domains solely loads 
(2S)-methylmalonyl-CoA onto the ACP (at least there is no other type of AT domain known so far). The 
stereogenic center of methylmalonyl is inversed to 2R-configuration upon claisen condensation 
mediated by the KS domain; hence, 2R is the typical configuration set by a PKS minimal module. The 
outcome of keto reduction for the different KR types is depicted in Figure 40 A. At this point it is 
important to mention, that the stereochemical classification of KR types is only correct as long as the 
chain tail has per definition a lower priority than the chain head in terms of Cahn-Ingold-Prelog 
nomenclature. Moreover, double bond configuration may be predicted based on the KR domains as the 
stereogenic center of the KR-derived 3-hydroxy ester is directing the succeeding dehydration toward a 
(Z) or an (E)-double bond, respectively. The typical (3R)-hydroxy carbonyl moiety tethered to ACP via an 
thioester bond will result in an (E)-double bond.15 
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Figure 40: A The stereochemistry of ketoreduction as found in PKS-related biosynthesis is predictable by checking 
for the presence or absence of fingerprint motifs within the KR protein sequence. Six types of KR domains exist. B 
Analysis of the fingerprint motifs for the KR domains of microsclerodermin and pellasoren biosynthesis. C The first 
iteration of microsclerodermin MscC-KR results in the same stereochemistry as predicted. The outcome of the 
second iteration cannot be determined as the 3-OH group is transformed to an amino group. The effect of this 
transformation on stereochemistry is not known. D Prediction of the stereochemistry set by pellasoren PelE-KR is in 
accordance to the real structure.  
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With this knowledge, the structure of pellasoren and microsclerodermin is compared to the information 
derived from alignment analysis. In pellasoren biosynthesis, PelE-KR creates a 2R,3R-configured 
elongation product. In microsclerodermin, the iteratively acting MscC-KR creates a 2R,3S-configured 
product in the first iteration cycle and MscG-KR creates a 3S-hydroxyl group. The respective KR domains 
are aligned in order to compare the in silico prediction to the real structure and indeed all predictions fit 
to the observed stereochemistry (Figure 40 B). Also the double bond configuration fits to the predicted 
B-type KR domains. 
Thus, all configurations found in pellasoren and microsclerodermin are in agreement with the in 
silico results. It can be concluded that prediction of KR domain specificity is reliable by referring to 
currently available classifiers. However, uncertainties may be introduced by variations of presumably 
conserved motifs, e.g. the LDD motif which has been regarded as highly conserved for B-type domains is 
replaced by a FDN motif in case of PelE-KR Figure 40. Such deviations of typical classifiers may 
complicate drawing conclusions from results of in silico analyses.  
5.1.5 Conclusion 
In silico based prediction of NRPS or PKS-related biosynthetic pathways is a powerful tool for 
natural product research. However, to comment on the power of this technique, a clear cut between (1) 
predicting a core structure of a molecule and (2) characterizing single domains of a biosynthetic 
pathway is essential.  
Predicting a tentative structure correctly based only on in silico analysis is hard to accomplish.  A 
first idea of how the core structure of a secondary metabolite would look like is in principal possible as 
exemplified for pellasoren. However, pellasoren biosynthesis follows the co-linearity rule and does not 
exhibit complicating factors. When complexity increases predictions are less reliable, e.g. many natural 
products are cyclized by a terminal TE domain, a process that is not yet linked to special structural 
features and cannot be foreseen. For example, the way microsclerodermin is cyclized (lactame 
formation) is not predictable by means of in silico analysis. Aside of this, biosynthetic pathways that do 
not follow common textbook biosynthetic logic are common. As soon as iterations occur or tailoring 
enzymes may act on the compound, the diversity of derivatives increases dramatically. The number of 
iterations is currently not predictable although hints on whether an iteration can occur may be 
identified based on alignment analysis,16 e.g. in case of microsclerodermin an iterative PKS module is 
assumed based on the phylogenetic analysis of KS domains (Chapter 3). The position where tailoring 
enzymes act, and more important, how they act is also not known and remains a mere assumption 
when the structure is not yet known. A good example is the pyrrolidone moiety of microsclerodermin. 
The same holds true for trans-AT clusters that frequently show up with a “distorted” module 
organization. All these aspects are the reason why it is neither possible nor reasonable to create an in 
198 Discussion 
 
silico model and use the resulting “molecule” to search for the resulting hypothetical m/z value in LC-MS 
data.  
Nevertheless, various bioinformatics tools have become indispensable helpers when it comes to an 
in-depth characterization of single catalytic domains.  All information gathered by such analyses 
eventually supports the overall process of full structural elucidation, especially in terms of characterizing 
stereogenic centers, which may be challenging when dealing with natural products. In silico models may 
assist this process although it was shown that several types of analyses not yet reached high reliability 
as exemplified for the ER domains. At the same time, predictions of amino acid-derived stereogenic 
centers or those related to KR domain activity are trustworthy.  
Irrespective of the approach that is followed with these techniques, a full characterization by 
suitable techniques such as NMR is inevitable whereas models to predict biosynthetic specificities are 
powerful tools to support this process. With more and more biosyntheses characterized, in silico models 
will gain reliability which may in turn lead to higher success rates in assignment of preferred substrates 
and stereochemical outcome of single domains. Moreover, and even of higher importance, is the 
understanding of catalytic reactions when it comes to genetic engineering aiming to optimize existing 
biosynthetic pathways or even create new ones using synthetic biology. All these methods benefit of 
each other by contributing to models that aim to fully understand how biosynthesis works down to the 
last detail. 
 
5.2 Secondary Metabolomics 
While the current capabilities and limitations of genome-based in silico analysis of biosynthetic 
pathways were extensively discussed in the preceding sections, this chapter addresses the analysis of 
biosynthesis products by using LC-MS and advanced methods for data mining with complex metabolite-
containing extracts.  
LC-MS has evolved as the most widely applied method for the analyses of complex small-molecule 
mixtures as it combines two orthogonal and powerful yet robust separation techniques at a time. While 
chromatographic separation results in compound-specific retention based on physicochemical 
properties such as molecule polarity, separation according to m/z ratios and subsequent acquisition of 
fragment spectra yield a plethora of highly informational data on distinct compounds. However, both 
the tools to effectively mine these data and the development of analytical methods to produce suitable 
data as input for computational tools currently still lag behind the standards in the field of proteomics, 
which has benefitted over years from the developments of LC-MS techniques and vice versa. In 
proteomics, highly efficient chromatographic separations in combination with sensitive MS and MS/MS 
techniques constitute a crucial prerequisite for the analysis of digested proteins in whole cell lysates.17 
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While the computational analysis of mass spectral data from peptides has reached a highly automated 
and at the same time impressively reliable level, this is to date not the case for any other type of small 
molecules such as secondary metabolites. Nevertheless, those established LC-MS techniques are 
advantageous for all analytical problems where complex biological samples need to be identified in a 
fast and robust fashion in order to get detailed insights into the sample’s molecular composition. With 
respect to natural product research, this aim becomes even more important as research rapidly 
developed during the past couple of years away from the traditional analysis of single compounds from 
individual strains toward large-scale screening projects in steadily growing collections. To achieve a high 
analytical depth per sample – including the identification of both known and unknown compounds ─ and 
at the same time enabling an overview across numerous samples is the primary objective of secondary 
metabolomics. 
Working with microbial producers of secondary metabolites involves dealing with crude extracts of 
cells or culture supernatants being rich in diverse chemical classes of small molecules including the 
secondary metabolites of interest. With respect to the amount and complexity of mass spectral data 
produced in today’s natural product screening workflows it becomes evident that automated data 
processing is needed to extract the necessary information from the acquired data in order to achieve 
dereplication and maintain at the same time a comprehensive overview of metabolite profiles.18  
The identification of known compounds in samples using LC-MS is sufficiently well accomplished by 
database queries based on matching retention time, accurate m/z, isotope pattern analysis or spectral 
matching of fragment data. In addition, these targeted methods may be readily included into largely 
automated screening workflows. However, the most challenging goal of secondary metabolomics is the 
identification of new compounds, thus demanding for new methods that specifically address the 
identification and classification of unknown analytes rather than searching only for knowns. For obvious 
reasons the principles of simple spectral matching are not applicable to identify unknowns since ─ as a 
matter of fact ─ no reference data is available.  
This shortcoming has been recently addressed by a growing number of computational methods 
dealing with the characterization and identification of the unknowns, i.e. compounds that are not 
included in any database. When dealing with unknowns an important hallmark is the identification of a 
correct sum formula. Here, considering the isotope peak pattern is regarded as a highly efficient 
measure to narrow down the number of putative sum formulas that can be generated just based on an 
exact m/z value.19,20 Computational tools such as Sirius21, mzMINE22 and Bruker’s SigmaFit increase the 
positive hit rate by comparing the measured isotope pattern to the set of calculated ones followed by a 
scoring of hits. Another promising method of getting a correct sum formula takes fragment spectra into 
account. The Sirius2 software21 and Bruker’s SmartFormula3D™ implement this approach which is based 
on the constraint that a fragment’s sum formula has to be a subset of the parent’s sum formula. Such a 
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filtering reduces the false-positive rate by excluding parent sum formulas that could never match the 
fragment ones; however, it should be noted that accurate m/z values of fragment ions are mandatory 
for the success of this method. 
Besides supporting sum formula determination, it is well-known that fragmentation data can 
essentially aid to generate detailed structural information of unknown compounds.18,23 Especially 
electron impact (EI) ionization as commonly used in GC-MS setups is a well-established and well-studied 
method to identify and characterize compounds as it causes a strong, reproducible, and highly 
informational fragmentation of analytes.24 In a similar fashion, collision induced dissociation (CID) as 
frequently used in LC-ESI-MS setups provides insight into a compound’s structure by creating fragments. 
While a detailed evaluation of MS/MS or MSn data used to rely on the expertise of a skilled user, such a 
manual approach is inappropriate when considering the flood of data that is created for a single LC-
MS/MS run of a complex sample; as an example, each auto-MS² run executed as part of this thesis 
frequently covered around 1000 MS/MS spectra. Hence, software-aided methods are urgently needed 
to generate useful information from fragment spectra in a more or less unsupervised fashion.18,23 With 
respect to this, several objectives and methods can be distinguished: 
 
 Methods for clustering of MS/MS data according to similarity  
 Methods that classify MS/MS spectra by scoring their similarity to known compounds  
 Methods that match MS/MS-derived information to biosynthetic gene cluster  
 Methods aiming at de novo prediction of compound structures based on MS/MS data  
 
Since a comprehensive analysis is the ultimate goal in secondary metabolite-related screening 
projects a totally unbiased approach of data mining is highly appreciated. In line with this, unsupervised 
clustering of MS/MS spectra is a powerful method to classify spectra according to similarity, which is in 
turn advantageous to identify structurally related compounds, e.g. members of a compound class. Yang 
et al. described a method of “molecular networking” which is capable to link MS/MS spectra that are 
most likely related to each other as indicated by similar fragmentation.25 Moreover, it has been shown 
that this technique has the potential to identify presumably new derivatives since those tend to cluster 
with known compounds of a given class. For example, spotting formerly unknown spectra together with 
a spectrum of a known compound triggers further work on the compounds represented by these new 
spectra. Böcker et al. introduced a different approach which creates hypothetical fragmentation trees 
for signals observed in fragment spectra.26 The method uses fragment spectra with accurate m/z 
information and evaluates which fragment signals are related to each other based on neutral loss 
analysis. With the knowledge about typical neutral losses and rudimental chemical logic the method 
creates a fragmentation pathway for the signals found in a MS/MS spectrum of one parent ion.27 In a 
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second step, a grouping of distinct MS/MS spectra can be achieved by alignment of the obtained 
fragmentation trees. Both spectral networking and fragmentation tree alignment may be used for 
clustering unknowns as well as for a similarity-based matching of unknowns to known compounds. The 
power of the spectral networks approach has been exemplified by analyzing microbial cultures using 
imaging mass spectrometry. 28,29  
 
Figure 41: Possible secondary metabolomics workflow benefitting from computational tools that evaluate 
LC-MS/MS data. Acquired fragment spectra are essential for these tools and allow for a structural classification of 
unknown compounds at an early stage of natural product research. A pre-selection of precursor ions as introduced 
in this work leads to an increased informational content of the raw data that is used by subsequent data mining 
tools. 
Other methods of data mining critically depend on the availability of reference spectra in order to 
perform a comparison on spectral level, e.g. by using the similarity of fragment spectra30 or by 
establishing a computational model by machine learning algorithms applied to known spectra in a first 
pass.31 Kersten et al. showed that indicative fragmentation patterns can lead to the identification of 
characteristic neutral losses attributed to amino acid building blocks or glycosylations upon which the 
genome is searched for matching biosynthetic modules. These techniques have been termed 
peptidogenomics and glycogenomics.32,33 Ambitions to use MS/MS data to de novo predict a structure 
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are still limited to peptide-like molecules owing to their characteristic and well understood 
fragmentation. Here, notable progress has been recently made with the computational analysis of cyclic 
peptides, e.g. by the CYCLONE tool.34,35  However, it must be noted that this limitation to peptide-like 
analytes will certainly lead to a biased result when analyzing complex samples. In summary, all these 
methods can contribute to comprehensive screening approaches in natural product research.  
Despite their different underlying methods and scopes, the above-mentioned approaches have one 
thing in common: They rely on high-quality MS/MS spectra whereas accurate mass acquisition is 
beneficial or even mandatory for the success of analysis. As these methods are located at the very 
downstream end of mass spectrometric analysis workflow it is of utmost importance to take care of the 
preceding steps, namely the acquisition and preprocessing of MS/MS data. This is exactly where the 
method devised in this thesis acts. 
A few publications specifically address the issue of improving the informational content of small-
molecule MS/MS spectra or increasing the number of meaningful spectra obtained from a sample.36 
With respect to MS/MS precursor selection, a pre-selection of relevant ions may be achieved by 
scanning for special isotope ratios, e.g. when screening for isotopically labelled scavenger compounds 
like it has been shown for glutathion.37 While this highly targeted MS/MS technique is capable to direct 
MS/MS fragmentation towards ions of interest, its application is limited to a single marker in one 
specialized context, and thus not useful for comprehensive screening. Other approaches are based on 
indicative neutral losses in MS² scans upon which the mass spectrometer will initiate a MS³ scan.38,39 
Such neutral loss scan techniques lack high accurate mass acquisition as they are commonly conducted 
on low resolution but very fast QqQ-MS systems. Although being useful for a range of applications 
including proteomic investigations and biomarker studies, the main drawback of these methods is the 
very high bias introduced by the type data-dependent acquisition is achieved. Schmidt et al. reviewed 
approaches that deal with hypothesis-based selection of precursor ions in proteomics applications 
which they refer to as inclusion-list driven MS.36 Those methods are following the idea of finding 
relevant features in a first pass followed by subsequent fragmentation of the features in a second step 
in order to improve peptide coverage in shot-gun proteomics.40,41 Jaffe et al. introduced the PEPPeR 
workflow which specifically identifies and selects features related to differentially expressed proteins for 
subsequent fragmentation.42 
In line with this, the combination of statistical data evaluation and SPL-MS² introduced in this work 
is a promising approach for natural product analytics as it is totally unbiased with respect to the 
precursor ion selection. The method is based solely on the comparison of sample-specific molecular 
feature sets which consist of retention time, m/z, and intensity. This comparison has no preference 
toward specific compound classes or structural moieties. In addition, the method devised in this thesis is 
suitable for the rather time-consuming acquisition of high accurate MS/MS spectra owing to the fact 
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that MS/MS acquisition time is exclusively devoted to measuring signals of interest. In comparison to 
auto-MS² methods using intensity-based precursor selection, acquiring MS/MS data in this new mode is 
beneficial for the identification of both known and unknown analytes for two reasons: 
 The MS/MS coverage amongst potentially interesting compounds is tremendously 
increased owing to the fact that precursor signal intensities are irrelevant. 
 The MS/MS data set is of high informational content as most part of the data is related to 
relevant signals. 
Thus, when working with these improved MS/MS data sets, the results of computational methods 
applied downstream ─ e.g. unsupervised clustering using spectral networking or fragmentation tree 
construction ─ will exclusively perform on relevant data. This pre-filtered approach is considered highly 
advantageous, for example when thinking of complex cultivation media which will certainly add a 
plethora of matrix signals. Such nutrient molecules could potentially exhibit secondary metabolite-like 
structures and fragmentation behavior, e.g. peptides. Hence, a data set which covers MS/MS spectra of 
matrix signals is prone to introduce a bias to the clustering algorithm as these “irrelevant” signals could 
easily outnumber the compounds of interest. For example, a NRPS-derived natural product with several 
proteinogenic amino acid building blocks likely cluster with media-derived peptides of similar 
constitution. This potential influence on a computational analysis workflow is easily avoided by pre-
filtering the MS/MS precursors as proposed in the approach presented in this work.  
In conclusion, carefully selecting the input data is instrumental for increasing the significance of 
results from unsupervised computational analyses, thereby improving the utility of such tools for natural 
products screening in the future. Directing MS/MS spectra acquisition to pre-filtered compounds of 
interest aids both the classification and identification of unknowns and their prioritization for further 
characterization as they move along the natural product discovery pipeline. In light of the remarkable 
progress made over the past couple of years regarding our capabilities for genome mining, instrumental 
analytics, and computational tools, the result of modern natural products discovery workflows relies 
more than ever on the tight interplay of all contributing methods and the analytical data used as input 
for these methods. An almost perfect LC-MS/MS data set can never compensate a genome sequence 
with bad coverage when aiming for a peptidogenomics approach as it was the case for the new 
lipothiazole compound class isolated from Sorangium cellulosum So ceGT47 (Chapter 4.5.7). Similar 
problems may be observed when approaching from the opposite direction, i.e. when the genome 
sequence is exceptionally good but the fragmentation pattern of a compound does not indicate which 
structural building blocks form the basis of the compound. This is the case for pellasoren where the 
available genome sequence of So ce38 is almost perfect but the lack of indicative pellasoren fragments 
prevented the assignment to a gene cluster. Especially compounds related to NRPS/PKS biosynthetic 
pathways frequently lack characteristic fragments from amino acid building blocks and thereby prevent 
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their successful classification. As a consequence, unbiased approaches such as fragmentation trees43 and 
spectral networking44 are better choices when it comes to the analysis of highly complex samples 
without a designated preference for what is searched. These approaches gained momentum in the last 
couple of years and will certainly evolve to valuable tools for small molecule mass spectrometry. 
Final Words 
In summary, the newly established method of precursor pre-selection as introduced in this work 
has the potential to improve advanced MS techniques while the detailed characterization of 
microsclerodermin and pellasoren biosynthesis contributes to the understanding of microbial secondary 
metabolite biosynthesis. Although this thesis approached the diverse field of natural product research 
from two supposedly rather unrelated starting points, it should become clear that both aspects 
eventually contribute to a screening workflow aiming for the improvement of detection and 
characterization of new natural products from microbial sources. 
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Author’s effort in the work presented in this thesis 
Chapter 2 
The author cultivated and extracted So ce38 following the isolation of both pellasoren A and B with full 
structural characterization. The author hold responsible for the identification, annotation, and full 
characterization of the gene cluster by analyzing a draft genome of So ce38. All measurements were 
planned, executed and analyzed by the author (except of the acquisition of NMR spectra). The knock-out 
mutant was created by Stefan Müller. 
 
Chapter 3 
The author isolated microsclerodermin M from a large-scale fermentation of So ce38. 
Microsclerodermin D and L were extracted from crude extract of MSr9139 which was provided by Suvd 
Nadmid and Ronald Garcia. All the necessary steps to fully characterize the structure with their 
stereochemistry such as derivatization, feeding experiments and the analyses of respective results were 
performed by the author (except of the ozonolysis reaction). The author identified, annotated and 
characterized the gene cluster in So ce38 and was involved in annotation of the gene cluster MSr9139. 
The author performed the detailed in silico analysis for both gene clusters. All measurements were 
planned, executed and analyzed by the author (except of the acquisition of NMR spectra). The knock-out 
mutant was created by Stefan Müller. 
 
Chapter 4 
The author planned, measured, and evaluated everything that is part of this chapter except of the 
bioactivity assays which were performed by Jennifer Herrmann and Viktoria Schmidt. 
 
